Top

Prithviraj Bose, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Bose

After obtaining his medical degree in 2001 from the University of Calcutta in his hometown of Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose began a residency in general medicine at the Institute of Post-Graduate Medical Education and Research in Kolkata, which he left in early 2004 to move to the United States. He then completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington in 2005, and residency at the Henry Ford Hospital in Detroit, Michigan in 2007, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma from 2017 through 2010. Dr. Bose became American Board of Internal Medicine-certified in hematology and medical oncology in 2010.

He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center between July 2010 and January 2015. At VCU, Dr. Bose took care of patients with diverse hematologic malignancies and teamed up with noted translational scientist, Steven Grant, to design early phase clinical trials of novel, targeted drug combinations in AML.

In the Department of Leukemia at The University of Texas MD Anderson Cancer Center, which he joined in early 2015, Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He works closely with Dr. Srdan Verstovsek, chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis. He has presented his research at international conferences and regularly speaks on MPN topics. Dr. Bose’s other area of interest is chronic lymphocytic leukemia (CLL). His clinical practice consists largely of patients with MPNs or CLL, although he also treats many patients with MDS, CML and acute leukemias.

Dr. Bose sits on the MPN panel of the National Comprehensive Cancer Network. His work has appeared in leading peer-reviewed journals such as The New England Journal of Medicine, Blood, and Cancer Cell, as well as in Williams’ Hematology. Dr. Bose was previously editor-in-chief of Drug Target Insights, and is currently on the editorial board of Hematology. In 2011, Dr. Bose, then a first-year faculty member at Virginia Commonwealth University, was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. Now a naturalized US citizen, Dr. Bose was granted permanent residence in the United States in 2013 in the select “outstanding researcher” (first preference) category.

7 things to know about myelofibrosis

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001	Calcutta Medical College, University of Calcutta, Kolkata, WB, IN, Medicine and Surgery, MBBS

Postgraduate Training

2007-2010	Clinical Fellowship, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
2005-2007	Clinical Residency, Internal Medicine, Henry Ford Hospital, Detroit, Michigan
2004-2005	Clinical Internship, Internal Medicine, Internal Medicine Residency Spokane, Spokane, Washington
2003-2004	Clinical Residency, General Medicine, Institute of Post Graduate Medical Education and Research, Kolkata

Licenses & Certifications

2023	Alabama Board of Medical Examiners
2022	Georgia Composite Medical Board
2022	Louisiana Medical Board
2022	Oklahoma Board of Medical Licensure and Supervision
2022	Tennessee Board of Medical Examiners
2022	Mississippi State Board of Medical Licensure
2022	Arizona Medical Board
2022	State of Washington Department of Health
2021	State of Florida- telehealth provider
2015	Texas Medical Board
2010	American Board of Internal Medicine - Medical Oncology
2010	American Board of Internal Medicine - Hematology
2009	Virginia Board of Medicine - Medicine and Surgery
2007	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 2017 - 2023

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017

Assistant Professor, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, 2010 - 2015

Administrative Appointments/Responsibilities

Co-Leader, Section of Myeloproliferative Neoplasms, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

Other Professional Positions

Assistant Professor, Member, Protocol Review and Monitoring Committee, Virginia Commonwealth/ Massey Cancer Center, Richmond, VA, 2010 - 2015

ER Physician, Oklahoma City VA Medical Center, Oklahoma City, OK, 2009 - 2010

House Officer, AMRI Apollo Hospitals, Kolkata, West Bengal, 2002 - 2002

Extramural Institutional Committee Activities

Member, Transfusion and Patient Blood Management Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Readmissions Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, MPN, SM and MLNEo committee, National Comprehensive Cancer Network, 2018 - 2023

Member, Scientific Review Committee (CRC) # 4, The University of Texas MD Anderson Cancer Center, 2016 - 2023

Editorial Activities

Editor in Chief, Current Hematologic Malignancy Reports, 2025 - Present

Associate Editor, Clinical Lymphoma Myeloma Leuk, 2023 - Present

MPN Section Editor, Current Hematologic Malignancy Reports, 2022 - 2024

Editorial Board Member, Clin Lymphoma Myeloma Leuk, 2021 - 2023

Editorial Board Member, Hematology, 2018 - Present

Editor-in-chief, Drug Target Insights, 2011 - 2014

Honors & Awards

2020 - 2021	Waun Ki Hong Award: Excellence in Team Science, UT MD Anderson Cancer Center
2011 - 2014	Physician's Recognition Award with Commendation, American Medical Association
2011 - 2012	Clinical Research Training Institute, American Society of Hematology

Professional Memberships

Indian Doctors Association of Houston

2016 - Present

Harris County Medical Society

2015 - Present

Society of Hematologic Oncology

2015 - Present

Texas Medical Association

2015 - Present

Southwest Oncology Group

2015 - Present

American College of Surgeons Oncology Group

2011 - 2015

American Association of Physicians of Indian Origin

2011 - Present

Cancer and Leukemia Group B

2010 - 2015

Indo American Cancer Association

2010 - Present

Gynecology Oncology Group

2010 - 2015

National Surgical Adjuvant Breast and Bowel Project

2010 - 2015

North Central Cancer Treatment Group

2010 - 2015

American Society of Clinical Oncology

2007 - Present

American Society of Hematology

2007 - Present

Selected Presentations & Talks

Local Presentations

2025. Myelofibrosis. Invited. Leukemia fellows' lecture. Houston, Texas, US.
2025. MF Update from ASH 2024 (CME-accredited). Invited. Leukemia Research Meeting. Houston, Texas, US.
2024. JAK inhibition for myelofibrosis: past, present and future. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2024. JAK Inhibition for the Treatment of Myelofibrosis. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2024. Myelofibrosis Therapy Updates from ASH 2023. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2023. MPN Therapy Updates from ASCO/EHA 2023. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2023. Novel Therapeutic Strategies for Myelofibrosis: Current and Future Directions. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2023. Update on Systemic Mastocytosis. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2023. JAKi-based Frontline Combinations in Myelofibrosis: Focus on Selinexor. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2022. Current Treatment Practices and Unmet Needs in Myelofibrosis. Invited. Curio Science. Houston, TX, US.
2022. Disease Modification in Myelofibrosis: are we there yet?. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Systemic Mastocytosis. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Myelofibrosis. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Update on Sytemic Mastocytosis. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Pelabresib (CPI-0610) in myelofibrosis: MANIFEST data. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2020. Drug Development for Myelofibrosis: State of the Art. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2020. A pilot study of the SLAMF7 monoclonal antibody, elotuzumab, in myelofibrosis. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2019. Systemic Mastocytosis. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2018. Atypical MPN. Invited. UT MDACC. Houston, TX, US.
2018. Myelofibrosis. Invited. Baylor College of Medicine. Houston, TX, US.
2017. Myelofibrosis with cytopenias. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Building on JAK inhibition and other novel targets for drug development in myelofibrosis. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Does anything work for post-MPN AML?. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Lower Dose Ibrutinib for Chronic Lymphocytic Leukemia. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2016. Rational Combinations and other Translational Projects in Leukemia. Invited. UT MD Anderson Cancer Center. Houston, TX, US.
2014. Rational Combinations of Targeted Agents in AML. Invited. UT MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2025. Solving the Puzzle: Diagnostic and Treatment Innovations in Myelofibrosis (CME-accredited). Invited. Asian Physician Medical Association, US.
2025. Leveraging Real-world Insights to Inform Patient-Centered Care. Modern JAKi Strategies in Individualized Myelofibrosis Management (CME-accredited). Invited. NYU Langone Medical Center. New York, NY, US.
2025. Leveraging Real-world Insights to Inform Patient-Centered Care. Modern JAKi Strategies in Individualized Myelofibrosis Management (CME-accredited). Invited. BRCN Cancer Center of Southeast Texas. Port Arthur, TX, US.
2025. Management of Anemia in the Treatment of Myelofibrosis. Invited. Aptitude Health CASES program. Atlanta, GA, US.
2025. Current Management and Emerging Therapeutic Approaches in MF. Invited. Aptitude Health CASES program. Atlanta, GA, US.
2025. Solving the Puzzle: Diagnostic and Treatment Innovations in Myelofibrosis (CME-accredited). Invited. HCA Houston Clear Lake Hospital. Houston, TX, US.
2025. Leveraging Real-world Insights to Inform Patient-Centered Care. Modern JAKi Strategies in Individualized Myelofibrosis Management (CME-accredited). Invited. California Oncology Associates. San Francisco, CA, US.
2025. Leveraging Real-world Insights to Inform Patient-Centered Care. Modern JAKi Strategies in Individualized Myelofibrosis Management (CME-accredited). Invited. Riverside Regional Medical Center. Newport News, VA, US.
2025. Systemic Mastocytosis (CME-accredited). Invited. Research to Practice General Medical Oncology Summit. Miami, FL, US.
2025. Current Management and Emerging Therapeutic Approaches in MF. Invited. Aptitude Health CARE program, US.
2025. Leveraging Real-world Insights to Inform Patient-Centered Care. Modern JAKi Strategies in Individualized Myelofibrosis Management (CME-accredited). Invited. Greater Houston Oncology Associates. Houston, TX, US.
2024. Personalizing Myelofibrosis Care: Expert Insights on New Evidence and Novel Strategies (CME accredited). Invited. Alaska Oncology and Hematology, LLC. Anchorage (virtual speaker), AK, US.
2023. A Community Practitioner’s Guide to Contemporary Management of Polycythemia Vera: Data Review and Case Challenges Illustrating Current Best Practice. Invited. Jackson Oncology Associates. Jackson (Virtual Speaker), MS, US.
2023. CASES in Myelofibrosis. Invited. Aptitude Health. Virtual, US.
2023. CASES in Myelofibrosis. Invited. Aptitude Health. Virtual, US.
2023. Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis (CME-accredited). Invited. Lankenau Hospital. Wynnewood (Virtual Speaker), PA, US.
2023. A Community Practitioner’s Guide to Contemporary Myelofibrosis Care: Data Review and Case Challenges Illustrating Current Therapeutic Standards (CME-accredited). Invited. California Pharmacists Association. Fremont (Virtual Speaker), CA, US.
2022. Opinions in Myelofibrosis. Invited. Curio Science. Virtual, US.
2022. Risk-Adapted Treatment of Myelofibrosis: A Focus on Quality of Life. Invited. University of Alabama Medical Center, Birmingham, AL. Virtual, US.
2022. Risk-Adapted Treatment of Myelofibrosis: A Focus on Quality of Life. Invited. Sarah Cannon Cancer Center, Overland Park, KS. Virtual, US.
2022. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Invited. Curio Science. Virtual, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Invited. Curio Science. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Invited. Aptitude Health. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Invited. Aptitude Health. Virtual, US.
2022. Updates in MPNs and Mastocytosis. Invited. The University of Alabama at Birmingham. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Invited. Aptitude Health. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Invited. Aptitude Health. Virtual, US.
2021. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Invited. Curio Science. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. North Florida/South Georgia VA Health System, Lake City, FL. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. University of Alabama Medical Center, Birmingham, AL. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. UT MD Anderson Cancer Center. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. Northside Hospital, Lawrenceville, GA. Virtual, US.
2020. Managing Myelofibrosis: Writing the Next Chapter in the JAK inhibitor Story. Invited. Estate Restaurant and Bar. Santa Monica, CA, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. Webinar, US.
2019. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Invited. Cape Fear Valley Medical Center. Fayettville, NC, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions: An Oncology Exchange Initiative. Invited. Union Hospital. Terre Haute, IN, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions: An Oncology Exchange Initiative. Invited. Cancer Treatment Centers of America. Goodyear, AZ, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Invited. Memorial Healthcare System. Miami, FL, US.
2019. What is new in ET, PV and MF?. Invited. Oncology Meeting Innovations (DAVA Oncology). Seattle, WA, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Invited. Halifax Health. Daytona Beach, FL, US.
2019. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Invited. Oncology Nursing Society (Treasure Coast chapter). Sebastian, FL, US.
2019. Recent Updates in the Diagnosis and Prognosis of Myelofibrosis. Invited. Oncology Nursing Society (Treasure Coast chapter). Sebastian, FL, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Invited. University Medical Center of Southern Nevada. Las Vegas, NV, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Invited. Northwestern Prentice Women’s Hospital. Chicago, IL, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Invited. Potomac Center for Medical Education/Rockpointe Oncology. Salt Lake City, UT, US.
2018. Classic Philadelphia chromosome negative MPN. Invited. Local hematologists and hematopathologists. Kolkata, IN.
2018. Developmental Therapeutics in MPN. Invited. Oncology Meeting Innovations (DAVA Oncology). Seattle, WA, US.
2018. Developmental Therapeutics in MPN. Invited. Oncology Meeting Innovations (DAVA Oncology). Boston, MA, US.
2018. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Invited. Oncology Nursing Society, northern Ohio chapter. Lima, OH, US.
2018. Understanding the Biological Complexity of Myeloproliferative Neoplasms. Invited. Oncology Nursing Society, northern Ohio chapter. Lima, OH, US.
2018. Myelofibrosis and Polycythemia vera: Integrating Recent Advances Into Clinical Practice. Invited. VA Western NY Healthcare System. Buffalo, NY, US.
2018. Challenges in Diagnosis and Management of Essential Thrombocythemia. Invited. Oncology Nursing Society, Louisiana chapter. Mandeville, LA, US.
2018. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Invited. Oncology Nursing Society, Louisiana chapter. Mandeville, LA, US.
2018. Myelofibrosis and Polycythemia Vera: Integrating Recent Advances Into Clinical Practice. Invited. Robert Wood Johnson Hamilton Hospital. Hamilton, NJ, US.
2018. Myelofibrosis and Polycythemia Vera: Integrating Recent Advances Into Clinical Practice. Invited. Thomas E. Creek VA Medical Center. Amarillo, TX, US.
2017. What is new in myeloproliferative neoplasms?. Invited. OMI (Dava Oncology). Pasadena, CA, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Invited. St. Mary's Hospital and Medical Center. Evansville, IN, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Invited. Holmes Regional Medical Center. Melbourne, FL, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Invited. Bayfront Health St Petersburg. St Petersburg, FL, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Invited. Western Maryland Regional Medical Center. Cumberland, MD, US.
2016. Management and Treatment of Polycythemia Vera. Invited. Quillen College of Medicine, East Tennessee State University. Johnson City, TN, US.
2015. 2015 Update on Chronic Lymphocytic Leukemia. Invited. North Carolina Oncology Association. Asheville, NC, US.
2015. 2015 update on CLL and MDS. Invited. Virginia Association of Hematologists and Oncologists. Hot Springs, VA, US.
2015. Myelodysplastic syndromes. Invited. Virginia Oncology Associates. Virginia Beach, VA, US.
2014. CLL, CML and MDS: where do we stand in 2014?. Invited. Virginia Association of Hematologists and Oncologists. Hot Springs, VA, US.
2013. Targeted therapies and rational combinations for the myeloid malignancies. Invited. VCU Massey Cancer Center. Richmond, VA, US.
2013. Concomitant HDAC and Wee1 inhibition in AML. Invited. Southeast Phase 2 Consortium. Clearwater Beach, FL, US.
2007. Pasteurella hemolytica: An unusual cause of osteomyelitis. Conference. American College of Physicians. Kalamazoo, MI, US.
2007. Legionnaire’s Disease: Ubiquitous But Under-recognized. Conference. American College of Physicians. East Lansing, MI, US.
2007. Hepatic presentation of primary(AL) amyloidosis. Conference. American College of Physicians. East Lansing, MI, US.
2007. Hypokalemic Periodic Paralysis: Not Always Familial. Conference. American College of Physicians. East Lansing, MI, US.
2006. Daptomycin-Induced Rhabdomyolysis. Conference. Society of General Internal Medicine. Chicago, IL, US.
2006. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. Conference. American College of Physicians. Troy, MI, US.
2006. Gorham’s (Vanishing Bone) Disease: A Medical Mystery. Conference. American College of Physicians. Troy, MI, US.
2006. Strongyloidiasis following Autologous Stem Cell Transplantation (SCT) for Non Hodgkin’s Lymphoma (NHL) treated with Rituximab and Conventional Chemotherapy. Conference. American College of Physicians. Troy, MI, US.
2005. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. Conference. Society of General Internal Medicine. Chicago, IL, US.

National Presentations

2025. Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study. Conference. 2025 ASCO Annual Meeting. Chicago, IL, US.
2025. Novel Small Molecules and JAK inhibitor-based combinations in Myelofibrosis. Invited. 6th Annual US Focus meeting on MPNs and MDS. Austin, TX, US.
2024. Disease Modification in Myeloproliferative Neoplasms. Invited. XIXth Annual Post-ASH CML and MPN Workshop. La Jolla, CA, US.
2024. Optimizing Selection of Available JAK Inhibitors in MF. Invited. XIIth Annual meeting of the Society of Hematologic Oncology. Houston, TX, US.
2024. Prefibrotic Myelofibrosis: Special considerations for a new entity. Invited. MPN Workshop of the Carolinas. Asheville, NC, US.
2024. Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Current Treatment Strategies for Anemia of MF. Invited. GSK. La Jolla, CA, US.
2024. Novel Mechanisms of Drug Action in MF. Invited. MD Education. La Jolla, CA, US.
2024. Current Therapy for Intermediate/High Risk Myelofibrosis. Invited. Physicians Education Resource. Miami Beach, FL, US.
2023. Evolving Strategies for the Management of Anemia in MF. Invited. Alpine Oncology Foundation. La Jolla, CA, US.
2023. Current Myelofibrosis Treatment Landscape. Invited. Medscape Oncology. San Diego, CA, US.
2023. Optimizing Clinical Decision-Making for Patients with MF. Invited. Research to Practice. Houston, TX, US.
2023. Current and Emerging Therapies for Systemic Mastocytosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2023. Current and Emerging Treatment Options for Patients with ET and PV. Invited. Curio Science National Summit. Marco Island, FL, US.
2023. Post Hoc Analyses and Indirect Comparisons Among JAK Inhibitors. Invited. Curio Science Congress Connect - Myelofibrosis: ASCO/EHA 2023. Virtual, US.
2023. VONJO (pacritinib) capsules. Part of "The role of VONJO (pacritinib) capsules in myelofibrosis". Invited. CTI BioPharma. Virtual, US.
2023. Current treatment strategies for anemic MF patients and underlying gaps (part of “Understanding challenges and treatment options in the anemic Myelofibrosis (MF) patient”). Invited. MD Education. Phoenix, AZ, US.
2023. What to do When Blasts Increase in MPN. Invited. MD Education. Phoenix, AZ, US.
2023. Progress in Polycythemia Vera. Invited. PER. Miami Beach, FL, US.
2022. Novel Therapies in MF as Single Agents Beyond JAKi: Importance of spleen volume and symptom burden reduction. Invited. MPN Controversies and Debates. Virtual, US.
2022. Myelofibrosis. Invited. Philippine College of Hematology and Blood Transfusion. Webinar, US.
2022. Management of Pre-Fibrotic Primary Myelofibrosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2022. Management of cytopenias in MF: an Emerging Area for Therapeutic Approaches and Drug Development. Invited. TX MPN Workshop. San Antonio, TX, US.
2022. Indolent Systemic Mastocytosis. Invited. "TeleEcho" program. Virtual, US.
2022. Managing Anemia in the Era of JAK Inhibition (as part of "The Evolving Challenge of Anemia in Myelofibrosis"). Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Status of Unmet Need in Cytopenic MF and Clinical Prognosis (as part of "Cytopenic MF: an Update"). Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Advanced Systemic Mastocytosis: State of the Art. Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Advanced Systemic Mastocytosis: Patient Quality Initiative. Invited. NCODA. Virtual, US.
2022. Myelofibrosis. Invited. Mumbai Hematology Group. Virtual (webinar), US.
2022. Essential Thrombocythemia. Invited. Clinical Care Options. Virtual, US.
2022. Key MPN Presentations from the 63rd (2021) American Society of Hematology (ASH) Annual Meeting. Invited. Research To Practice. Virtual, US.
2022. The Evolving Landscape in Systemic Mastocytosis: KIT and Beyond. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. Improving Anemia in Myelofibrosis with Momelotinib. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. "Disease Modification" in Myelofibrosis: An Elusive Goal?. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. Other JAK inhibitors and future treatments. As part of a Masterclass on CML and MPN. Invited. Turkish Hematology Academy. Virtual, US.
2021. Novel Therapies for Anemia in Myelofibrosis. Invited. Alpine Oncology Foundation (XVIth Annual Post-ASH MPN/CML Workshop). Virtual, US.
2021. A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis. Conference. American Society of Hematology. Atlanta (presented virtually), GA, US.
2021. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Conference. American Society of Hematology. Atlanta (presented virtually), GA, US.
2021. Polycythemia Vera and Essential Thrombocythemia. Invited. Mumbai Hematology Group. Virtual, US.
2021. Pelabresib. As part of Virtual Think Tank on Myelofibrosis Targeting Apoptosis, Telomerase and Epigenetics. Invited. DAVA Oncology (Oncology Meeting Innovations). Virtual, US.
2021. Pelabresib (CPI-0610) Improved Anemia Associated With Myelofibrosis: Interim Results From Ongoing MANIFEST Phase 2 Study. Conference. Society of Hematologic Oncology. Virtual, US.
2021. Emerging Approaches to Treating Cytopenic MF. As part of “Exploring New Approaches for Treating Patients with Cytopenic Myelofibrosis”. Invited. Medscape. Virtual, US.
2021. Indolent Systemic Mastocytosis. Invited. Texas MPN Workshop. Virtual, US.
2021. Systemic Mastocytosis Research at MDACC. Invited. American Initiative on Mast Cell Diseases. Virtual, US.
2021. Hydroxyurea-resistant polycythemia vera. As part of MPN Virtual Tumor Board. Invited. Targeted Oncology. Virtual, US.
2021. Survival in MF. As part of “Ruxolitinib – A Decade as Standard of Care for Myelofibrosis – Lessons Learned”. Invited. Incyte Corporation (Independent Satellite Sympoisum). Virtual, US.
2021. How do you manage treatment failure in myelofibrosis?: Failure due to cytopenias. Invited. BMS (Independent Satellite Symposium). Virtual.
2020. Update on avapritinib in advanced systemic mastocytosis. Invited. Alpine Oncology Foundation (XVth post-ASH CML/MPN workshop). Virtual, US.
2020. Sotatercept (ACE-011) for Anemia of Myelofibrosis. Conference. American Society of Hematology. Virtual, US.
2020. Understanding the Evolving Treatment Landscape of Polycythemia Vera. Invited. Physicians' Education Resource. Virtual, US.
2020. Management of side effects and loss of response to ruxolitinib. Invited. MD Education. Virtual, US.
2020. Optimizing JAK inhibition in myelofibrosis. Invited. Incyte Corporation. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. Next questions: Myeloproliferative Neoplasms. Invited. Society of Hematologic Oncology. Virtual, US.
2020. A young woman with thrombocytosis. Invited. Society of Hematologic Oncology. Virtual, US.
2020. ET: Disease outcomes, unmet needs and therapeutic strategies. Invited. Texas MPN Workshop. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. MPN Transition from Chronic to Blast Phase MPN. Invited. Targeted Oncology. Virtual, US.
2020. Ruxolitinib-based Combination Therapies for Myelofibrosis. Invited. ALMPN Expert Forum. Dallas, TX, US.
2020. Navigating the Treatment Landscape in MF: Risk-Adapted Therapy and the New JAK Inhibitor Era. Invited. PeerView. Orlando, FL, US.
2019. Activin Receptor Ligand Traps and the way forward with targeting TGF-β in MF. Invited. Alpine Oncology Foundation. Orlando, FL, US.
2019. Emerging Treatment Options for MPNs. Invited. Medscape. Orlando, FL, US.
2019. Identifying and Treating “Progression” in Myelofibrosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2019. Preference categorization of therapies for advanced systemic mastocytosis. Invited. National Comprehensive Cancer Network. Plymouth Meeting, PA, US.
2019. Emerging Therapies in Myeloproliferative Neoplasms. Invited. Curio Science - Vaniam Group. Miami, FL, US.
2018. Ruxolitinib-based combinations in myelofibrosis: past, present and future. Invited. Alpine Oncology Foundation. San Diego, CA, US.
2018. Polycythemia Vera. Invited. Incyte Corporation. Atlanta, GA, US.
2018. Emerging agents in myelofibrosis. Invited. 4th Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2018. Prognostic implications of recent advances in genomics in MPN. Invited. 4th Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2017. ET: unresolved questions and unmet needs. Invited. Alpine Oncology Foundation. Atlanta, GA, US.
2017. A PK/PD pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Sotatercept Alone and with Ruxolitinib in Patients with MPN-associated Myelofibrosis and Anemia. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients with Myelofibrosis. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Myelofibrosis with cytopenias. Invited. Society of Hematologic Oncology. Houston, TX, US.
2017. Ruxolitinib: what are the successes and challenges in MPN?. Invited. 3rd Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2016. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Conference. American Society of Hematology. San Diego, CA, US.
2016. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Conference. American Society of Hematology. San Diego, CA, US.
2013. AML: Current concepts, recent advances and future directions. Invited. OMICS Group. Raleigh, NC, US.
2008. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Conference. American Society of Hematology. San Francisco, CA, US.
2006. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. Conference. Society of General Internal Medicine. Los Angeles, CA, US.
2006. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. Conference. Society of General Internal Medicine. Los Angeles, CA, US.
Individualizing Treatment for Patients With Myeloproliferative Neoplasms. Invited. Clinical Care Options (Clinical Education Alliance). Virtual, US.
Management of Anemia in Myelofibrosis (part of 2023 MPN Clinical Roadmap). Invited. MD Education. Virtual, US.

International Presentations

2025. Updates on JAK inhibitors and JAKi-naïve studies in MF. Invited. 3rd annual iwMDS-MPN meeting. Lisbon, PT.
2025. When Should a Lower Risk Patient with MF be Treated and with What?. Invited. 3rd annual iwMDS-MPN meeting. Lisbon, PT.
2025. Final Results of a Pilot Study of Elotuzumab in Patients with Myelofibrosis. Poster. 2025 EHA Annual Congress. Milan, IT.
2025. Clinical Experience with Ropeginterferon alfa-2b in the treatment of Polycythemia Vera. Invited. MPN Asia. Beijing (presented virtually), CN.
2024. Myeloproliferative Neoplasms. Invited. Tata Medical Center. Kolkata, IN.
2024. Treatment of Myelofibrosis: the earlier, the better?. Invited. HEMO. Sao Paolo, BR.
2024. MF: Defining disease modification in the era of targeted therapy. Invited. Inaugural BMS Anemia Forum. Amsterdam, NL.
2024. Current Treatment Options for Patients with Myelofibrosis who have Anemia. Invited. GSK. Madrid, ES.
2024. Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia. Poster. EHA 2024 Hybrid Congress. Madrid, ES.
2024. THE ACTIVIN RECEPTOR-LIKE KINASE-2 INHIBITOR ZILURGISERTIB (INCB000928) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS: PHASE 1/2 STUDY RESULTS. Poster. EHA 2024 Hybrid Congress. Madrid, ES.
2024. Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study. Poster. EHA 2024 Hybrid Congress. Madrid, ES.
2024. Selecting Initial Treatment for Patients with Myelofibrosis. Invited. Clinical Care Options. Chicago, US.
2024. Novel Therapies for High Risk MPN. Invited. European School of Hematology. Mandelieu La Napoule, FR.
2024. Cutting Edge Treatment Strategy for PV based on Real World Besremi experiences. Invited. Pharma Essentia. Virtual, JP.
2024. Clinical Experience with Ropeginterferon alfa-2b for the Treatment of Polycythemia Vera in the United States. Invited. MPN Asia 2024. Osaka, JP.
2024. Diagnosis and management of systemic mastocytosis: what's new in 2024?. Invited. International Academy of Clinical Hematology (IACH). Virtual, US.
2023. UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS. Poster. European Hematology Association. Frankfurt, DE.
2023. Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). Poster. European Hematology Association. Frankfurt, DE.
2023. Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study. Poster. European Hematology Association. Frankfurt, DE.
2023. A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS. Poster. European Hematology Association. Frankfurt, DE.
2023. Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias. Poster. American Society of Clinical Oncology. Chicago, US.
2023. Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). Poster. American Society of Clinical Oncology. Chicago, US.
2023. Treatment of Myelofibrosis in non-transplant candidates. Invited. Novartis. Buenos Aires (Virtual Speaker), AR.
2023. Risk stratification in Myelofibrosis: Identifying Myelofibrosis patients for Stem Cell Transplant. Invited. Novartis. Buenos Aires (Virtual Speaker), AR.
2023. Ruxolitinib in Myelofibrosis and Polycythemia Vera. Invited. Novartis. Medellin, CO.
2022. Avapritinib in Advanced Systemic Mastocytosis. Invited. Blueprint Medicines Corporation. New York City, US.
2021. Current Therapies and Clinical Advances in Myelofibrosis. As part of "Providing Patient-Centric Care in MDS and MPNs: Improving Outcomes and Quality of Life With New Therapeutic Options”. Invited. Physicians' Education Resource. Virtual, US.
2021. Case #4: Post-PV MF after Failure on Ruxolitinib. As part of “Providing Patient-Centric Care in MDS and MPNs: Improving Outcomes and Quality of Life With New Therapeutic Options”. Invited. Physicians' Education Resource. Virtual, US.
2020. A 55-year-old Patient with PV Resistant to Hydroxyurea. Invited. Medicom Worldwide. Virtual, US.
2020. Exploring Evidence-Based Approaches in MF: The Latest on Approved and Emerging Options. Invited. PeerView. Virtual, US.
2019. Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): An open-label, prospective study. Poster. 9th Trends in Medical Mycology Conference. Nice, FR.
2019. Interactive Case Studies: Treatment Decisions after JAK inhibitor “Failure”. Invited. Medicom Worldwide. Houston, US.
2019. Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia. Conference. European Hematology Association. Amsterdam, NL.
2019. Early Results of a Phase II study of combined Ruxolitinib and Thalidomide in patients with Myelofibrosis. Poster. European Hematology Association. Amsterdam, NL.
2019. Phase 1/2 study of Ruxolitinib (RUX) Plus Decitabine (DAC) in Patients (pts) With Post-MPN AML. Poster. European Hematology Association. Amsterdam, NL.
2019. Characterizing Myelofibrosis for a Risk-Adapted Approach to Management in the JAK Inhibitor Era. Invited. PeerView. Chicago, US.
2019. Take home messages: MPN. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2019. Prognostication in myelofibrosis: state of the art. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2019. Prognostication and thrombotic risk stratification of PV/ET in the genomic era. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2018. Current understanding of who responds to (needs) JAK2 inhibition in MPN. Invited. 5th Annual Summit on Hematologic Malignancies. Whistler, CA.
2017. Mutational Landscape of MDS/MPN-U. Poster. European Hematology Association. Madrid, ES.
2007. Hypokalemic Periodic Paralysis: Not Always Familial. Poster. Society of General Internal Medicine. Toronto, CA.
2007. Daptomycin-Induced Rhabdomyolysis. Poster. Society of General Internal Medicine. Toronto, CA.
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response. Invited. Medicom Worldwide. Virtual, US.
Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies. Invited. Medicom Worldwide. Virtual, US.

Formal Peers

2025. Emerging Data and Real World Findings in MPNs (keynote lecture at annual speaker training event).
2025. Anemia of Myelofibrosis: Current and Emerging Treatment Landscape.
2025. An Overview of the Classic Myeloproliferative Neoplasms (Leukemia lecture series for Houston area hematology/oncology fellows). Houston, Texas, US.
2025. Myeloproliferative Neoplasms (UNMC Hematology Highlights: an ASH 2024 review). Omaha, Nebraska, US.
2024. An Overview of the Classic Myeloproliferative Neoplams. Visiting. Houston, TX, US.
2023. MF Updates from ASCO/EHA 2023. Invited. Virtual, US.
2023. A Review of the Classic Myeloproliferative Neoplasms. Invited. Houston (Virtual Speaker), TX, US.
2022. Emerging and Future Treatments for Myelofibrosis. Invited. Dallas, TX, US.
2022. Myelofibrosis. Invited. Dallas, TX, US.
2022. State of the Art Update on Polycythemia Vera. Invited. Virtual, US.
2021. Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610): ASH 2021 Clinical Updates from Arms 2 and 1. Invited. Virtual, US.
2021. Anemia in Myelofibrosis & Prior Momelotinib Data in Anemic MF Patients. As part of “Review of Momelotinib for the Potential Treatment of Myelofibrosis”. Invited. Virtual, US.
2021. Current Topics in MPNs. Keynote lecture at Incyte Jakafi® Virtual Speaker Training Meeting. Invited. Virtual, US.
2021. Optimizing JAK inhibition and moving beyond JAK inhibitors in myelofibrosis. Invited. Virtual, US.
2020. Beyond ruxolitinib: Novel agents and combinations for myelofibrosis. Invited. Houston, TX, US.
2020. Classic Myeloproliferative Neoplasms: An Update from ASH 2019. Invited. Morristown, NJ, US.
2019. Myelofibrosis Clinical Cases. Invited. Orlando, FL, US.
2019. Classic MPN. Invited. Houston, TX, US.
2018. Treatment options for refractory CLL: new and novel small molecule inhibitors. Visiting. Houston, TX, US.
2018. Classic MPN. Invited. Houston, TX, US.
2018. Emerging Data in MPNs. Invited. Chicago, IL, US.
2018. Myelofibrosis. Invited. Houston, TX, US.
2017. Treatment options for refractory CLL: new and novel small molecule inhibitors. Visiting. Houston, TX, US.
2017. The JAK-STAT pathway and cyclin-dependent kinases: an overview. Visiting. Houston, TX, US.
2017. MOST Study Rationale. Invited. Phoenix, AZ, US.
2013. Tumor Lysis Syndrome. Invited. Las Vegas, NV, US.

Less

Grant & Contract Support

Date:	2023 - 2024
Title:	2022-0955-4362 - A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Funding Source:	Sumitomo Dainippon Pharma Oncology, Inc
Role:	PI
ID:	BBI-TP-3654-102

Date:	2023 - 2026
Title:	2022-0745 - A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Funding Source:	Janssen Pharmaceuticals
Role:	PI

Date:	2022 - 2027
Title:	2022-0291 - A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability of DISC-0974 in Subjects with Myelofibrosis and Anemia
Funding Source:	Disc Medicine
Role:	PI
ID:	DISC-09714-102

Date:	2022 - 2027
Title:	2022-0183 - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects with MF who have a Suboptimal Response to Ruxolitinib
Funding Source:	Telios Pharma
Role:	PI
ID:	TL-895-209

Date:	2022 - 2027
Title:	2022-0072 - A Randomized, Double-Blind, Placebo- Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Funding Source:	Blueprint Medicines Corporation
Role:	PI
ID:	BLU-263-1201

Date:	2022 - 2029
Title:	2021-0897: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
Funding Source:	Ionis Pharmaceuticals
Role:	PI
ID:	AWD00006708

Date:	2022 - 2029
Title:	2021-1092-A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Funding Source:	Incyte Corporation
Role:	PI
ID:	2021-1092

Date:	2022 - 2029
Title:	2021-0880 (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS CGT9486-21-202
Funding Source:	Cogent Biosciences
Role:	PI
ID:	2021-0880

Date:	2021 - 2028
Title:	2020-1010 - A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on concomitant JAK2 Inhibitor Therapy and Who Require red Blood Cell Transfusions
Funding Source:	Celgene
Role:	Principal Investigator-MDACC

Date:	2021 - 2028
Title:	2020-1141- A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Funding Source:	Geron Corporation
Role:	Principal Investigator-MDACC

Date:	2021 - 2028
Title:	2021-0587 A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Funding Source:	Cogent Biosciences
Role:	PI
ID:	2021-0587

Date:	2021 - 2026
Title:	2021-0331 BLU-285-2203 - A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Funding Source:	Blueprint Medicine
Role:	PI
ID:	2021-0332

Date:	2021 - 2022
Title:	Molecular Basis and Preclinical Efficacy of targeting LSD1 (KDM1A) in post-MPN secondary AML
Funding Source:	MD Anderson
Role:	Investigator
ID:	RCTS#2021-0060087-Y1

Date:	2021 - 2026
Title:	2020-0739 - A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Funding Source:	Constellation Pharmaceuticals
Role:	Principal Investigator-MDACC

Date:	2020 - 2027
Title:	2020-0522_"A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis"
Funding Source:	Bristol-Myers Squibb
Role:	PI
ID:	2020-0522

Date:	2020 - 2025
Title:	2020-0409 - A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Funding Source:	Incyte Corporation
Role:	Principal Investigator-MDACC

Date:	2020 - 2024
Title:	2020-0279_An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2020-0279

Date:	2019 - 2024
Title:	2018-0943_An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Funding Source:	Blueprint Medicines
Role:	PI
ID:	2018-0943

Date:	2019 - 2020
Title:	2018-0907_A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2018-0907

Date:	2019 - 2023
Title:	2018-0906_An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2018-0906

Date:	2018 - 2023
Title:	2018-0202_A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Funding Source:	Constellation Pharmaceuticals, Inc
Role:	PI
ID:	2018-0202

Date:	2018 - 2021
Title:	2018-0022_An Open-Label, Multi-center, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Funding Source:	Incyte Corporation
Role:	PI
ID:	2018-0022

Date:	2018 - 2021
Title:	2017-0504_A phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept (ACE-536) in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia with and without red blood cell-transfusion dependence
Funding Source:	Celgene Corporation
Role:	PI
ID:	2017-0504

Date:	2017 - 2020
Title:	2017-0512_EVALUATION OF RUXOLITINIB and THALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	PI
ID:	2017-0512

Date:	2017 - 2021
Title:	2017-0320_An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Funding Source:	CTI BioPharma
Role:	PI
ID:	2017-0320

Date:	2017 - 2019
Title:	2016-0373_A Phase II study of isavuconazole prophylaxis in adult patients with AML/MDS and neutropenia
Funding Source:	Astellas Pharma
Role:	PI
ID:	2016-0373

Date:	2017 - 2019
Title:	2017-0111_A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
Funding Source:	Incyte Corporation
Role:	PI
ID:	2017-0111

Date:	2016 - 2019
Title:	2015-0832_A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Funding Source:	Blueprint Medicines Corporation
Role:	PI
ID:	2015-0832

Date:	2015 - 2019
Title:	2015-0787_Alternating or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Funding Source:	Pfizer
Role:	PI
ID:	2015-0787

Date:	2013 - 2020
Title:	2013-0051_A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
Funding Source:	Promedior
Role:	PI
ID:	2013-0051

Date:	2012 - 2022
Title:	2012-0534_A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA
Funding Source:	Celgene
Role:	PI
ID:	2012-0534

Date:	2011 - 2021
Title:	2011-0090_A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
Funding Source:	NS Pharma
Role:	PI
ID:	2011-0090

Selected Publications

Peer-Reviewed Articles

DiNardo CD, Croden J, Abdel-Salam HM, Kadia T, Molica M, Bazinet A, Bose P, Maiti A, Haddad F, Burger J, Kantarjian H, Wierda W, Jain N, Ferrajoli A. Clinical, genetic, and familial features of POT1 tumor predisposition syndrome. Cancer 132(4):e70315, 2026. e-Pub 2026. PMID: 41686515.
Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study. Blood Cancer Discov, 2026. e-Pub 2026. PMID: 41678768.
Laas V, Feindt FC, Bose P, Zimmermann T, Klimicevs P, Hagenstein J, Ehnold LI, Herrnstadt GR, Warkotsch MT, Paust HJ, Panzer U, Krebs CF, Huber TB, Wiech T, Steinmetz OM, Melderis S. Urinary CD4(+) T helper cells are a potential biomarker for tubulointerstitial nephritis in Sjogren's disease. Sci Rep 16(1):5943, 2026. e-Pub 2026. PMID: 41673408.
Senapati J, Croden J, Garcia-Manero G, Takahashi K, Daver NG, Kadia TM, Borthakur G, Short NJ, Jabbour E, Haddad F, Marvin-Peek J, Abbas HA, Bose P, Tang G, Loghavi S, Shpall EJ, Ramdial J, Popat UR, Champlin RE, Ravandi F, Kantarjian HM, Dinardo CD. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. Hemasphere 10(2):e70317, 2026. e-Pub 2026. PMID: 41694734.
Lokanc S, Sipila P, Cuvelier GDE, Murguia-Favela L, Wright NA, Grunebaum E, Bose P, Narendran A. Gene alterations in inborn errors of immunity and their presence in cancers: implications for oncogenesis, progression, and outcomes. Hum Immunol 87(3):111671, 2026. e-Pub 2026. PMID: 41616493.
Gotlib J, Reiter A, Radia DH, Alvarez-Twose I, Deininger MW, George TI, Panse JP, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu C, Mesa RA, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lubke J, Bidollari I, Lin HM, Rylova SN, Dimitrijevic S, Munoz-Gonzalez JI, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. Blood Adv, 2026. e-Pub 2026. PMID: 41604606.
Singh B, Gaur P, Bose P, Zhang Y, Li Y, Zhang Z, Kandhavelu J, Klotzbier W, Jayatilake M, Bansal S, Farhan M, Deol S, Banerjee PP, Unger K, Gupta S, Verma V, Cheema AK. Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer. Signal Transduct Target Ther 11(1):31, 2026. e-Pub 2026. PMID: 41545338.
Mirzaei R, McNeil R, D'Mello C, Wong B, Sarkar S, Visser F, Poon C, Bose P, Yong VW. Spatial single-cell profiling identifies protein kinase Cdelta-expressing microglia with anti-tumor function in glioblastoma. iScience 29(1):114281, 2026. e-Pub 2026. PMID: 41503214.
Breitenmoser L, Eggimann S, Sharma A, Bose P, Campling P, Hugi C. Phosphorus recovery from Indian sewage sludge by acidification and precipitation. Sci Rep 16(1):3804, 2026. e-Pub 2026. PMID: 41530349.
Srinivasan T, Mallik N, Bose P, Kumar A, Lal B, Jawallia K, Sharma P, Sreedharanunni S, Sachdeva MUS, Das R, Khadwal A, Malhotra P, Tehran A. Comparative Analysis of 12 Flow Cytometry-Based Markers in B-Lymphoblastic Leukemia/Lymphoma and Their Utility in Detecting Minimal/Measurable Residual Disease. Int J Lab Hematol, 2025. e-Pub 2025. PMID: 41466451.
Bose P, Sau S. A replication stress safeguard provided by the Elg1 Replication Factor C-like complex. Genetics 231(4), 2025. e-Pub 2025. PMID: 40985265.
Marchetti, M, Vannucchi, AM, Mascarenhas, J, Alvarez-Larrán, A, Bose, P, Gale, RP, Harrison, C, Hehlmann, R, Kiladjian, JJ, Koschmieder, S, Mesa, RA, Passamonti, F, Rambaldi, A, Tefferi, A, Barbui, T. European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41285724.
Srinivasan T, Mallik N, Sachdeva MUS, Bose P, Kumar A, Lal B, Sharma P, Sreedharanunni S, Malhotra P, Trehan A. CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute Lymphoblastic Leukemia. Eur J Haematol 115(6):591-598, 2025. e-Pub 2025. PMID: 40944441.
Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica, 2025. e-Pub 2025. PMID: 41262043.
Thies JL, Appleseth HJ, Yamaguchi N, Bose PG, Speen AM, Peraza N, Cobos-Uribe C, Perryman AA, Tackett AP, Rebuli ME. IQOS product use in adults who smoke cigarettes daily does not change respiratory inflammatory markers. medRxiv, 2025. e-Pub 2025. PMID: 41332829.
Fiskus, WC, Masarova, L, Mill, CP, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Manshouri, T, Dunbar, A, Sharma, S, Kadia, TM, DiNardo, C, Bose, P, Pemmaraju, N, Loghavi, S, Su, X, Rampal, R, Törngren, M, Bhalla, K. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Advances 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
Mascarenhas, J, Bose, P, Hillis, C, Yacoub, A, El Chaer, F, Maze, D, Abu-Zeinah, G, Qin, A, Priego, V, Tashi, T, Cerquozzi, S, Babu, S, Foltz, L, Goel, S, Bhave, RR, Lee, S, Oh, ST, Reeves, B, Benton, CB, Fletcher, L, Sirhan, S, Safah, HF, Salib, H, Villeneuve, PJ, Zagrijtschuk, O, Castro, H, Masarova, L. ECLIPSE-PV. Acta haematologica 148(6):675-681, 2025. e-Pub 2025. PMID: 40043697.
Mesa, RA, Gill, H, Zhang, L, Jin, J, Kirito, K, Komatsu, N, Qin, A, Xiao, Z, Tashi, T, Shimoda, K, Ohishi, K, Chen, S, Zuo, X, Shirane, S, Hu, Y, Zhang, SJ, Wang, Y, Takenaka, K, Ichii, M, Xu, N, Shih, LY, Lim, KH, Lee, SE, Bae, SH, Teo, WZ, Maze, D, Oh, ST, Bose, P, Sato, T, Zagrijtschuk, O, Lin, S, Shih, WJ, Mascarenhas, J, Masarova, L. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET). The Lancet Haematology 12(11):e862-e875, 2025. e-Pub 2025. PMID: 41193116.
Bose P, Desikan P, Khan Z, Panwalkar N, Rangnekar A. A hospital-based epidemiological study of the genes coding for carbapenemase production among carbapenem resistant Acinetobacter isolates in India. Indian J Med Microbiol 58:100983, 2025. e-Pub 2025. PMID: 40998170.
Thies JL, Appleseth HJ, Yamaguchi N, Bose PG, Speen AM, Peraza N, Cobos-Uribe C, Perryman AA, Graham AA, Tackett AP, Rebuli ME. Noninvasive repeated sampling technique reveals specific respiratory cytokine signatures for electronic-cigarette and dual-product users obtained from a remote cohort of young adults. medRxiv, 2025. e-Pub 2025. PMID: 41282787.
Bose, P, Nagler, E, Nawaz, MS, Rampal, R, Tashi, T, Thota, S, Mascarenhas, J. Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera. Annals of Hematology 104(10):5063-5075, 2025. e-Pub 2025. PMID: 41091181.
Ghahremanifard P, An J, Chanda A, Chan AMY, Nakoneshny SC, Matthews TW, Chandarana SP, Hart RD, Hyrcza MD, Dort JC, Bonni S, Bose P. PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma. Cancers (Basel) 17(17), 2025. e-Pub 2025. PMID: 40941002.
Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
Makhoul, J, Chiu, CY, Berthelot, C, Mays, SR, Bose, P, John, TM. Ruxolitinib Meets a Forgotten Malady. Clinical Infectious Diseases 81(2):355-357, 2025. e-Pub 2025. PMID: 40971899.
Ghosh D, Halder P, Samanta P, Chowdhury G, Shaw S, Bose P, Roy D, Roy N, Kitahara K, Ramamurthy T, Koley H, Miyoshi SI, Dutta S, Mukhopadhyay AK. Lactose fermenting enteroinvasive Escherichia coli from diarrhoeal cases confers enhanced virulence. Sci Rep 15(1):24040, 2025. e-Pub 2025. PMID: 40617833.
Ghatak S, Bose P. Epstein-Barr Virus-Induced Minimal Change Disease: A Cause of Nephrotic Syndrome in Infectious Mononucleosis. Cureus 17(7):e87315, 2025. e-Pub 2025. PMID: 40655059.
Tsuda S, Hou J, Thompson FJ, Bose PK. Traumatic brain injury-induced anxiety: Injury and plasticity of the central noradrenergic system. Exp Neurol 388:115182, 2025. e-Pub 2025. PMID: 39929384.
Chen LS, Bose P, Qiao W, Jiang Y, Wu Q, Cruz ND, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy. Leuk Lymphoma 66(6):1166-1168, 2025. e-Pub 2025. PMID: 39921535.
Narasimhan R, Roy S, Koralla M, Thomas PK, Ilambarathi M, Balamurugan S, Harish M, Sabarinath R, Medikeri G, Bose P, Pattabhiraman VR, Rajasekar MK, Gayathri AR, Dhanasekar T, Nandagopal V, Gananathan G, Ravichandran SK, Shankar MN, Majumder A, Shamim S, Juvekar M, Singh VK, Mohankumar T, Prasanna Kumar S, Jash D, Bendre S, Neliyathodi S, Unnithan SJ, Karadkhele A. Expert Panel Consensus Recommendations for Allergic Rhinitis in Patients with Asthma in India. Pulm Ther 11(2):129-155, 2025. e-Pub 2025. PMID: 39414754.
Rampal, R, Grosicki, S, Chraniuk, D, Abruzzese, E, Bose, P, Gerds, A, Vannucchi, AM, Palandri, F, Lee, SE, Gupta, V, Lucchesi, A, Oh, ST, Kuykendall, A, Patriarca, A, Alvarez-Larrán, A, Mesa, RA, Kiladjian, JJ, Talpaz, M, Scandura, JM, Lavie, D, Harris, M, Kays, SK, Li, Q, Boxhammer, R, Brown, B, Jegg, AM, Harrison, C, Mascarenhas, J. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis. Nature medicine 31(5):1531-1538, 2025. e-Pub 2025. PMID: 40065169.
Wanner IB, McCabe JT, Huie JR, Harris NG, Paydar A, McMann-Chapman C, Tobar A, Korotcov A, Burns MP, Koehler RC, Wan J, Allende Labastida J, Tong J, Zhou J, Davis LM, Radabaugh HL, Ferguson AR, Van Meter TE, Febo M, Bose P, Wang KK, Kobeissy F, Apiliogullari S, Zhu J, Rubenstein R, Awwad HO. Prospective Harmonization, Common Data Elements, and Sharing Strategies for Multicenter Pre-Clinical Traumatic Brain Injury Research in the Translational Outcomes Project in Neurotrauma Consortium. J Neurotrauma 42(9-10):877-897, 2025. e-Pub 2025. PMID: 39831841.
Plott N, Rougraff A, Bose P, Tolliver KM, Waseem S, Hoskins BJ. A clear approach: Hemostatic gel as a novel adjunct for pediatric upper gastrointestinal bleeding. JPGN Rep 6(2):157-161, 2025. e-Pub 2025. PMID: 40386338.
Radabaugh HL, Harris NG, Wanner IB, Burns MP, McCabe JT, Korotcov AV, Dardzinski BJ, Zhou J, Koehler RC, Wan J, Allende Labastida J, Moghadas B, Bibic A, Febo M, Kobeissy FH, Zhu J, Rubenstein R, Hou J, Bose PK, Apiliogullari S, Beattie MS, Bresnahan JC, Rosi S, Huie JR, Ferguson AR, Wang KKW. Translational Outcomes Project in Neurotrauma (TOP-NT) Pre-Clinical Consortium Study: A Synopsis. J Neurotrauma 42(9-10):898-912, 2025. e-Pub 2025. PMID: 39841551.
Das SJ, Pathak B, Dutta S, Bose S, Bose PD. Role of serum endotoxin, FGF19, TLR2, TNF-alpha, IL-12 and IL-10 in NAFLD-associated T2DM pathogenesis: Insights into Th1 bias and protective mechanisms. Indian J Gastroenterol 44(2):171-180, 2025. e-Pub 2025. PMID: 38780878.
Bose P, Sobur KA, Lijon B, Rahman Z, Ahamed T, Sultana P, Muktaruzzaman M, Khatun M, Islam A. Characterization of enterotoxin, antibiotic resistance genes, and antimicrobial susceptibility profiling of Staphylococcus aureus isolated from table eggs: Implications for food safety and public health. Open Vet J 15(3):1187-1205, 2025. e-Pub 2025. PMID: 40276192.
Ray S, Bandyopadhyay S, Bhattacharjee P, Mukherjee P, Karmakar S, Bose P, Choudhury B, Paul D, Karak A. Drug-coated balloon in patients with in-stent restenosis: A prospective observational study. Indian Heart J 77(2):105-109, 2025. e-Pub 2025. PMID: 40043905.
Fiskus, WC, Mill, CP, Bose, P, Masarova, L, Pemmaraju, N, Dunbar, A, Birdwell, C, Davis, JA, Das, K, Hou, H, Manshouri, T, Jain, A, Malovannaya, A, Philip, K, Alhamadani, N, Matthews, A, Lin, K, Flores, L, Loghavi, S, DiNardo, C, Su, X, Rampal, R, Bhalla, K. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2025. e-Pub 2025. PMID: 39561280.
Gagnon R, Kish EK, Cook S, Takemura K, Cheng BYC, Bressler K, Heng DYC, Alimohamed N, Ruether D, Lee-Ying RM, Bose P, Kolinsky MP, Vasquez C, Samuel D, Lewis J, Faridi R, Borkar M, Fairey A, Bismar T, Yip S. Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer. Clin Genitourin Cancer 23(1):102274, 2025. e-Pub 2025. PMID: 39689666.
Bose P, Zhang W, Mehrpouya-Bahrami P, Collins K, Zhao J, Cannon AM, Albright E, Idrees MT, Perkins A, Gupta SK, Hon EC, Kaplan MH. Increased expression of proton pump and allergic inflammation genes predicts PPI failure in pediatric eosinophilic esophagitis. Dis Esophagus 38(1), 2025. e-Pub 2025. PMID: 39237116.
Bose P, Srikrishnarka P, Paatelainen M, Nonappa, Kini AR, Som A, Pradeep T. Nanocluster reaction-driven in situ transformation of colloidal nanoparticles to mesostructures. Nanoscale 17(2):803-812, 2025. e-Pub 2025. PMID: 39377419.
Masarova, L, Reeves, B, El Chaer, F, Foltz, L, Tashi, T, Abu-Zeinah, G, Lucas, J, Halpern, AB, Maze, D, Qin, A, Safah, HF, Lan, F, O'Connell, C, Goel, S, Rein, LA, Fang, B, How, J, Babu, S, Li, Z, Cerquozzi, S, Oh, ST, Hunter, AM, Podoltsev, N, Vachhani, P, Yacoub, A, Cunningham, JM, Hillis, C, Otoukesh, S, Zagrijtschuk, O, Castro, H, Bose, P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada. Frontiers in Medicine 12, 2025. e-Pub 2025. PMID: 40330782.
Harrison, C, Barbui, T, Bose, P, Kiladjian, JJ, Mascarenhas, J, McMullin, MF, Mesa, RA, Vannucchi, AM. Polycythaemia vera. Nature Reviews Disease Primers 11(1), 2025. e-Pub 2025. PMID: 40246933.
Mascarenhas, J, Maher, KR, Rampal, R, Bose, P, Podoltsev, N, Hong, J, Chai, Y, Kye, S, Method, M, Harrison, C. Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis. Future Oncology 21(7):807-813, 2025. e-Pub 2025. PMID: 39911057.
Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
Desai, RJ, Vachhani, P, Bose, P. Momelotinib–a tale of trials, tribulations, transfusion independence, and triumph. Expert Opinion on Drug Discovery 20(6):699-709, 2025. e-Pub 2025. PMID: 40405506.
Mughal, TI, Mascarenhas, J, Rampal, R, Bose, P, Lion, T, Ajufo, HO, Yacoub, A, Meshinchi, S, Masarova, L, Mesa, RA, Jamieson, C, Barbui, T, Saglio, G, van Etten, RA. Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms. Hematological Oncology 43(1), 2025. e-Pub 2025. PMID: 39825826.
Bakshi S, Puar S, Bose PP. The Sisyphean breath: role of anxiety sensitivity and distress tolerance in dyspnea among adults with asthma and COPD. J Asthma 62(1):64-72, 2025. e-Pub 2025. PMID: 39087926.
Hans C, Sharma P, Saini R, Sachdeva MUS, Khadwal AR, Bose PL, Das R. Bone Marrow Erythroblastic Dysplasia on Morphology Correlates Significantly with Flow Cytometric Apoptosis and Peripheral Blood Eryptosis. J Microsc Ultrastruct 13(1):1-7, 2025. e-Pub 2025. PMID: 40351748.
Bose P. . Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. The Lancet Haematology 12(11):e862-e875, 2025. e-Pub 2025.
Daksh S, Bose P, Kumar S, Kumar N, Kumaran SS, Verma YK, Deep S, Datta A. Tuned Manganese-Impregnated Mesoporous Silica Nanoparticles as a pH-Responsive Dual Imaging Probe. ACS Appl Bio Mater 7(12):8503-8516, 2024. e-Pub 2024. PMID: 39587397.
Nag S, Basu N, Bose P, Bandyopadhyay SK. A Novel Grammar-Based Approach for Patients' Symptom and Disease Diagnosis Information Dissemination to Maintain Confidentiality and Information Integrity. Bioengineering (Basel) 11(12), 2024. e-Pub 2024. PMID: 39768084.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
Singla S, Sreedharanunni S, Singh A, Singh C, Bose P, Kumar A, Balakrishnan A, Jain A, Khadwal A, Lad D, Prakash G, Sharma P, Mallik N, Sachdeva MUS, Das R, Malhotra P. Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma. Ann Hematol 103(12):5473-5481, 2024. e-Pub 2024. PMID: 39264433.
Rahman MZ, Islam MA, Bose P, Khatun MM, Parvin R. Immune response and protective efficacy of an experimentally developed inactivated oil adjuvant Brucella abortus vaccine in BALB/c mice. J Adv Vet Anim Res 11(4):914-923, 2024. e-Pub 2024. PMID: 40013279.
Rajwani J, Vishnevskiy D, Turk M, Naumenko V, Gafuik C, Kim DS, Mah LK, Snelling S, Gonzales GA, Xue J, Chanda A, Potts KG, Todesco HM, Lau KCK, Hildebrand KM, Chan JA, Liao S, Monument MJ, Hyrcza M, Bose P, Jenne CN, Canton J, Zemp FJ, Mahoney DJ. VSV(∆M51) drives CD8(+) T cell-mediated tumour regression through infection of both cancer and non-cancer cells. Nat Commun 15(1):9933, 2024. e-Pub 2024. PMID: 39548070.
Kim DH, Jia F, Patel KP, Bose P, Wang SA, Bueso-Ramos C, Ok CY. Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow. Clin Lymphoma Myeloma Leuk 24(11):e878-e882, 2024. e-Pub 2024. PMID: 39107203.
Patysheva MR, Kolegova ES, Khozyainova AA, Prostakishina EA, Korobeynikov VY, Menyailo ME, Iamshchikov PS, Loos DM, Kovalev OI, Zavyalova MV, Fedorova IK, Kulbakin DE, Larionova IV, Polyakov AP, Yakovleva LP, Kropotov MA, Sukortseva NS, Lu Y, Jia L, Arora R, Choinzonov EL, Bose P, Denisov EV. Revealing molecular mechanisms of early-onset tongue cancer by spatial transcriptomics. Sci Rep 14(1):26255, 2024. e-Pub 2024. PMID: 39482351.
Gagelmann N, Bose P, Gupta V, McLornan DP, Vachhani P, Al-Ali HK, Ali H, Treskes P, Buckley S, Roman-Torres K, Scott B. Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. Clin Lymphoma Myeloma Leuk 24(11):796-803, 2024. e-Pub 2024. PMID: 39034203.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison CN, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kröger N, Kuykendall AT, Loscocco GG, Mascarenhas JO, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani AD, Patel AA, Pemmaraju N, Rambaldi A, Rampal RK, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi AM, Barbui T. Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood 144(17):1813-1820, 2024. e-Pub 2024. PMID: 39116296.
Saj F, Vasudevan Nampoothiri R, Lad D, Jandial A, Sachdeva MUS, Bose P, Varma N, Khadwal A, Prakash G, Malhotra P. Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib. Indian J Hematol Blood Transfus 40(4):580-587, 2024. e-Pub 2024. PMID: 39469161.
Gerds AT, Harrison CN, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji RS, Bose P, Kremyanskaya M, Mead A, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC MD, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Advances 8(17):4511-4522, 2024. e-Pub 2024. PMID: 38820422.
Kashyap N, Das CR, Datta R, Begum A, Islam M, Bose S, Bose PD. Unravelling the oxygen factor - An investigation of transcriptional activation of hypoxia associated placental angiogenesis in recurrent pregnancy loss (RPL) patients from Assam, India. Placenta 154:66-73, 2024. e-Pub 2024. PMID: 38905849.
Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology 85(3):503-509, 2024. e-Pub 2024. PMID: 38973399.
Cerrato-Izaguirre D, Gonzalez-Ruiz J, Diaz-Chavez J, Ramirez A, Scavuzzo A, Jimenez MA, Cortes-Gonzalez C, Rubio JA, Perez-Montiel MD, Garcia-Cuellar CM, Herrera LA, Sanchez-Perez Y, Vaca-Paniagua F, Barquet-Munoz S, Cantu-de-Leon D, Bose P, Prada D. Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study. Discov Oncol 15(1):378, 2024. e-Pub 2024. PMID: 39196408.
Bose P. Momelotinib for the treatment of myelofibrosis. Blood 144(7):708-713, 2024. e-Pub 2024. PMID: 38958484.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
Chacko, B, Chaudhry, D, Peter, JV, Khilnani, GC, Saxena, P, Sehgal, IS, Ahuja, K, Rodrigues, C, Modi, M, Jaiswal, A, Joel Jasiel, G, Sahasrabudhe, S, Bose, P, Ahuja, A, Suprapaneni, V, Prajapat, B, Manesh, A, Chawla, R, Guleria, R. ISCCM Position Statement on the Approach to and Management of Critically Ill Patients with Tuberculosis. Indian Journal of Critical Care Medicine 28(S2):S67-S91, 2024. e-Pub 2024. PMID: 39234233.
Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Mascarenhas J, Mathews V, Passamonti F, Harrison C. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38(8):1831-1838, 2024. e-Pub 2024.
Tsuda S, Golam M, Hou J, Wang KKW, Thompson FJ, Bose P. Reduction of epinephrine in the lumbar spinal cord following repetitive blast-induced traumatic brain injury in rats. Neural Regen Res 19(7):1548-1552, 2024. e-Pub 2024. PMID: 38051898.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol 99(7):1434-1436, 2024. e-Pub 2024. PMID: 38613831.
Vatsayan R, Jain A, Jandial A, Bose P, Sachdeva MUS, Varma N, Jain A, Prakash G, Khadwal A, Malhotra P. Aberrant baseline cytokine profile in patients with newly diagnosed acquired aplastic anaemia correlates with disease severity and the treatment response. Blood Cells Mol Dis 107:102857, 2024. e-Pub 2024. PMID: 38815307.
Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, N, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Kadia, TM, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2), 2024. e-Pub 2024. PMID: 40454402.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. Haematologica 109(6):1977-1983, 2024. e-Pub 2024. PMID: 38268448.
Nwogbo OV, Fang H, Wang W, Xu J, Miranda RN, Bose P, Ok CY, Jorgensen JL, Medeiros LJ, Wang SA. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. Am J Clin Pathol 161(6):598-608, 2024. e-Pub 2024. PMID: 38372648.
Bean L, Bose PK, Rani A, Kumar A. Serine racemase expression profile in the prefrontal cortex and hippocampal subregions during aging in male and female rats. Aging (Albany NY) 16(10):8402-8416, 2024. e-Pub 2024. PMID: 38761177.
Balasubramaniam S, Bose P, Raviganesh PK, Pandian P, Selvaraj B, Sivaprakasam R, Balaji S, Am A, Sivakumar P, Ramasubramanian S. Vaccination and Its Impact on Lung Involvement in COVID-19 Patients: A Retrospective Study in India. Cureus 16(4):e58904, 2024. e-Pub 2024. PMID: 38800182.
Sharma P, Bose P, Mallik N, Gupta DG, Rachagiri S, Kumar A, Kaur J, Malhotra P, Varma N, Sachdeva MUS. FLAER as a standalone reagent for paroxysmal nocturnal hemoglobinuria: Do we need to reconsider the guidelines for testing?. Int J Lab Hematol 46(2):383-389, 2024. e-Pub 2024. PMID: 38069562.
Bose P, Singh M, Gupta A, Kumar S, Ansari FJ, Pandey VK, Singh AS, Tiwari VK. Design, synthesis, and docking study of saccharin N-triazolyl glycoconjugates. Carbohydr Res 538:109101, 2024. e-Pub 2024. PMID: 38574410.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Berner A, Das RN, Bhuma N, Golebiewska J, Abrahamsson A, Andreasson M, Chaudhari N, Doimo M, Bose PP, Chand K, Stromberg R, Wanrooij S, Chorell E. G4-Ligand-Conjugated Oligonucleotides Mediate Selective Binding and Stabilization of Individual G4 DNA Structures. J Am Chem Soc 146(10):6926-6935, 2024. e-Pub 2024. PMID: 38430200.
Gupta DG, Varma N, Abdulkadir SA, Sreedharanunni S, Sachdeva MUS, Naseem S, Bose P, Binota J, Malhotra P, Khadwal A, Trehan A, Varma S. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia. Cancer 130(5):713-726, 2024. e-Pub 2024. PMID: 37819686.
Thompson A, James B, David R, Youseff M, Gill N, Jefferies M, Bose P, Swamy GK. Urothelial Malignancy After Normal Hematuria Clinic Investigations: Does Non-visible Hematuria Need Reinvestigation?. Urol Res Pract 50(2):102-106, 2024. e-Pub 2024. PMID: 39128127.
Sarkar S, Chanda A, Khanolkar RA, Lambie M, Ailles L, Bratman SV, Narendran A, Bose P. Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and gamma-Radiation Therapy. Biomedicines 12(3), 2024. e-Pub 2024. PMID: 38540116.
Kumar N, Bose P, Kumar S, Daksh S, Verma YK, Roy BG, Som S, Singh JD, Datta A. Nanoapatite-Loaded kappa-Carrageenan/Poly(vinyl alcohol)-Based Injectable Cryogel for Hemostasis and Wound Healing. Biomacromolecules 25(2):1228-1245, 2024. e-Pub 2024. PMID: 38235663.
Deyssenroth MA, Williams RP, Lesseur C, Jacobson SW, Jacobson JL, Cheng H, Bose P, Li Q, Wainwright H, Meintjes EM, Hao K, Chen J, Carter RC. Prenatal alcohol exposure is associated with changes in placental gene co-expression networks. Sci Rep 14(1):2687, 2024. e-Pub 2024. PMID: 38302628.
Gupta L, Suku P, Dash A, Bose P, Sharma P, Mallik N, Sreedharanunni S, Varma N, Jandial A, Malhotra P, Sachdeva MUS. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters. Curr Probl Cancer 48:101025, 2024. e-Pub 2024. PMID: 37951052.
Bose P, Chowdhury G, Halder G, Ghosh D, Deb AK, Kitahara K, Miyoshi SI, Morita M, Ramamurthy T, Dutta S, Mukhopadhyay AK. Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019. PLoS Negl Trop Dis 18(2):e0011964, 2024. e-Pub 2024. PMID: 38377151.
Hunter AM, Bose P. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother 25(10):1391-1404, 2024. e-Pub 2024. PMID: 39067001.
Baron N, Purushotham R, Pullaiahgari D, Bose P, Zarivach R, Shapira M. LeishIF4E2 is a cap-binding protein that plays a role in Leishmania cell cycle progression. FASEB J 38(1):e23367, 2024. e-Pub 2024. PMID: 38095329.
Gupta DG, Varma N, Abdulkadir SA, Singh P, Sachdeva MUS, Naseem S, Siddiqui MR, Bose P, Binota J, Malhotra P, Khadwal A, Varma S. Identification and validation of the optimal reference genes for standardizing the gene expression profiling diagnostic panel of Ph-like B-lineage acute lymphoblastic leukemia. Clin Exp Med 23(8):4539-4551, 2023. e-Pub 2023. PMID: 37470909.
Gupta DG, Varma N, Sharma P, Truica MI, Abdulkadir SA, Singh P, Singh Sachdeva MU, Naseem S, Siddiqui MR, Bose P, Binota J, Malhotra P, Khadwal A, Trehan A, Varma S. Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India. Cancer 129(21):3390-3404, 2023. e-Pub 2023. PMID: 37498973.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Moving toward disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. e-Pub 2023. PMID: 37729609.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 7(19):5835-5842, 2023. e-Pub 2023. PMID: 37552106.
Bose P, Chacko B, Arul AO, Robinson Vimala L, Thangakunam B, Varghese GM, Jambugulam M, Lenin A, Peter JV. Delayed inflammatory pulmonary syndrome: A distinct clinical entity in the spectrum of inflammatory syndromes in COVID-19 infection?. World J Crit Care Med 12(4):226-235, 2023. e-Pub 2023. PMID: 37745259.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Abu Rayhan MS, Rahman MS, Bose PK, Sarower MG, Ali MY. Estimating peak breeding season, size at first maturity and variation in fecundity and egg-size at different sizes of Hilsa (Tenualosa ilisha). Heliyon 9(9):e19420, 2023. e-Pub 2023. PMID: 37681140.
Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, Samuel D, Arora RK, Matthews TW, Chandarana S, Hart R, Dort JC, Biernaskie J, Neri P, Hyrcza MD, Bose P. Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun 14(1):5029, 2023. e-Pub 2023. PMID: 37596273.
Gupta M, Kannappan S, Jain M, Douglass D, Shah R, Bose P, Narendran A. Development and validation of a 21-gene prognostic signature in neuroblastoma. Sci Rep 13(1):12526, 2023. e-Pub 2023. PMID: 37532697.
Bose P, Singh M, Singh AS, Jaiswal MK, Tiwari VK. Design, Synthesis, and Docking Study of Quinine-9-Triazolyl Conjugates. Chem Biodivers 20(8):e202300478, 2023. e-Pub 2023. PMID: 37410812.
Gupta DG, Varma N, Sreedharanunni S, Abdulkadir SA, Naseem S, Sachdeva MUS, Binota J, Bose P, Malhotra P, Khadwal A, Varma S. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting. Br J Cancer 129(1):143-152, 2023. e-Pub 2023. PMID: 37156894.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
Bose P, Agrahari AK, Singh R, Singh M, Kumar S, Singh RK, Tiwari VK. Click inspired synthesis of piperazine-triazolyl sugar-conjugates as potent anti-Hela activity. Carbohydr Res 529:108846, 2023. e-Pub 2023. PMID: 37245419.
Bourhill T, Rohani L, Kumar M, Bose P, Rancourt D, Johnston RN. Modulation of Reoviral Cytolysis (II): Cellular Stemness. Viruses 15(7), 2023. e-Pub 2023. PMID: 37515162.
Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid 2(6):EVIDoa2200339, 2023. e-Pub 2023. PMID: 38320129.
Mirzaei R, D'Mello C, Liu M, Nikolic A, Kumar M, Visser F, Bose P, Gallo M, Yong VW. Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor-Initiating Cells. Cancer Res 83(10):1725-1741, 2023. e-Pub 2023. PMID: 37067922.
Bose P, Jaiswal MK, Singh SK, Singh RK, Tiwari VK. Growing impact of sialic acid-containing glycans in future drug discovery. Carbohydr Res 527:108804, 2023. e-Pub 2023. PMID: 37031650.
Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, Matthews TW, Chandarana S, Hart RD, Jones SJM, Dort JC, Itani D, Chanda A, Bose P. NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma. Cancer Gene Ther 30(5):752-765, 2023. e-Pub 2023. PMID: 36635327.
Gupta DG, Varma N, Kumar A, Naseem S, Sachdeva MUS, Sreedharanunni S, Binota J, Bose P, Khadwal A, Malhotra P, Varma S. Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients. Cancer 129(8):1217-1226, 2023. e-Pub 2023. PMID: 36738086.
Wilson PW, Cho C, Allsing N, Khanum S, Bose P, Grubschmidt A, Sant KE. Tris(4-chlorophenyl)methane and tris(4-chlorophenyl)methanol disrupt pancreatic organogenesis and gene expression in zebrafish embryos. Birth Defects Res 115(4):458-473, 2023. e-Pub 2023. PMID: 36470842.
Kumar M, Meode M, Blough M, Cairncross G, Bose P. PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. NPJ Genom Med 8(1):6, 2023. e-Pub 2023. PMID: 36841881.
Mock JR, Tune MK, Bose PG, McCullough MJ, Doerschuk CM. Comparison of different methods of initiating lung inflammation and the sex-specific effects on inflammatory parameters. Am J Physiol Lung Cell Mol Physiol 324(2):L199-L210, 2023. e-Pub 2023. PMID: 36594854.
Kashyap N, Islam M, Kaur H, Tiwari D, Begum A, Bose M, Das CR, Saikia AK, Kalita P, Bose PD, Bose S. Oxidative stress-A key determinant of complications and negative outcome in hepatitis E virus infected pregnancies: A comprehensive account involving cases from northeast India. J Med Virol 95(2):e28576, 2023. e-Pub 2023. PMID: 36779361.
Bose P, Kuykendall AT, Miller C, Kurtin S, Farina K, Harting DM, Mascarenhas JO, Mesa RA. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opinion on Pharmacotherapy 24(9):1091-1100, 2023. e-Pub 2023. PMID: 37163478.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol 146(6):522-529, 2023. e-Pub 2023. PMID: 37699357.
Bose P, Baron N, Pullaiahgari D, Ben-Zvi A, Shapira M. LeishIF3d is a non-canonical cap-binding protein in Leishmania. Front Mol Biosci 10:1191934, 2023. e-Pub 2023. PMID: 37325473.
Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini MS, Cavalieri S, Licitra L, Hoebers F, Brakenhoff RH, Leemans CR, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort JC, Shaikh MH, Ryan SEB, Dawson A, Khan MI, Howlett CJ, Stecho W, Plantinga P, Daniela da Silva S, Hier M, Khan H, MacNeil D, Mendez A, Yoo J, Fung K, Lang P, Winquist E, Palma DA, Ziai H, Amelio AL, Li SS, Boutros PC, Mymryk JS, Nichols AC. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine 86:104373, 2022. e-Pub 2022. PMID: 36442320.
Hasan A, Bose P, Aktar MT, Haque ZF, Islam MR, Hossain MT, Siddique MP. groEL gene-based molecular detection and antibiogram profile of Riemerella anatipestifer from duck in Bangladesh. J Adv Vet Anim Res 9(4):684-693, 2022. e-Pub 2022. PMID: 36714514.
Standing S, Tran S, Murguia-Favela L, Kovalchuk O, Bose P, Narendran A. Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers. Cancers (Basel) 14(23), 2022. e-Pub 2022. PMID: 36497424.
Reiter, A, Schwaab, J, DeAngelo, DJ, Gotlib, J, Deininger, M, Pettit, K, Alvarez-Twose, I, Vannucchi, AM, Panse, J, Platzbecker, U, Hermine, O, Dybedal, I, Lin, HM, Rylova, SN, Ehlert, K, Dimitrijevic, S, Radia, D, Drummond, MW, Hexner, E, Bose, P, Robinson, W, Hunter, AM, Tashi, T, Heaney, ML, Mesa, RA, Ustun, C, Oh, ST, Griffiths, EA, Sperr, WR, Livideanu, CB, Triggiani, M, Zanotti, R. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances 6(21):5750-5762, 2022. e-Pub 2022. PMID: 35640224.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Dellon ES, Gonsalves N, Abonia JP, Alexander JA, Arva NC, Atkins D, Attwood SE, Auth MKH, Bailey DD, Biederman L, Blanchard C, Bonis PA, Bose P, Bredenoord AJ, Chang JW, Chehade M, Collins MH, Di Lorenzo C, Dias JA, Dohil R, Dupont C, Falk GW, Ferreira CT, Fox AT, Genta RM, Greuter T, Gupta SK, Hirano I, Hiremath GS, Horsley-Silva JL, Ishihara S, Ishimura N, Jensen ET, Gutierrez-Junquera C, Katzka DA, Khoury P, Kinoshita Y, Kliewer KL, Koletzko S, Leung J, Liacouras CA, Lucendo AJ, Martin LJ, McGowan EC, Menard-Katcher C, Metz DC, Miller TL, Moawad FJ, Muir AB, Mukkada VA, Murch S, Nhu QM, Nomura I, Nurko S, Ohtsuka Y, Oliva S, Orel R, Papadopoulou A, Patel DA, Pesek RD, Peterson KA, Philpott H, Putnam PE, Richter JE, Rosen R, Ruffner MA, Safroneeva E, Schreiner P, Schoepfer A, Schroeder SR, Shah N, Souza RF, Spechler SJ, Spergel JM, Straumann A, Talley NJ, Thapar N, Vandenplas Y, Venkatesh RD, Vieira MC, von Arnim U, Walker MM, Wechsler JB, Wershil BK, Wright BL, Yamada Y, Yang GY, Zevit N, Rothenberg ME, Furuta GT, Aceves SS. International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clin Gastroenterol Hepatol 20(11):2474-2484.e3, 2022. e-Pub 2022. PMID: 35181570.
Saha J, Bose P, Dhakal S, Ghosh P, Rangachari V. Ganglioside-Enriched Phospholipid Vesicles Induce Cooperative Abeta Oligomerization and Membrane Disruption. Biochemistry 61(20):2206-2220, 2022. e-Pub 2022. PMID: 36173882.
Dey TK, Bose P, Paul S, Karmakar BC, Saha RN, Gope A, Koley H, Ghosh A, Dutta S, Dhar P, Mukhopadhyay AK. Protective efficacy of fish oil nanoemulsion against non-typhoidal Salmonella mediated mucosal inflammation and loss of barrier function. Food Funct 13(19):10083-10095, 2022. e-Pub 2022. PMID: 36094160.
Bose P, Jacobs AS, Cordova JG, Gray BW, Huff KA, Molleston JP. Endoscopy in Infants With Gastrointestinal Bleeding Has Limited Diagnostic or Therapeutic Benefit. J Pediatr Gastroenterol Nutr 75(4):514-520, 2022. e-Pub 2022. PMID: 35848737.
Rozovski, U, Veletik, I, Harris, D, Li, P, Liu, Z, Jain, P, Manshouri, T, Ferrajoli, A, Burger, JA, Bose, P, Thompson, PA, Jain, N, Wierda, WG, Verstovsek, S, Keating, M, Estrov, Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clinical Lymphoma, Myeloma and Leukemia 22:S271, 2022. e-Pub 2022. PMID: 36163878.
Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian JJ, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S335-S336, 2022. e-Pub 2022. PMID: 36164005.
Harrison, C, Bose, P, Mesa, RA, Gerds, A, Oh, ST, Kiladijan, JJ, Garcia-Gutierrez, V, Vannucchi, AM, Scheid, C, Sobas, M, Verstovsek, S, Buckley, S, Roman-Torres, K, Mascarenhas, J. MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia. Clinical Lymphoma, Myeloma and Leukemia 22:S326-S327, 2022. e-Pub 2022. PMID: 36163987.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. e-Pub 2022. PMID: 36164003.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. e-Pub 2022. PMID: 36164004.
Oh S, Mesa R, Harrison C, Bose P, Gerds A, Gupta V, Swami A, Tyavanagimatt S, Buckley S, Roman-Torres K, Verstovsek S. MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S327, 2022. e-Pub 2022. PMID: 36163989.
Julqarnain SM, Bose P, Rahman MZ, Khatun MM, Islam MA. Bacteriological quality and prevalence of foodborne bacteria in broiler meat sold at live bird markets at Mymensingh City in Bangladesh. J Adv Vet Anim Res 9(3):405-411, 2022. e-Pub 2022. PMID: 36382049.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033-1062, 2022. e-Pub 2022. PMID: 36075392.
Bose P, Goenka U, Moitra S, Majumdar S, Goenka MK, Sen SG. COVID-19 vaccine-associated myositis - a case report. Clin Case Rep 10(9):e6314, 2022. e-Pub 2022. PMID: 36110335.
Pan X, Taherzadeh M, Bose P, Heon-Roberts R, Nguyen ALA, Xu T, Para C, Yamanaka Y, Priestman DA, Platt FM, Khan S, Fnu N, Tomatsu S, Morales CR, Pshezhetsky AV. Glucosamine amends CNS pathology in mucopolysaccharidosis IIIC mouse expressing misfolded HGSNAT. J Exp Med 219(8), 2022. e-Pub 2022. PMID: 35704026.
Ray S, Bandyopadhyay S, Bhattacharjee P, Mukherjee P, Karmakar S, Bose PK, Mitra S, Dalui A, Ray S. Nano-crush technique in narrow-angle (<70 degrees ) bifurcation: bench test, CT reconstruction, fluid dynamics, and clinical outcomes. Minerva Cardiol Angiol 70(4):459-467, 2022. e-Pub 2022. PMID: 34472773.
Jiang J, Zhang L, Ming C, Zhou H, Bose P, Guo Y, Hu Y, Wang B, Chen Z, Jia R, Pendse S, Xiang Y, Xia Y, Lu Z, Wen X, Cai Y, Sun C, Wang GC, Lu TM, Gall D, Sun YY, Koratkar N, Fohtung E, Shi Y, Shi J. Giant pyroelectricity in nanomembranes. Nature 607(7919):480-485, 2022. e-Pub 2022. PMID: 35859196.
Bose P, Chang JW, Dellon ES, Furuta GT, Aceves SS, Gonsalves N. Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. J Pediatr Gastroenterol Nutr 74(6):e160-e161, 2022. e-Pub 2022. PMID: 35442234.
Gupta DG, Varma N, Kumar A, Naseem S, Sachdeva MUS, Bose P, Binota J, Gupta M, Sonam P, Rana P, Malhotra P, Varma S. Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia. Mol Biol Rep 49(6):4841-4848, 2022. e-Pub 2022. PMID: 35344115.
Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
Bose P, Mesa RA. Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leuk Lymphoma 63(4):1-15, 2022. e-Pub 2022. PMID: 34775887.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Vachhani P, Verstovsek S, Bose P. "Disease Modification" in Myelofibrosis: an elusive goal?. J Clin Oncol 40(11):1147-1154, 2022. e-Pub 2022. PMID: 35084934.
Abdulrahman GO, Das N, Chandrasekaran TV, Khot U, Drew PJ, Bose P, Vet JN, Tofazzal N, Roberts S, Lutchman Singh K. Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406539.
Bose P, Albright E, Idrees MT, Perkins A, Sawyers C, Gupta SK, Hon EC. Eosinophilic Esophagitis Symptom Scores Are High in Children Without Eosinophilic Disease. J Pediatr Gastroenterol Nutr 74(3):396-401, 2022. e-Pub 2022. PMID: 34636795.
Gupta DG, Varma N, Kumar A, Naseem S, Sachdeva MUS, Binota J, Bose P, Gupta M, Sonam P, Rana P, Malhotra P, Khadwal A, Trehan A, Varma S. PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients. Leuk Lymphoma 63(3):633-643, 2022. e-Pub 2022. PMID: 34783280.
Gupta DG, Varma N, Naseem S, Sachdeva MUS, Bose P, Binota J, Kumar A, Gupta M, Rana P, Sonam P, Malhotra P, Trehan A, Khadwal A, Varma S. Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients. Turk J Haematol 39(1):1-12, 2022. e-Pub 2022. PMID: 34617433.
Luige O, Karale K, Bose PP, Bollmark M, Tedebark U, Murtola M, Stromberg R. Influence of sequence variation on the RNA cleavage activity of Zn(2+)-dimethyl-dppz-PNA-based artificial enzymes. RSC Adv 12(9):5398-5406, 2022. e-Pub 2022. PMID: 35425588.
Esquer C, Echeagaray O, Firouzi F, Savko C, Shain G, Bose P, Rieder A, Rokaw S, Witon-Paulo A, Gude N, Sussman MA. Fundamentals of vaping-associated pulmonary injury leading to severe respiratory distress. Life Sci Alliance 5(2), 2022. e-Pub 2022. PMID: 34810278.
Gerds AT, Bose P, Hobbs GS, Kuykendall AT, Neilson LM, Song J, Klencke B, Harrison CN. Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: current evidence and real-world implications. Hemasphere 6(10):e778, 2022. e-Pub 2022. PMID: 36204692.
Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12(1):23, 2022. e-Pub 2022. PMID: 35102145.
Bose PS. Refugee research in the shadow of fear. GeoJournal 87(Suppl 2):195-207, 2022. e-Pub 2022. PMID: 33281274.
Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol 366:83-124, 2022. e-Pub 2022. PMID: 35153007.
Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med 27(12):2192-2199, 2021. e-Pub 2021. PMID: 34873345.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183-2191, 2021. e-Pub 2021. PMID: 34873347.
Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
Das SL, Bose P, Lejeune E, Reich DH, Chen C, Eyckmans J. Extracellular Matrix Alignment Directs Provisional Matrix Assembly and Three Dimensional Fibrous Tissue Closure. Tissue Eng Part A 27(23-24):1447-1457, 2021. e-Pub 2021. PMID: 33979548.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Mirzaei R, Gordon A, Zemp FJ, Kumar M, Sarkar S, Luchman HA, Bellail AC, Hao C, Mahoney DJ, Dunn JF, Bose P, Yong VW. PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFkappaB pathway. Sci Adv 7(45):eabh2148, 2021. e-Pub 2021. PMID: 34739319.
Begum A, Mishra A, Das CR, Das S, Dutta R, Kashyap N, Bose PD, Bose S. Impact of TNF-alpha profile in recurrent pregnancy loss pathogenesis: A patient based study from Assam. J Reprod Immunol 148:103430, 2021. e-Pub 2021. PMID: 34619412.
Bose PK, Ray D, Biswas P, Arafat SMY. Suicidal cut-throat wound during LSD intoxication. Clin Case Rep 9(11):e05100, 2021. e-Pub 2021. PMID: 34815882.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II Study of Azacitidine with Pembrolizumab in Patients with Intermediate-1 or Higher-Risk Myelodysplastic Syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
Sidhu J, Gogoi MP, Agarwal P, Mukherjee T, Saha D, Bose P, Roy P, Phadke Y, Sonawane B, Paul P, Saha V, Krishnan S. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer 68(11):e29046, 2021. e-Pub 2021. PMID: 33939263.
Luttrell HM, Bennett WE, Bose P. What's Inside of a AA Battery? An Unusual Caustic Ingestion in an Infant. JPGN Rep 2(4):e118, 2021. e-Pub 2021. PMID: 37206455.
Luige O, Bose PP, Stulz R, Steunenberg P, Brun O, Andersson S, Murtola M, Stromberg R. Zn(2+)-Dependent peptide nucleic acid-based artificial ribonucleases with unprecedented efficiency and specificity. Chem Commun (Camb) 57(83):10911-10914, 2021. e-Pub 2021. PMID: 34590632.
Bose P, Hon EC, Vitalpur GV, Bennett WE Jr. The Effects of Patient Demographics on Outpatient Endoscopy Utilization in Children With Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 73(4):537-541, 2021. e-Pub 2021. PMID: 33938526.
Gautam A, Sreedharanunni S, Sachdeva MUS, Rana S, Kashyap D, Bose P, Bal A, Prakash G, Malhotra P, Das R, Varma N. The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study. Int J Lab Hematol 43(5):1123-1131, 2021. e-Pub 2021. PMID: 33455071.
Sharma P, Singh Sachdeva MU, Varma N, Bose P, Aggarwal R, Malhotra P. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data. J Cancer Res Ther 17(6):1515-1520, 2021. e-Pub 2021. PMID: 34916387.
Mitra S, Rahman MH, Motalab M, Rakib T, Bose P. Tuning the mechanical properties of functionally graded nickel and aluminium alloy at the nanoscale. RSC Adv 11(49):30705-30718, 2021. e-Pub 2021. PMID: 35479865.
Dzikowski L, Mirzaei R, Sarkar S, Kumar M, Bose P, Bellail A, Hao C, Yong VW. Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells. Brain Pathol 31(5):e12947, 2021. e-Pub 2021. PMID: 33694259.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol 34(9):1673-1685, 2021. e-Pub 2021. PMID: 33990705.
Para C, Bose P, Bruno L, Freemantle E, Taherzadeh M, Pan X, Han C, McPherson PS, Lacaille JC, Bonneil E, Thibault P, O'Leary C, Bigger B, Morales CR, Di Cristo G, Pshezhetsky AV. Early defects in mucopolysaccharidosis type IIIC disrupt excitatory synaptic transmission. JCI Insight 6(15), 2021. e-Pub 2021. PMID: 34156977.
Virk H, Rana S, Sharma P, Bose PL, Yadav DD, Sachdeva MUS, Varma N, Trehan A, Lad D, Khadwal AR, Malhotra P, Sreedharanunni S. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. Ann Hematol 100(8):2031-2041, 2021. e-Pub 2021. PMID: 34159401.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
Tiwari D, Das CR, Sultana R, Kashyap N, Islam M, Bose PD, Saikia AK, Bose S. Increased homocysteine mediated oxidative stress as key determinant of hepatitis E virus (HEV) infected pregnancy complication and outcome: A study from Northeast India. Infect Genet Evol 92:104882, 2021. e-Pub 2021. PMID: 33905889.
Bose P, Verstovsek S. Avapritinib for Systemic Mastocytosis. Expert Rev Hematol 14(8):687-696, 2021. e-Pub 2021. PMID: 34289787.
Jain A, Khadwal A, Sachdeva MUS, Bose P, Lad D, Bhattacharya S, Prakash G, Malhotra P, Varma N, Varma S. Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post-transplant Period?. Indian J Hematol Blood Transfus 37(3):484-488, 2021. e-Pub 2021. PMID: 34267471.
Jain A, Deo P, Sachdeva MUS, Bose P, Lad D, Prakash G, Khadwal A, Varma N, Varma S, Malhotra P. Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. Blood Cells Mol Dis 89:102565, 2021. e-Pub 2021. PMID: 33831662.
Kapoor R, Sleeman WC 4th, Nalluri JJ, Turner P, Bose P, Cherevko A, Srinivasan S, Syed K, Ghosh P, Hagan M, Palta JR. Automated data abstraction for quality surveillance and outcome assessment in radiation oncology. J Appl Clin Med Phys 22(7):177-187, 2021. e-Pub 2021. PMID: 34101349.
Sharma R, Jamwal M, Senee HK, Uppal V, Hira JK, Bose P, Kumar N, Bansal D, Trehan A, Malhotra P, Ahluwalia J, Das R. Next-Generation Sequencing Based Approach to Identify Underlying Genetic Defects of Glanzmann Thrombasthenia. Indian J Hematol Blood Transfus 37(3):414-421, 2021. e-Pub 2021. PMID: 34267460.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
Sharma P, Sachdeva MUS, Kumar N, Bose S, Bose P, Uppal V, Malhotra P, Bansal D, Varma N, Ahluwalia J. A comparative study between light transmission aggregometry and flow cytometric platelet aggregation test for the identification of platelet function defects in patients with bleeding. Blood Res 56(2):109-118, 2021. e-Pub 2021. PMID: 34187944.
Roth S, Bose P, Alhamdani MSS, Mustafa SA, Tjaden C, Zamzow K, Hinz U, Michalski CW, Neoptolemos JP, Hoheisel JD, Buchler MW, Hackert T. Noninvasive Discrimination of Low and High-risk Pancreatic Intraductal Papillary Mucinous Neoplasms. Ann Surg 273(6):e273-e275, 2021. e-Pub 2021. PMID: 32649457.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Chowdhury G, Senapati T, Das B, Kamath A, Pal D, Bose P, Deb A, Paul S, Mukhopadhyay AK, Dutta S, Ramamurthy T. Laboratory evaluation of the rapid diagnostic tests for the detection of Vibrio cholerae O1 using diarrheal samples. PLoS Negl Trop Dis 15(6):e0009521, 2021. e-Pub 2021. PMID: 34129602.
Rahman MH, Islam MS, Islam MS, Chowdhury EH, Bose P, Jayan R, Islam MM. Phonon thermal conductivity of the stanene/hBN van der Waals heterostructure. Phys Chem Chem Phys 23(18):11028-11038, 2021. e-Pub 2021. PMID: 33942827.
Akerman S, Romero-Reyes M, Karsan N, Bose P, Hoffmann JR, Holland PR, Goadsby PJ. Therapeutic targeting of nitroglycerin-mediated trigeminovascular neuronal hypersensitivity predicts clinical outcomes of migraine abortives. Pain 162(5):1567-1577, 2021. e-Pub 2021. PMID: 33181579.
Karsan N, Perez-Rodriguez A, Nagaraj K, Bose PR, Goadsby PJ. The migraine postdrome: Spontaneous and triggered phenotypes. Cephalalgia 41(6):721-730, 2021. e-Pub 2021. PMID: 33423506.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327, 2021. e-Pub 2021. PMID: 33551345.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome. Leuk Lymphoma 62(5):1187-1194, 2021. e-Pub 2021. PMID: 33356689.
Karsan N, Bose P, Newman J, Goadsby PJ. Are some patient-perceived migraine triggers simply early manifestations of the attack?. J Neurol 268(5):1885-1893, 2021. e-Pub 2021. PMID: 33399964.
Sahu R, Kar RK, Sunita P, Bose P, Kumari P, Bharti S, Srivastava S, Pattanayak SP. LC-MS characterized methanolic extract of zanthoxylum armatum possess anti-breast cancer activity through Nrf2-Keap1 pathway: An in-silico, in-vitro and in-vivo evaluation. J Ethnopharmacol 269:113758, 2021. e-Pub 2021. PMID: 33359860.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Kapadia AB, Sharma P, Jain K, Sachdeva MUS, Bose PL, Gupta M, Khadwal AR, Bal A, Das R, Varma N. Evaluation of a flow cytometric test for G6PD-deficient erythrocytes. Trop Med Int Health 26(4):462-468, 2021. e-Pub 2021. PMID: 33415798.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol 144(5):484-499, 2021. e-Pub 2021. PMID: 33882481.
Ray Chowdhuri A, Spoorthi BK, Mondal B, Bose P, Bose S, Pradeep T. Ambient microdroplet annealing of nanoparticles. Chem Sci 12(18):6370-6377, 2021. e-Pub 2021. PMID: 34084436.
Akash TS, Subad RASI, Bose P, Islam MM. Nanomechanics of antimonene allotropes under tensile loading. Phys Chem Chem Phys 23(10):6241-6251, 2021. e-Pub 2021. PMID: 33735331.
Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res 23(1):29, 2021. e-Pub 2021. PMID: 33663585.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of Gli1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet Therapy with Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-mutated Acute Myeloid Leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
David RA, James B, Adeloye D, Bose P, Rai B, KandaSwamy GV. Accuracy of ultrasound vs computed tomography scan for upper urinary tract malignancies and development of a risk-based diagnostic algorithm for haematuria in a UK tertiary centre. Int Urol Nephrol 53(1):49-57, 2021. e-Pub 2021. PMID: 32844354.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver N, Kadia T, Chifotides H, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Venetoclax Combinations in Patients with Acute Leukemia from Myeloproliferative Neoplasms: Single Center Experience. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
Hildebrand KM, Singla AK, McNeil R, Marritt KL, Hildebrand KN, Zemp F, Rajwani J, Itani D, Bose P, Mahoney DJ, Jirik FR, Monument MJ. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade. PLoS One 16(7):e0253864, 2021. e-Pub 2021. PMID: 34242269.
Yang Z, Zhu T, Pompilus M, Fu Y, Zhu J, Arjona K, Arja RD, Grudny MM, Plant HD, Bose P, Wang KK, Febo M. Compensatory functional connectome changes in a rat model of traumatic brain injury. Brain Commun 3(4):fcab244, 2021. e-Pub 2021. PMID: 34729482.
Bose P, Roy S, Ghosh P. A Comparative NLP-Based Study on the Current Trends and Future Directions in COVID-19 Research. IEEE Access 9:78341-78355, 2021. e-Pub 2021. PMID: 34786315.
Chowdhury EH, Rahman MH, Bose P, Jayan R, Islam MM. Atomic-scale analysis of the physical strength and phonon transport mechanisms of monolayer beta-bismuthene. Phys Chem Chem Phys 22(48):28238-28255, 2020. e-Pub 2020. PMID: 33295342.
Ghahremanifard P, Chanda A, Bonni S, Bose P. TGF-beta Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33291370.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol 38(5):654-664, 2020. e-Pub 2020. PMID: 32592408.
Tsuda S, Golam M, Hou J, Nelson R, Bernavil P, Richardson K, Wang KKW, Thompson F, Bose P. Altered monoaminergic levels, spasticity, and balance disability following repetitive blast-induced traumatic brain injury in rats. Brain Res 1747:147060, 2020. e-Pub 2020. PMID: 32828734.
Bose P, Chakraborty P, Mohanty JS, Nonappa, Ray Chowdhuri A, Khatun E, Ahuja T, Mahendranath A, Pradeep T. Atom transfer between precision nanoclusters and polydispersed nanoparticles: a facile route for monodisperse alloy nanoparticles and their superstructures. Nanoscale 12(43):22116-22128, 2020. e-Pub 2020. PMID: 33118573.
Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, García-Gutiérrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 4(22):5825-5835, 2020. e-Pub 2020. PMID: 33232476.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Bullock N, Ellul T, Biers S, Armitage J, Cashman S, Narahari K, Tatarov O, Fenn N, Bose P, Featherstone J, Hughes O. Establishing a national high fidelity cadaveric emergency urology simulation course to increase trainee preparedness for independent on-call practice: a prospective observational study. BMC Med Educ 20(1):349, 2020. e-Pub 2020. PMID: 33028303.
De Boeck A, Ahn BY, D'Mello C, Lun X, Menon SV, Alshehri MM, Szulzewsky F, Shen Y, Khan L, Dang NH, Reichardt E, Goring KA, King J, Grisdale CJ, Grinshtein N, Hambardzumyan D, Reilly KM, Blough MD, Cairncross JG, Yong VW, Marra MA, Jones SJM, Kaplan DR, McCoy KD, Holland EC, Bose P, Chan JA, Robbins SM, Senger DL. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat Commun 11(1):4997, 2020. e-Pub 2020. PMID: 33020472.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
Hou J, Nelson R, Mohammad N, Mustafa G, Plant D, Thompson FJ, Bose P. Effect of Simultaneous Combined Treadmill Training and Magnetic Stimulation on Spasticity and Gait Impairments after Cervical Spinal Cord Injury. J Neurotrauma 37(18):1999-2013, 2020. e-Pub 2020. PMID: 32340533.
Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(9):1248-1269, 2020. e-Pub 2020. PMID: 32886902.
Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism 110:154297, 2020. e-Pub 2020. PMID: 32562798.
Suwathep P, Khan A, Husein R, Huasen B, Bose P, Brady M. Retroperitoneal fibrosis-the long and winding path. BJR Case Rep 6(2):20190086, 2020. e-Pub 2020. PMID: 33029368.
Tripathi A, Tyagi VK, Vivekanand V, Bose P, Suthar S. Challenges, opportunities and progress in solid waste management during COVID-19 pandemic. Case Stud Chem Environ Eng 2:100060, 2020. e-Pub 2020. PMID: 38620802.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
Bose P, Priyam A, Kar R, Pattanayak SP. Quercetin loaded folate targeted plasmonic silver nanoparticles for light activated chemo-photothermal therapy of DMBA induced breast cancer in Sprague Dawley rats. RSC Adv 10(53):31961-31978, 2020. e-Pub 2020. PMID: 35518142.
Rahman MH, Mitra S, Motalab M, Bose P. Investigation on the mechanical properties and fracture phenomenon of silicon doped graphene by molecular dynamics simulation. RSC Adv 10(52):31318-31332, 2020. e-Pub 2020. PMID: 35520677.
Awan MF, Bose P, Khaleghi A, Kansanen K, Balasingham I. Evaluation of Secrecy Capacity for Next-Generation Leadless Cardiac Pacemakers. IEEE Trans Biomed Eng 67(8):2297-2308, 2020. e-Pub 2020. PMID: 31831404.
Bose P, Verstovsek S. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma 61(8):1797-1809, 2020. e-Pub 2020. PMID: 32297800.
Murgai P, Sharma P, Sachdeva MUS, Bose PL, Gupta M, Das R, Varma N. A flow cytometric cell-cycle assay using methyl green. Anal Biochem 601:113782, 2020. e-Pub 2020. PMID: 32450059.
Theisen A, Bose P, Knight C, Oliver M. Leukoencephalopathy and cerebral edema as the presenting manifestations of SLE in an ANA-negative adolescent female: a case report and review of literature. Pediatr Rheumatol Online J 18(1):58, 2020. e-Pub 2020. PMID: 32660518.
Karsan N, Bose PR, Thompson C, Newman J, Goadsby PJ. Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study. Cephalalgia 40(8):828-841, 2020. e-Pub 2020. PMID: 32164428.
Karsan N, Bose PR, O'Daly O, Zelaya FO, Goadsby PJ. Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack. Headache 60(7):1244-1258, 2020. e-Pub 2020. PMID: 32568433.
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 29(6):525-536, 2020. e-Pub 2020. PMID: 32693648.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Jain A, Khadwal A, Sachdeva MUS, Bose P, Lad D, Bhattacharya S, Prakash G, Malhotra P, Varma N, Varma S. Variables affecting the presence of mesenchymal stromal cells in peripheral blood and their relationship with apheresis products. Br J Haematol 189(4):772-776, 2020. e-Pub 2020. PMID: 32011732.
Yarrow JF, Kok HJ, Phillips EG, Conover CF, Lee J, Bassett TE, Buckley KH, Reynolds MC, Wnek RD, Otzel DM, Chen C, Jiron JM, Graham ZA, Cardozo C, Vandenborne K, Bose PK, Aguirre JI, Borst SE, Ye F. Locomotor training with adjuvant testosterone preserves cancellous bone and promotes muscle plasticity in male rats after severe spinal cord injury. J Neurosci Res 98(5):843-868, 2020. e-Pub 2020. PMID: 31797423.
Sharma S, Ahluwalia J, Atreja CB, Modi M, Sachdeva MS, Kumar N, Bose P, Bose SK, Uppal V, Lal V, Varma N. Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients. J Thromb Thrombolysis 49(4):584-590, 2020. e-Pub 2020. PMID: 31701360.
Sarkar S, Yang R, Mirzaei R, Rawji K, Poon C, Mishra MK, Zemp FJ, Bose P, Kelly J, Dunn JF, Yong VW. Control of brain tumor growth by reactivating myeloid cells with niacin. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238578.
Tiwari D, Ray Das C, Sultana R, Kakoti S, Aasif Khan M, Dongre A, Husain SA, Bose PD, Bose S. Impact of modulation of telomerase and cancer stem-cell marker OCT4 axis in cervical cancer pathogenesis with underlying HPV16 infection. J Cell Biochem 121(4):2782-2791, 2020. e-Pub 2020. PMID: 31692038.
Roth S, Zamzow K, Gaida MM, Heikenwalder M, Tjaden C, Hinz U, Bose P, Michalski CW, Hackert T. Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer. EBioMedicine 54:102714, 2020. e-Pub 2020. PMID: 32259711.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
Bose P, Kumar S, Nebesio TD, Li C, Hon EC, Atkins D, Furuta GT, Gupta SK. Adrenal Insufficiency in Children With Eosinophilic Esophagitis Treated With Topical Corticosteroids. J Pediatr Gastroenterol Nutr 70(3):324-329, 2020. e-Pub 2020. PMID: 31688699.
Mishra N, Agrahari AK, Bose P, Singh SK, Singh AS, Tiwari VK. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors. Sci Rep 10(1):3586, 2020. e-Pub 2020. PMID: 32108142.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Bose P, Siddique MUM, Acharya R, Jayaprakash V, Sinha BN, Lapenna A, Pattanayak SP. Quinazolinone derivative BNUA-3 ameliorated [NDEA+2-AAF]-induced liver carcinogenesis in SD rats by modulating AhR-CYP1B1-Nrf2-Keap1 pathway. Clin Exp Pharmacol Physiol 47(1):143-157, 2020. e-Pub 2020. PMID: 31563143.
Sharma M, Varma N, Singh Sachdeva MU, Bose P, Varma S. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation. J Cancer Res Ther 16(1):105-109, 2020. e-Pub 2020. PMID: 32362618.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
Sarkar S, Li Y, Mirzaei R, Rawji KS, Poon CC, Wang J, Kumar M, Bose P, Yong VW. Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes. Front Immunol 11:272, 2020. e-Pub 2020. PMID: 32153581.
Obaid H, Kannappan S, Gupta M, Ruan Y, Zhang C, Bose P, Narendran A. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors. Curr Cancer Drug Targets 20(4):295-305, 2020. e-Pub 2020. PMID: 31713485.
Khan MA, Tiwari D, Dongre A, Sadaf, Mustafa S, Das CR, Massey S, Bose PD, Bose S, Husain SA. Exploring the p53 connection of cervical cancer pathogenesis involving north-east Indian patients. PLoS One 15(9):e0238500, 2020. e-Pub 2020. PMID: 32976537.
Roy D, Mahapatra T, Manna K, Kar A, Rana MS, Roy A, Bose PK, Banerjee B, Paul S, Chakraborty S. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. PLoS One 15(5):e0233230, 2020. e-Pub 2020. PMID: 32428019.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Acharya R, Chacko S, Bose P, Lapenna A, Pattanayak SP. Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer. Sci Rep 9(1):15743, 2019. e-Pub 2019. PMID: 31673107.
Arshee MR, Adnan S, Motalab M, Bose P. Inherent mechanical properties of bilayer germanene coupled by covalent bonding. RSC Adv 9(59):34437-34450, 2019. e-Pub 2019. PMID: 35529965.
Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, Bose P, Bebb DG, Lees-Miller SP. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. Br J Cancer 121(7):600-610, 2019. e-Pub 2019. PMID: 31481733.
Bose P, Tremblay E, Maios C, Narasimhan V, Armstrong GAB, Liao M, Parker JA, Robitaille R, Wen XY, Barden C, Drapeau P. The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis. Neurotherapeutics 16(4):1149-1166, 2019. e-Pub 2019. PMID: 31342410.
Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
Shen Y, Grisdale CJ, Islam SA, Bose P, Lever J, Zhao EY, Grinshtein N, Ma Y, Mungall AJ, Moore RA, Lun X, Senger DL, Robbins SM, Wang AY, MacIsaac JL, Kobor MS, Luchman HA, Weiss S, Chan JA, Blough MD, Kaplan DR, Cairncross JG, Marra MA, Jones SJM. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proc Natl Acad Sci U S A 116(38):19098-19108, 2019. e-Pub 2019. PMID: 31471491.
Rockley M, Hadziomerovic A, van Walraven C, Bose P, Scallan O, Jetty P. A new "angle" on aortic neck angulation measurement. J Vasc Surg 70(3):756-761.e1, 2019. e-Pub 2019. PMID: 30837183.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Singh AK, Mishra H, Firdaus Z, Yadav S, Aditi P, Nandy N, Sharma K, Bose P, Pandey AK, Chauhan BS, Neogi K, Vikram K, Srivastava A, Kar AG, Prakash P. MoS(2)-Modified Curcumin Nanostructures: The Novel Theranostic Hybrid Having Potent Antibacterial and Antibiofilm Activities against Multidrug-Resistant Hypervirulent Klebsiella pneumoniae. Chem Res Toxicol 32(8):1599-1618, 2019. e-Pub 2019. PMID: 31315397.
Bose P, Eyckmans J, Nguyen TD, Chen CS, Reich DH. Effects of Geometry on the Mechanics and Alignment of Three-Dimensional Engineered Microtissues. ACS Biomater Sci Eng 5(8):3843-3855, 2019. e-Pub 2019. PMID: 33438424.
Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv 3(15):2264-2271, 2019. e-Pub 2019. PMID: 31350306.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol 37(3):240-252, 2019. e-Pub 2019. PMID: 31013548.
Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol 42(8):649-654, 2019. e-Pub 2019. PMID: 31305287.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
Bose P, Verstovsek S. MF Management. Hemasphere 3(suppl 2):149-152, 2019. e-Pub 2019.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Bose P, Verstovsek S. MF management. Hemasphere 3(Suppl), 2019. e-Pub 2019. PMID: 35309812.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2019. PMID: 30575820.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2019. PMID: 30635233.
Datta AK, Das D, Bhattacharyya KB, Bose P, Mishra AK, Das SK. Frontal assessment battery in Parkinson's disease: A study on 170 patients. Neurol India 67(2):433-438, 2019. e-Pub 2019. PMID: 31085855.
Giri TK, Ghosh B, Bose P, Saha S, Sarkar A. Extraction of levetiracetam for therapeutic drug monitoring by transdermal reverse iontophoresis. Eur J Pharm Sci 128:54-60, 2019. e-Pub 2019. PMID: 30468869.
Kumar P, Bose PP. Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis. Drug Deliv Transl Res 9(1):249-259, 2019. e-Pub 2019. PMID: 30430452.
Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain 142(1):103-119, 2019. e-Pub 2019. PMID: 30596910.
Bose P, Armstrong GAB, Drapeau P. Neuromuscular junction abnormalities in a zebrafish loss-of-function model of TDP-43. J Neurophysiol 121(1):285-297, 2019. e-Pub 2019. PMID: 30461368.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Otzel DM, Conover CF, Ye F, Phillips EG, Bassett T, Wnek RD, Flores M, Catter A, Ghosh P, Balaez A, Petusevsky J, Chen C, Gao Y, Zhang Y, Jiron JM, Bose PK, Borst SE, Wronski TJ, Aguirre JI, Yarrow JF. Longitudinal Examination of Bone Loss in Male Rats After Moderate-Severe Contusion Spinal Cord Injury. Calcif Tissue Int 104(1):79-91, 2019. e-Pub 2019. PMID: 30218117.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of co-treatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Mainwaring AM, Wells H, Banks T, Ellul T, Bose P. Skeletal Muscle Metastasis to Vastus Lateralis from a Urothelial Carcinoma: A Case Report and Review of Its Diagnosis and Management. Case Rep Urol 2019:8923780, 2019. e-Pub 2019. PMID: 31886014.
Bose P. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs 7(10):415-425, 2019. e-Pub 2019. PMID: 33094033.
Desikan P, Rangnekar A, Khan Z, Panwalkar N, Bose P, Gulwani HV, Kaur S. Sero-Occurrence of HBV/HCV Co-infection and Levels of Liver Enzymes among Patients at a Tertiary Care Hospital in Central India: a Pilot Study. Cent Asian J Glob Health 8(1):313, 2019. e-Pub 2019. PMID: 31321151.
Bose P, Tarrant C, Mistri AK, Wilson A. Managing uncertainty: a qualitative study of GPs' views on the diagnosis and immediate management of transient ischaemic attack and the potential of a diagnostic tool. Fam Pract 35(6):738-743, 2018. e-Pub 2018. PMID: 29659795.
Pattanayak SP, Bose P, Sunita P, Siddique MUM, Lapenna A. Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways. Biomed Pharmacother 108:297-308, 2018. e-Pub 2018. PMID: 30227322.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(12):1500-1537, 2018. e-Pub 2018. PMID: 30545997.
Bose P, Khaleghi A, Albatat M, Bergsland J, Balasingham I. RF Channel Modeling for Implant-to-Implant Communication and Implant to Subcutaneous Implant Communication for Future Leadless Cardiac Pacemakers. IEEE Trans Biomed Eng 65(12):2798-2807, 2018. e-Pub 2018. PMID: 29993450.
Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun 9(1):4692, 2018. e-Pub 2018. PMID: 30410077.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-3, 2018. e-Pub 2018. PMID: 30242087.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
Sarkar S, Poon CC, Mirzaei R, Rawji KS, Hader W, Bose P, Kelly J, Dunn JF, Yong VW. Microglia induces Gas1 expression in human brain tumor-initiating cells to reduce tumorigenecity. Sci Rep 8(1):15286, 2018. e-Pub 2018. PMID: 30327548.
Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, Chan TA, Klimstra DS, Allis CD, Tang LH. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9(1):4158, 2018. e-Pub 2018. PMID: 30315258.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis 67(10):1610-1613, 2018. e-Pub 2018. PMID: 29771293.
Haque MW, Bose P, Siddique MUM, Sunita P, Lapenna A, Pattanayak SP. Taxifolin binds with LXR (alpha & beta) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway. Biomed Pharmacother 105:27-36, 2018. e-Pub 2018. PMID: 29843042.
Khurana H, Malhotra P, Sachdeva MU, Varma N, Bose P, Yanamandra U, Varma S, Khadwal A, Lad D, Prakash G. Danazol increases T regulatory cells in patients with aplastic anemia. Hematology 23(8):496-500, 2018. e-Pub 2018. PMID: 29415633.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(9):569-575.e1, 2018. e-Pub 2018. PMID: 30122201.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res 72(9):92-95, 2018. e-Pub 2018. PMID: 30118897.
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA. Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell 34(2):256-270.e5, 2018. e-Pub 2018. PMID: 30107176.
Karsan N, Bose P, Goadsby PJ. The Migraine Premonitory Phase. Continuum (Minneap Minn) 24(4, Headache):996-1008, 2018. e-Pub 2018. PMID: 30074545.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Bose P, Khaleghi A, Balasingham I. Wireless Channel Modeling for Leadless Cardiac Pacemaker: Effects ofVentricular Blood Volume. Annu Int Conf IEEE Eng Med Biol Soc 2018:3746-3749, 2018. e-Pub 2018. PMID: 30441181.
Bose P, Takei T, Li X, Minowa T, Rajmohan R, Vairaprakash P, Tashiro K. A Glutathione-Responsive Short Sequence of Metal-Organic Complex Array. Chembiochem, 2018. e-Pub 2018. PMID: 29806721.
Bhattacharjee S, Bose P, Patel K, Roy SG, Gain C, Gowda H, Robertson ES, Saha A. Transcriptional and epigenetic modulation of autophagy promotes EBV oncoprotein EBNA3C induced B-cell survival. Cell Death Dis 9(6):605, 2018. e-Pub 2018. PMID: 29789559.
Ziach K, Chollet C, Parissi V, Prabhakaran P, Marchivie M, Corvaglia V, Bose PP, Laxmi-Reddy K, Godde F, Schmitter JM, Chaignepain S, Pourquier P, Huc I. Single helically folded aromatic oligoamides that mimic the charge surface of double-stranded B-DNA. Nat Chem 10(5):511-518, 2018. e-Pub 2018. PMID: 29610464.
Das CR, Tiwari D, Dongre A, Khan MA, Husain SA, Sarma A, Bose S, Bose PD. Deregulated TNF-Alpha Levels Along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients. Viral Immunol 31(4):282-291, 2018. e-Pub 2018. PMID: 29608425.
Bose P, Swaminathan M. JAK inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34(5):1-6, 2018. e-Pub 2018. PMID: 29415577.
Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD, Khurana H, Sachdeva MUS, Bose P, Das R, Varma N, Varma S. Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. Indian J Hematol Blood Transfus 34(2):261-267, 2018. e-Pub 2018. PMID: 29622867.
Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang FF, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nat Commun 9(1):1057, 2018. e-Pub 2018. PMID: 29535300.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of Ruxolitinib in combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2018. PMID: 29134664.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep 6(1):155-611, 2018. e-Pub 2018. PMID: 29375856.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2018. PMID: 28919634.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
Shriwastav A, Ashok V, Thomas J, Bose P. A comprehensive mechanistic model for simulating algal-bacterial growth dynamics in photobioreactors. Bioresour Technol 247:640-651, 2018. e-Pub 2018. PMID: 28988050.
Bose P, Huang CY, Eyckmans J, Chen CS, Reich DH. Fabrication and Mechanical Properties Measurements of 3D Microtissues for the Study of Cell-Matrix Interactions. Methods Mol Biol 1722:303-328, 2018. e-Pub 2018. PMID: 29264812.
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clin Cancer Res 23(24):7521-7530, 2017. e-Pub 2017. PMID: 29246904.
Hobbs AJ, Brockton NT, Matthews TW, Chandarana SP, Bose P, Guggisberg K, Fick GH, Dort JC. Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study. Head Neck 39(11):2187-2199, 2017. e-Pub 2017. PMID: 28782304.
Brockton NT, Lohavanichbutr P, Enwere EK, Upton MP, Kornaga EN, Nakoneshny SC, Bose P, Chen C, Dort JC. Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients. Oncol Lett 14(5):5434-5442, 2017. e-Pub 2017. PMID: 29098033.
Tiwari D, Das CR, Bose PD, Bose S. Associative role of TYMS6bpdel polymorphism and resulting hyperhomocysteinemia in the pathogenesis of preterm delivery and associated complications: A study from Northeast India. Gene 627:129-136, 2017. e-Pub 2017. PMID: 28627444.
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58(9):1-17, 2017. e-Pub 2017. PMID: 28140720.
Hou J, Nelson R, Wilkie Z, Mustafa G, Tsuda S, Thompson FJ, Bose P. Mild and Mild-to-Moderate Traumatic Brain Injury-Induced Significant Progressive and Enduring Multiple Comorbidities. J Neurotrauma 34(16):2456-2466, 2017. e-Pub 2017. PMID: 28376701.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal Evolution and Outcomes in Myelofibrosis After Ruxolitinib Discontinuation. Blood 130(9):1125-31, 2017. e-Pub 2017. PMID: 28674026.
Singh SP, Guha S, Bose P. Impact of the composition of the bacterial population and additional carbon source on the pathway and kinetics of degradation of endosulfan isomers. Environ Sci Process Impacts 19(7):964-974, 2017. e-Pub 2017. PMID: 28657620.
Singh SP, Guha S, Bose P, Kunnikuruvan S. Mechanism of the Hydrolysis of Endosulfan Isomers. J Phys Chem A 121(27):5156-5163, 2017. e-Pub 2017. PMID: 28625063.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma. Leuk Lymphoma 58(6):1349-1357, 2017. e-Pub 2017. PMID: 28103725.
Shriwastav A, Thomas J, Bose P. A comprehensive mechanistic model for simulating algal growth dynamics in photobioreactors. Bioresour Technol 233:7-14, 2017. e-Pub 2017. PMID: 28258999.
Mustafa G, Hou J, Nelson R, Tsuda S, Jahan M, Mohammad NS, Watts JV, Thompson FJ, Bose P. Mild closed head traumatic brain injury-induced changes in monoamine neurotransmitters in the trigeminal subnuclei of a rat model: mechanisms underlying orofacial allodynias and headache. Neural Regen Res 12(6):981-986, 2017. e-Pub 2017. PMID: 28761433.
Bose P, Wilson A, Mistri A. Diagnosis and management of transient ischemic attacks in primary care: a systematic review. J Prim Health Care 9(2):114-130, 2017. e-Pub 2017. PMID: 29530223.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is Frequently Low in Patients with Myelofibrosis: Clinical Relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel Hematological Parameters for the Evaluation of Patients with Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
Krishnan P, Kartikueyan R, Patel SM, Bose PP, Mukherjee KK. Two Cases of Esophageal Injury Following Anterior Cervical Discectomy and Fusion: One Overt and One Covert. Ann Neurosci 24(2):126-130, 2017. e-Pub 2017. PMID: 28588368.
Santos MA, Bose PS, Maher S, Desai M. Chylous Ascites: An Unusual Complication of Necrotizing Pancreatitis. Am J Med 130(4):e151-e152, 2017. e-Pub 2017. PMID: 28159182.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2017. PMID: 27494751.
Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
Mafeld S, Nesbitt C, McCaslin J, Bagnall A, Davey P, Bose P, Williams R. Three-dimensional (3D) printed endovascular simulation models: a feasibility study. Ann Transl Med 5(3):42, 2017. e-Pub 2017. PMID: 28251121.
Sharma M, Sachdeva MUS, Bose P, Varma N, Varma S, Marwaha RK, Malhotra P. Haematological profile of patients with mixed-phenotype acute leukaemia from a tertiary care centre of north India. Indian J Med Res 145(2):215-221, 2017. e-Pub 2017. PMID: 28639598.
Bai L, Bose P, Gao Q, Li Y, Ganguly R, Zhao Y. Halogen-Assisted Piezochromic Supramolecular Assemblies for Versatile Haptic Memory. J Am Chem Soc 139(1):436-441, 2017. e-Pub 2017. PMID: 27966920.
Bose PP, Kumar P. High-throughput clone screening followed by protein expression cross-check: A visual assay platform. Anal Biochem 516:48-56, 2017. e-Pub 2017. PMID: 27756547.
Bommannan K, Singh Sachdeva MU, Varma N, Bose P, Bansal D. Role of Mid-induction Peripheral Blood Minimal Residual Disease Detection in Pediatric B-Lineage Acute Lymphoblastic Leukemia. Indian Pediatr 53(12):1065-1068, 2016. e-Pub 2016. PMID: 27889709.
Bose P, Verstovsek S. Investigational histone dea¬cetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs 25(12):1393-1403, 2016. e-Pub 2016. PMID: 27756180.
Bose P, Verstovsek S. Myelofibrosis: An Update on Drug Therapy in 2016. Expert Opin Pharmacother 17(18):2375-2389, 2016. e-Pub 2016. PMID: 27774820.
Bai L, Tou LJ, Gao Q, Bose P, Zhao Y. Remarkable colorimetric sensing of heavy metal ions based on thiol-rich nanoframes. Chem Commun (Camb) 52(94):13691-13694, 2016. e-Pub 2016. PMID: 27819081.
Bose PP, Kumar P. Visual assessment of parasitic burden in infected macrophage by plasmonic detection of leishmania specific marker RNA. Biochem Biophys Res Commun 480(1):81-86, 2016. e-Pub 2016. PMID: 27720714.
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 12(11):1-12, 2016. e-Pub 2016. PMID: 27686109.
Tiwari D, Bose PD, Sultana R, Das CR, Bose S. Preterm delivery and associated negative pregnancy outcome - A tale of faulty progesterone receptor signalling pathway and linked derailed immunomodulation: A study from Northeast India. J Reprod Immunol 118:76-84, 2016. e-Pub 2016. PMID: 27728856.
Bose P, Sukul PK, Yaghi OM, Tashiro K. Synthesis of a Water-soluble Metal-Organic Complex Array. J Vis Exp(116), 2016. e-Pub 2016. PMID: 27768089.
Bommannan K, Sachdeva MU, Gupta M, Bose P, Kumar N, Sharma P, Naseem S, Ahluwalia J, Das R, Varma N. Vortex-dislodged cells from bone marrow trephine biopsy yield satisfactory results for flow cytometric immunophenotyping. Int J Lab Hematol 38(5):543-9, 2016. e-Pub 2016. PMID: 27339905.
Aseervatham GS, Suryakala U, Doulethunisha, Sundaram S, Bose PC, Sivasudha T. Expression pattern of NMDA receptors reveals antiepileptic potential of apigenin 8-C-glucoside and chlorogenic acid in pilocarpine induced epileptic mice. Biomed Pharmacother 82:54-64, 2016. e-Pub 2016. PMID: 27470339.
Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30(8):1803-4, 2016. e-Pub 2016. PMID: 27198052.
Mustafa G, Hou J, Tsuda S, Nelson R, Sinharoy A, Wilkie Z, Pandey R, Caudle RM, Neubert JK, Thompson FJ, Bose P. Trigeminal neuroplasticity underlies allodynia in a preclinical model of mild closed head traumatic brain injury (cTBI). Neuropharmacology 107:27-39, 2016. e-Pub 2016. PMID: 26972829.
Tsuda S, Hou J, Nelson RL, Wilkie ZJ, Mustafa G, Sinharoy A, Watts JV, Thompson FJ, Bose PK. Prolonged hippocampal cell death following closed-head traumatic brain injury in rats. Neuroreport 27(10):724-9, 2016. e-Pub 2016. PMID: 27213933.
Bose PP, Bhattacharjee S, Singha S, Mandal S, Mondal G, Gupta P, Chatterjee BP. A glucose/mannose binding lectin from litchi (Litchi chinensis) seeds: Biochemical and biophysical characterizations. Biochem Biophys Rep 6:242-252, 2016. e-Pub 2016. PMID: 29214228.
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 7(27):42625-42638, 2016. e-Pub 2016. PMID: 27213589.
Bose PP, Kumar P, Dwivedi MK. Hemoglobin guided nanocarrier for specific delivery of amphotericin B to Leishmania infected macrophage. Acta Trop 158:148-159, 2016. e-Pub 2016. PMID: 26945483.
Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA. Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell 29(5):737-750, 2016. e-Pub 2016. PMID: 27165745.
Ananth DA, Rameshkumar A, Jeyadevi R, Aseervatham GSB, Sripriya J, Bose PC, Sivasudha T. Amelioratory effect of flavonoids rich Pergularia daemia extract against CFA induced arthritic rats. Biomed Pharmacother 80:244-252, 2016. e-Pub 2016. PMID: 27133063.
Mondal G, Saroha A, Bose PP, Chatterjee BP. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 33(2):209-18, 2016. e-Pub 2016. PMID: 27034286.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22(5):1067-75, 2016. e-Pub 2016. PMID: 26446942.
Sukul PK, Bose P, Takei T, Yaghi OM, He Y, Lee M, Tashiro K. A water-soluble metal-organic complex array as a multinuclear heterometallic peptide amphiphile that shows unconventional anion dependency in its self-assembly. Chem Commun (Camb) 52(8):1579-81, 2016. e-Pub 2016. PMID: 26558655.
Bose PP, Mandal G, Kumar D, Duseja A, Chatterjee BP. Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA--a new platform for cirrhosis diagnosis. Analyst 141(1):76-84, 2016. e-Pub 2016. PMID: 26568048.
Singha S, Dutta G, Bose PP, Das S, Bardhan M, Chatterjee BP, Ganguly T. Use of Spectroscopic Techniques to Reveal the Nature of the Interactions of Two Sialic Acid Specific Lectins with Gold Nanoparticles. J Nanosci Nanotechnol 16(1):515-25, 2016. e-Pub 2016. PMID: 27398481.
Sreedharanunni S, Sachdeva MU, Bose P, Varma N, Bansal D, Trehan A. Frequency of Paroxysmal Nocturnal Hemoglobinuria Clones by Multiparametric Flow Cytometry in Pediatric Aplastic Anemia Patients of Indian Ethnic Origin. Pediatr Blood Cancer 63(1):93-7, 2016. e-Pub 2016. PMID: 26230286.
Thompson FJ, Hou J, Bose PK. Closed-Head TBI Model of Multiple Morbidity. Methods Mol Biol 1462:521-36, 2016. e-Pub 2016. PMID: 27604736.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leuk Lymphoma 57(3):1-30, 2016. e-Pub 2016. PMID: 26284612.
Bose PP, Kumar P, Munagala N. Concurrent visual diagnosis and susceptibility profiling of the first line drug against visceral leishmaniasis by plasmonic detection of PCR amplified genetic biomarker. Acta Trop 152:208-214, 2015. e-Pub 2015. PMID: 26394185.
Bose P, Rompre PP, Warren RA. Neurotensin enhances glutamatergic EPSCs in VTA neurons by acting on different neurotensin receptors. Peptides 73:43-50, 2015. e-Pub 2015. PMID: 26296323.
Bai L, Gao Q, Xia Y, Ang CY, Bose P, Tan SY, Zhao Y. The photoirradiation induced p-n junction in naphthylamine-based organic photovoltaic cells. Nanoscale 7(35):14612-7, 2015. e-Pub 2015. PMID: 26263850.
Tripathi MK, Yasir M, Gurjar VS, Bose P, Dubey A, Shrivastava R. Insights from the Molecular Docking of Hydrolytic Products of Methyl Isocyanate (MIC) to Inhibition of Human Immune Proteins. Interdiscip Sci 7(3):287-94, 2015. e-Pub 2015. PMID: 26297312.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized Multicenter Phase 2 Study of Timed Sequential Therapy with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed Adult Acute Myeloid Leukemia (AML). Haematologica 100(9):172-179, 2015. e-Pub 2015. PMID: 26022709.
Bose P, Bai L, Ganguly R, Zou R, Zhao Y. Rational Design and Synthesis of a Highly Porous Copper-Based Interpenetrated Metal-Organic Framework for High CO(2) and H(2) Adsorption. Chempluschem 80(8):1259-1266, 2015. e-Pub 2015. PMID: 31973289.
Bose P, Bai L, Ganguly R, Zou R, Zhao Y. Frontispiece: Rational Design and Synthesis of a Highly Porous Copper-Based Interpenetrated Metal-Organic Framework for High CO(2) and H(2) Adsorption. Chempluschem 80(8), 2015. e-Pub 2015. PMID: 31973306.
Bai L, Yang X, Ang CY, Nguyen KT, Ding T, Bose P, Gao Q, Mandal AK, Sun XW, Demir HV, Zhao Y. A quinoxaline based N-heteroacene interfacial layer for efficient hole-injection in quantum dot light-emitting diodes. Nanoscale 7(27):11531-5, 2015. e-Pub 2015. PMID: 26091137.
Cusulin C, Chesnelong C, Bose P, Bilenky M, Kopciuk K, Chan JA, Cairncross JG, Jones SJ, Marra MA, Luchman HA, Weiss S. Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes. Stem Cell Reports 5(1):1-9, 2015. e-Pub 2015. PMID: 26095605.
Ramachandran D, Mulle JG, Locke AE, Bean LJ, Rosser TC, Bose P, Dooley KJ, Cua CL, Capone GT, Reeves RH, Maslen CL, Cutler DJ, Sherman SL, Zwick ME. Contribution of copy-number variation to Down syndrome-associated atrioventricular septal defects. Genet Med 17(7):554-60, 2015. e-Pub 2015. PMID: 25341113.
Xu F, Zhao R, Liu AS, Metz T, Shi Y, Bose P, Reich DH. A microfabricated magnetic actuation device for mechanical conditioning of arrays of 3D microtissues. Lab Chip 15(11):2496-503, 2015. e-Pub 2015. PMID: 25959132.
Bose P, Brockton NT, Guggisberg K, Nakoneshny SC, Kornaga E, Klimowicz AC, Tambasco M, Dort JC. Fractal analysis of nuclear histology integrates tumor and stromal features into a single prognostic factor of the oral cancer microenvironment. BMC Cancer 15:409, 2015. e-Pub 2015. PMID: 25976920.
Sachdeva MU, Varma N, Chandra D, Bose P, Malhotra P, Varma S. Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia. Ann Hematol 94(5):721-8, 2015. e-Pub 2015. PMID: 25465235.
Beggs LA, Ye F, Ghosh P, Beck DT, Conover CF, Balaez A, Miller JR, Phillips EG, Zheng N, Williams AA, Aguirre JI, Wronski TJ, Bose PK, Borst SE, Yarrow JF. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss. J Bone Miner Res 30(4):681-9, 2015. e-Pub 2015. PMID: 25359699.
Bai L, Wang P, Bose P, Li P, Zou R, Zhao Y. Macroscopic architecture of charge transfer-induced molecular recognition from electron-rich polymer interpenetrated porous frameworks. ACS Appl Mater Interfaces 7(9):5056-60, 2015. e-Pub 2015. PMID: 25707851.
Tiwari D, Bose PD, Das S, Das CR, Datta R, Bose S. MTHFR (C677T) polymorphism and PR (PROGINS) mutation as genetic factors for preterm delivery, fetal death and low birth weight: A Northeast Indian population based study. Meta Gene 3:31-42, 2015. e-Pub 2015. PMID: 25709895.
Tripathi MK, Yasir M, Gurjar VS, Bose P, Dubey A, Shrivastava R. Insights from the molecular docking of hydrolytic products of methyl iso cyanate (MIC) to inhibition of human immune proteins. Interdiscip Sci, 2015. e-Pub 2015. PMID: 25595583.
Dang M, Lysack JT, Wu T, Matthews TW, Chandarana SP, Brockton NT, Bose P, Bansal G, Cheng H, Mitchell JR, Dort JC. MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 36(1):166-70, 2015. e-Pub 2015. PMID: 25258367.
Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P. Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma 56(8):2424-8, 2015. e-Pub 2015. PMID: 25393804.
Cutler DJ, Zwick ME, Okou DT, Prahalad S, Walters T, Guthery SL, Dubinsky M, Baldassano R, Crandall WV, Rosh J, Markowitz J, Stephens M, Kellermayer R, Pfefferkorn M, Heyman MB, LeLeiko N, Mack D, Moulton D, Kappelman MD, Kumar A, Prince J, Bose P, Mondal K, Ramachandran D, Bohnsack JF, Griffiths AM, Haberman Y, Essers J, Thompson SD, Aronow B, Keljo DJ, Hyams JS, Denson LA, Kugathasan S. Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping. PLoS One 10(6):e0128074, 2015. e-Pub 2015. PMID: 26098103.
Rouibi K, Bose P, Rompre PP, Warren RA. Ventral Midbrain NTS1 Receptors Mediate Conditioned Reward Induced by the Neurotensin Analog, D-Tyr[11]neurotensin. Front Neurosci 9:470, 2015. e-Pub 2015. PMID: 26733785.
Whiteland H, Spencer-Harty S, Morgan C, Kynaston H, Thomas DH, Bose P, Fenn N, Lewis P, Jenkins S, Doak SH. A role for STEAP2 in prostate cancer progression. Clin Exp Metastasis 31(8):909-20, 2014. e-Pub 2014. PMID: 25248617.
Choong AM, Das S, Mulrenan N, Hamady M, Bose P. Don't get in a flap!: a case report of progression through the spectrum of an acute aortic syndrome. Vascular 22(6):454-7, 2014. e-Pub 2014. PMID: 24488171.
Ashok V, Shriwastav A, Bose P. Nutrient removal using algal-bacterial mixed culture. Appl Biochem Biotechnol 174(8):2827-38, 2014. e-Pub 2014. PMID: 25293638.
Vachhani P, Bose N, Brodeur JP, Holkova B, Bose P. Remission of rheumatoid arthritis on brentuximab vedotin. Rheumatology (Oxford) 53(12):2314-5, 2014. e-Pub 2014. PMID: 25239883.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20(22):5652-62, 2014. e-Pub 2014. PMID: 25248382.
Honcharenko D, Bose PP, Maity J, Kurudenkandy FR, Juneja A, Floistrup E, Biverstal H, Johansson J, Nilsson L, Fisahn A, Stromberg R. Synthesis and evaluation of antineurotoxicity properties of an amyloid-beta peptide targeting ligand containing a triamino acid. Org Biomol Chem 12(34):6684-93, 2014. e-Pub 2014. PMID: 25030615.
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323-36, 2014. e-Pub 2014. PMID: 24769080.
Sinha A, Bose P. Modeling of 2-chloronaphthalene interaction with high carbon iron filings (HCIF) in semi-batch and continuous systems. Environ Sci Pollut Res Int 21(17):10442-52, 2014. e-Pub 2014. PMID: 24764006.
Yarrow JF, Ye F, Balaez A, Mantione JM, Otzel DM, Chen C, Beggs LA, Baligand C, Keener JE, Lim W, Vohra RS, Batra A, Borst SE, Bose PK, Thompson FJ, Vandenborne K. Bone loss in a new rodent model combining spinal cord injury and cast immobilization. J Musculoskelet Neuronal Interact 14(3):255-66, 2014. e-Pub 2014. PMID: 25198220.
Hou J, Nelson R, Nissim N, Parmer R, Thompson FJ, Bose P. Effect of combined treadmill training and magnetic stimulation on spasticity and gait impairments after cervical spinal cord injury. J Neurotrauma 31(12):1088-106, 2014. e-Pub 2014. PMID: 24552465.
Bose PD, Das BC, Hazam RK, Kumar A, Medhi S, Kar P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. J Gen Virol 95(Pt 6):1266-1271, 2014. e-Pub 2014. PMID: 24622580.
Bose P, Thakur SS, Brockton NT, Klimowicz AC, Kornaga E, Nakoneshny SC, Riabowol KT, Dort JC. Tumor cell apoptosis mediated by cytoplasmic ING1 is associated with improved survival in oral squamous cell carcinoma patients. Oncotarget 5(10):3210-9, 2014. e-Pub 2014. PMID: 24912621.
Yarrow JF, Conover CF, Beggs LA, Beck DT, Otzel DM, Balaez A, Combs SM, Miller JR, Ye F, Aguirre JI, Neuville KG, Williams AA, Conrad BP, Gregory CM, Wronski TJ, Bose PK, Borst SE. Testosterone dose dependently prevents bone and muscle loss in rodents after spinal cord injury. J Neurotrauma 31(9):834-45, 2014. e-Pub 2014. PMID: 24378197.
Okou DT, Mondal K, Faubion WA, Kobrynski LJ, Denson LA, Mulle JG, Ramachandran D, Xiong Y, Svingen P, Patel V, Bose P, Waters JP, Prahalad S, Cutler DJ, Zwick ME, Kugathasan S. Exome sequencing identifies a novel FOXP3 mutation in a 2-generation family with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 58(5):561-8, 2014. e-Pub 2014. PMID: 24792626.
Bose P, Hermetz KE, Conneely KN, Rudd MK. Tandem repeats and G-rich sequences are enriched at human CNV breakpoints. PLoS One 9(7):e101607, 2014. e-Pub 2014. PMID: 24983241.
Zhang L, Bose P, Warren RA. Dopamine preferentially inhibits NMDA receptor-mediated EPSCs by acting on presynaptic D1 receptors in nucleus accumbens during postnatal development. PLoS One 9(5):e86970, 2014. e-Pub 2014. PMID: 24784836.
Ahluwalia J, Naseem S, Sachdeva MU, Bose P, Bose SK, Kumar N, Thapa BR, Varma N, Chawla YK. Paroxysmal Nocturnal Hemoglobinuria is rare cause for thrombosis of the intra-abdominal veins in the ethnic Indian population - results from FLAER-based flowcytometry screening. Eur J Haematol 92(5):435-43, 2014. e-Pub 2014. PMID: 24400962.
Vachhani P, Bose P. Isolated gastric myeloid sarcoma: a case report and review of the literature. Case Rep Hematol 2014:541807, 2014. e-Pub 2014. PMID: 25105036.
Ramadoss D, Lakkineni VK, Bose P, Ali S, Annapurna K. Mitigation of salt stress in wheat seedlings by halotolerant bacteria isolated from saline habitats. Springerplus 2(1):6, 2013. e-Pub 2013. PMID: 23449812.
Gopinath VS, Pinjari J, Dere RT, Verma A, Vishwakarma P, Shivahare R, Moger M, Kumar Goud PS, Ramanathan V, Bose P, Rao MV, Gupta S, Puri SK, Launay D, Martin D. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. Eur J Med Chem 69:527-36, 2013. e-Pub 2013. PMID: 24095747.
Klimowicz AC, Bose P, Petrillo SK, Magliocco AM, Dort JC, Brockton NT. The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. Br J Cancer 109(7):1859-66, 2013. e-Pub 2013. PMID: 24008660.
Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis PD, Bodger O, Jenkins S, Doak SH. Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer. Exp Mol Pathol 95(2):220-6, 2013. e-Pub 2013. PMID: 23933194.
Bose P, Thakur S, Thalappilly S, Ahn BY, Satpathy S, Feng X, Suzuki K, Kim SW, Riabowol K. ING1 induces apoptosis through direct effects at the mitochondria. Cell Death Dis 4(9):e788, 2013. e-Pub 2013. PMID: 24008732.
Dutta R, Bose P, Ghosh P. Arsenate recognition in aqueous media by a simple tripodal urea. Dalton Trans 42(32):11371-4, 2013. e-Pub 2013. PMID: 23842663.
Bose P, Dort JC, Brockton NT. Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX. Cell Cycle 12(16):2535-6, 2013. e-Pub 2013. PMID: 23907133.
Skiver BM, Patel SB, Bose P. It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation. Eur J Haematol 91(2):191-2, 2013. e-Pub 2013. PMID: 23489225.
Singh SP, Bose P, Guha S, Gurjar SK, Bhalekar S. Impact of addition of amendments on the degradation of DDT and its residues partitioned on soil. Chemosphere 92(7):811-20, 2013. e-Pub 2013. PMID: 23706893.
Bose P, Dutta R, Ghosh P. Tris(2-aminoethyl)amine based tripodal urea receptors for oxalate: encapsulation of staggered vs. planar conformers. Org Biomol Chem 11(28):4581-4, 2013. e-Pub 2013. PMID: 23764916.
Bose P, Hou J, Nelson R, Nissim N, Parmer R, Keener J, Wacnik PW, Thompson FJ. Effects of acute intrathecal baclofen in an animal model of TBI-induced spasticity, cognitive, and balance disabilities. J Neurotrauma 30(13):1177-91, 2013. e-Pub 2013. PMID: 23268729.
Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 54(5):1012-9, 2013. e-Pub 2013. PMID: 23009220.
Bose P, Bathri R, De S, Maudar KK. CD14 C-159T polymorphism and its association with chronic lung diseases: A pilot study on isocyanate exposed population of Central India. Indian J Hum Genet 19(2):188-95, 2013. e-Pub 2013. PMID: 24019621.
Ye F, Baligand C, Keener JE, Vohra R, Lim W, Ruhella A, Bose P, Daniels M, Walter GA, Thompson F, Vandenborne K. Hindlimb muscle morphology and function in a new atrophy model combining spinal cord injury and cast immobilization. J Neurotrauma 30(3):227-35, 2013. e-Pub 2013. PMID: 22985272.
Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep 2(1):18-20, 2013. e-Pub 2013. PMID: 23977454.
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep 2(1):12-14, 2013. e-Pub 2013. PMID: 23977453.
Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, Zwick ME. Excess variants in AFF2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet 21(19):4356-64, 2012. e-Pub 2012. PMID: 22773736.
Bose P, Ravikumar I, Akhuli B, Ghosh P. A series of amino acid functionalized tripodal hexaamide anion receptors: ion-pair-assisted capped-cleft formation by a pentafluorophenyl-functionalized amide. Chem Asian J 7(10):2373-80, 2012. e-Pub 2012. PMID: 22829307.
Klimowicz AC, Bose P, Nakoneshny SC, Dean M, Huang L, Chandarana S, Magliocco AM, Wayne Matthews T, Brockton NT, Dort JC. Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. Eur J Cancer 48(14):2166-74, 2012. e-Pub 2012. PMID: 22892062.
Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT, Dort JC. Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer 12:332, 2012. e-Pub 2012. PMID: 22852863.
Bose P, Murugan P, Gillies E, Holter JL. Extraosseous Ewing's sarcoma of the pancreas. Int J Clin Oncol 17(4):399-406, 2012. e-Pub 2012. PMID: 21892669.
Brockton NT, Klimowicz AC, Bose P, Petrillo SK, Konno M, Rudmik L, Dean M, Nakoneshny SC, Matthews TW, Chandarana S, Lau HY, Magliocco AM, Dort JC. High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol 48(7):615-22, 2012. e-Pub 2012. PMID: 22366443.
Ahmed SN, Evans MD, Bose P, Drew P, Beynon J, Davies M. Rectal cancer following abdomino-perineal pull-through for imperforate anus. Colorectal Dis 14(6):e363-4, 2012. e-Pub 2012. PMID: 22568648.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 69(6):1657-67, 2012. e-Pub 2012. PMID: 22349810.
Bose P, Bathri R. Association of microsatellite instability and chronic obstructive pulmonary disorder in isocyanate-Exposed population of Bhopal. Indian J Hum Genet 18(2):172-6, 2012. e-Pub 2012. PMID: 23162291.
Varma S, Varma N, Reddy VV, Naseem S, Bose P, Malhotra P. Detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma. Indian J Pathol Microbiol 55(2):206-10, 2012. e-Pub 2012. PMID: 22771645.
Abbs A, Nandakumar T, Bose P, Mooraby D. Listeria rhomboencephalitis. Pract Neurol 12(2):131-2, 2012. e-Pub 2012. PMID: 22450462.
Bose PK, Hou J, Parmer R, Reier PJ, Thompson FJ. Altered patterns of reflex excitability, balance, and locomotion following spinal cord injury and locomotor training. Front Physiol 3:258, 2012. e-Pub 2012. PMID: 22934014.
McIntyre JB, Bose P, Klimowicz AC, Brockton NT, Petrillo S, Matthews W, Easaw J, Magliocco A, Dort JC. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma. PLoS One 7(2):e31723, 2012. e-Pub 2012. PMID: 22359620.
Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int 11(1):44, 2011. e-Pub 2011. PMID: 22206574.
Bose P, Ravikumar I, Ghosh P. Anion binding in the C3v-symmetric cavity of a protonated tripodal amine receptor: potentiometric and single crystal X-ray studies. Inorg Chem 50(21):10693-702, 2011. e-Pub 2011. PMID: 21942271.
Bose P, Kunnacherry A, Maliakal P. Central pontine myelinolysis without hyponatraemia. J R Coll Physicians Edinb 41(3):211-4, 2011. e-Pub 2011. PMID: 21949915.
Das S, Mandal MC, Gharami BB, Bose P. Authors' reply. Indian J Anaesth 55(5):547-8, 2011. e-Pub 2011. PMID: 22174485.
Bose PD, Das BC, Kumar A, Gondal R, Kumar D, Kar P. High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome. J Hepatol 54(6):1107-13, 2011. e-Pub 2011. PMID: 21145845.
Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 49(4):1674-5, 2011. e-Pub 2011. PMID: 21270218.
Bose P, Ahamed BN, Ghosh P. Functionalized guanidinium chloride based colourimetric sensors for fluoride and acetate: single crystal X-ray structural evidence of -NH deprotonation and complexation. Org Biomol Chem 9(6):1972-9, 2011. e-Pub 2011. PMID: 21264410.
Das S, Mandal MC, Gharami BB, Bose P. Fibreoptic aided retrograde intubation in an oral cancer patient. Indian J Anaesth 55(2):202-3, 2011. e-Pub 2011. PMID: 21712885.
Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 26(2):312-8, 2011. e-Pub 2011. PMID: 21261721.
James KH, Bose P. SELF-GENERATED ACTIONS DURING LEARNING OBJECTS AND SOUNDS CREATE SENSORI-MOTOR SYSTEMS IN THE DEVELOPING BRAIN. Cogn Brain Behav 15(4):485-503, 2011. e-Pub 2011. PMID: 25541615.
De D, Bhattacharya S, Adhikari SM, Kumar A, Bose PK, Ghatak KP. Simple theoretical analysis of the photoemission from quantum confined effective mass superlattices of optoelectronic materials. Beilstein J Nanotechnol 2:339-62, 2011. e-Pub 2011. PMID: 22003442.
Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: A two minute cell fractionation method. BMC Res Notes 3:294, 2010. e-Pub 2010. PMID: 21067583.
Sridhara AM, Reddy KR, Keshavayya J, Goud PS, Somashekar BC, Bose P, Peethambar SK, Gaddam SK. Synthesis and antimicrobial activity of 2-substituted [4-(1,3,4-oxadiazol-2-yl methyl)] phthalazin-1(2H)-one derivatives. Eur J Med Chem 45(11):4983-9, 2010. e-Pub 2010. PMID: 20813436.
Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tfayli A. c-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res 30(11):4731-6, 2010. e-Pub 2010. PMID: 21115932.
Deka M, Bose M, Baruah B, Bose PD, Medhi S, Bose S, Saikia A, Kar P. Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J Gastroenterol 16(38):4800-8, 2010. e-Pub 2010. PMID: 20939108.
Bose PP, Chatterjee U, Hubatsch I, Artursson P, Govender T, Kruger HG, Bergh M, Johansson J, Arvidsson PI. In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation. Bioorg Med Chem 18(16):5896-902, 2010. e-Pub 2010. PMID: 20659803.
Bose PS, Naspinski J, Kartha G, Bennett PS, Wang CJ, Haynes JI 2nd, Benetti L. Development of a high-throughput rubella virus infectivity assay based on viral activation of caspases. J Virol Methods 167(2):199-204, 2010. e-Pub 2010. PMID: 20399228.
Liu M, Stevens-Lapsley JE, Jayaraman A, Ye F, Conover C, Walter GA, Bose P, Thompson FJ, Borst SE, Vandenborne K. Impact of treadmill locomotor training on skeletal muscle IGF1 and myogenic regulatory factors in spinal cord injured rats. Eur J Appl Physiol 109(4):709-20, 2010. e-Pub 2010. PMID: 20213470.
Bose P, Ghosh P. Visible and near-infrared sensing of fluoride by indole conjugated urea/thiourea ligands. Chem Commun (Camb) 46(17):2962-4, 2010. e-Pub 2010. PMID: 20386837.
Tamannai M, Farhangi S, Truss M, Sinn B, Wurm R, Bose P, Henze G, Riabowol K, von Deimling A, Tallen G. The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res 18(10):469-80, 2010. e-Pub 2010. PMID: 20681406.
Mukhopadhyay N, Bose PK. Further theoretical studies of modified cyclone separator as a diesel soot particulate emission arrester. J Environ Sci Eng 51(4):283-94, 2009. e-Pub 2009. PMID: 21117422.
Sunger N, Bose P. Autotrophic denitrification using hydrogen generated from metallic iron corrosion. Bioresour Technol 100(18):4077-82, 2009. e-Pub 2009. PMID: 19398198.
Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JN. Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol 84(7):459-61, 2009. e-Pub 2009. PMID: 19484732.
Slater A, Planner A, Bungay HK, Bose P, Milburn S. Three-day regimen improves faecal tagging for minimal preparation CT examination of the colon. Br J Radiol 82(979):545-8, 2009. e-Pub 2009. PMID: 19188239.
Wruck CJ, Huppertz B, Bose P, Brandenburg LO, Pufe T, Kadyrov M. Role of a fetal defence mechanism against oxidative stress in the aetiology of preeclampsia. Histopathology 55(1):102-6, 2009. e-Pub 2009. PMID: 19614772.
Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 82(6):490-2, 2009. e-Pub 2009. PMID: 19220417.
Sinha A, Bose P. Interaction of 2,4,6-trichlorophenol with high carbon iron filings: Reaction and sorption mechanisms. J Hazard Mater 164(1):301-9, 2009. e-Pub 2009. PMID: 18838219.
Bose P, Jennifer L Holter, George B. Selby. Bevacizumab in hereditary hemorrhagic telangiectasia. N. Engl J Med 360(20), 2009. e-Pub 2009. PMID: 19439755.
Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143-4, 2009. e-Pub 2009. PMID: 19439755.
Pekosz A, Newby C, Bose PS, Lutz A. Sialic acid recognition is a key determinant of influenza A virus tropism in murine trachea epithelial cell cultures. Virology 386(1):61-7, 2009. e-Pub 2009. PMID: 19195676.
Bose P, Unwin E, Warakaulle D, Uthappa V. Migration of embolization coils: our experience. Cardiovasc Intervent Radiol 32(1):195-6, 2009. e-Pub 2009. PMID: 18389182.
Han X, Feng X, Rattner JB, Smith H, Bose P, Suzuki K, Soliman MA, Scott MS, Burke BE, Riabowol K. Tethering by lamin A stabilizes and targets the ING1 tumour suppressor. Nat Cell Biol 10(11):1333-40, 2008. e-Pub 2008. PMID: 18836436.
Chatterjee U, Bose PP, Dey S, Singh TP, Chatterjee BP. Antiproliferative effect of T/Tn specific Artocarpus lakoocha agglutinin (ALA) on human leukemic cells (Jurkat, U937, K562) and their imaging by QD-ALA nanoconjugate. Glycoconj J 25(8):741-52, 2008. e-Pub 2008. PMID: 18521747.
Gordon PM, Soliman MA, Bose P, Trinh Q, Sensen CW, Riabowol K. Interspecies data mining to predict novel ING-protein interactions in human. BMC Genomics 9:426, 2008. e-Pub 2008. PMID: 18801192.
Vinson JA, Bose P, Proch J, Al Kharrat H, Samman N. Cranberries and cranberry products: powerful in vitro, ex vivo, and in vivo sources of antioxidants. J Agric Food Chem 56(14):5884-91, 2008. e-Pub 2008. PMID: 18558697.
Liu M, Bose P, Walter GA, Thompson FJ, Vandenborne K. A longitudinal study of skeletal muscle following spinal cord injury and locomotor training. Spinal Cord 46(7):488-93, 2008. e-Pub 2008. PMID: 18283294.
Bose P, Hinojosa J. Reported experiences from occupational therapists interacting with teachers in inclusive early childhood classrooms. Am J Occup Ther 62(3):289-97, 2008. e-Pub 2008. PMID: 18557005.
Das SK, Biswas A, Roy J, Bose P, Roy T, Banerjee TK, Mukherjee C, Raut DK, Chowdhury A, Hazra A. Prevalence of major neurological disorders among geriatric population in the metropolitan city of Kolkata. J Assoc Physicians India 56:175-81, 2008. e-Pub 2008. PMID: 18697633.
Norweg A, Bose P, Snow G, Berkowitz ME. A pilot study of a pulmonary rehabilitation programme evaluated by four adults with chronic obstructive pulmonary disease. Occup Ther Int 15(2):114-32, 2008. e-Pub 2008. PMID: 18465754.
Sinha A, Bose P. Interaction of 2-chloronaphthalene with high carbon iron filings (HCIF): adsorption, dehalogenation and mass transfer limitations. J Colloid Interface Sci 314(2):552-61, 2007. e-Pub 2007. PMID: 17574567.
Bose PP, Drew MG, Banerjee A. Decoration of Au and Ag nanoparticles on self-assembling pseudopeptide-based nanofiber by using a short peptide as capping agent for metal nanoparticles. Org Lett 9(13):2489-92, 2007. e-Pub 2007. PMID: 17542598.
Das SK, Bose P, Biswas A, Dutt A, Banerjee TK, Hazra AM, Raut DK, Chaudhuri A, Roy T. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 68(23):2019-26, 2007. e-Pub 2007. PMID: 17548552.
Bose P, Reckhow DA. The effect of ozonation on natural organic matter removal by alum coagulation. Water Res 41(7):1516-24, 2007. e-Pub 2007. PMID: 17275876.
Saha D, Bose PK, Banthia AK, Dhabal S. Analysis and characterization of alumina particles reinforced ultra high molecular weight polyethylene composite for acetabular cup. Int J Artif Organs 30(2):144-52, 2007. e-Pub 2007. PMID: 17377909.
Syed R, Nazir SA, Lwin KY, Bose P, Evans P, Choji K. Occurrence of synchronous invasive lobular breast carcinoma and poorly differentiated ovarian carcinoma in a single peritoneal deposit. Oncology 73(1-2):136-40, 2007. e-Pub 2007. PMID: 18337627.
Wang L, Bose PS, Sigworth FJ. Using cryo-EM to measure the dipole potential of a lipid membrane. Proc Natl Acad Sci U S A 103(49):18528-33, 2006. e-Pub 2006. PMID: 17116859.
Stevens JE, Liu M, Bose P, O'Steen WA, Thompson FJ, Anderson DK, Vandenborne K. Changes in soleus muscle function and fiber morphology with one week of locomotor training in spinal cord contusion injured rats. J Neurotrauma 23(11):1671-81, 2006. e-Pub 2006. PMID: 17115912.
Vinson JA, Proch J, Bose P, Muchler S, Taffera P, Shuta D, Samman N, Agbor GA. Chocolate is a powerful ex vivo and in vivo antioxidant, an antiatherosclerotic agent in an animal model, and a significant contributor to antioxidants in the European and American Diets. J Agric Food Chem 54(21):8071-6, 2006. e-Pub 2006. PMID: 17032011.
Kumar A, Saroj DP, Tare V, Bose P. Treatment of distillery spent-wash by ozonation and biodegradation: significance of pH reduction and inorganic carbon removal before ozonation. Water Environ Res 78(9):994-1004, 2006. e-Pub 2006. PMID: 17120459.
Bose PP, Drew MG, Das AK, Banerjee A. Formation of triple helical nanofibers using self-assembling chiral benzene-1,3,5-tricarboxamides and reversal of the nanostructure's handedness using mirror image building blocks. Chem Commun (Camb)(30):3196-8, 2006. e-Pub 2006. PMID: 17028741.
Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG 113(8):919-24, 2006. e-Pub 2006. PMID: 16907938.
Bose P, Kadyrov M, Goldin R, Hahn S, Backos M, Regan L, Huppertz B. Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta 27(8):869-75, 2006. e-Pub 2006. PMID: 16289730.
Liu M, Bose P, Walter GA, Anderson DK, Thompson FJ, Vandenborne K. Changes in muscle T2 relaxation properties following spinal cord injury and locomotor training. Eur J Appl Physiol 97(3):355-61, 2006. e-Pub 2006. PMID: 16770473.
Srivastava S, Bose P, Tare V. Enhancement of chemical-oxygen demand and color removal of distillery spent-wash by ozonation. Water Environ Res 78(4):409-20, 2006. e-Pub 2006. PMID: 16749309.
Apte AD, Tare V, Bose P. Extent of oxidation of Cr(III) to Cr(VI) under various conditions pertaining to natural environment. J Hazard Mater 128(2-3):164-74, 2006. e-Pub 2006. PMID: 16297546.
Jha D, Bose P. Use of pyrite for pH control during hydrogenotrophic denitrification using metallic iron as the ultimate electron donor. Chemosphere 61(7):1020-31, 2005. e-Pub 2005. PMID: 16257322.
Apte AD, Verma S, Tare V, Bose P. Oxidation of Cr(III) in tannery sludge to Cr(VI): field observations and theoretical assessment. J Hazard Mater 121(1-3):215-22, 2005. e-Pub 2005. PMID: 15885424.
Saroj DP, Kumar A, Bose P, Tare V, Dhopavkar Y. Mineralization of some natural refractory organic compounds by biodegradation and ozonation. Water Res 39(9):1921-33, 2005. e-Pub 2005. PMID: 15899291.
Frank HG, Bose P, Albieri-Borges A, Borges M, Greindl A, Neulen J, Potgens AJ, Kaufmann P. Evaluation of fusogenic trophoblast surface epitopes as targets for immune contraception. Contraception 71(4):282-93, 2005. e-Pub 2005. PMID: 15792647.
Vinson JA, Zubik L, Bose P, Samman N, Proch J. Dried fruits: excellent in vitro and in vivo antioxidants. J Am Coll Nutr 24(1):44-50, 2005. e-Pub 2005. PMID: 15670984.
Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 192(1):23-30, 2005. e-Pub 2005. PMID: 15671997.
Bose P, Parmer R, Reier PJ, Thompson FJ. Morphological changes of the soleus motoneuron pool in chronic midthoracic contused rats. Exp Neurol 191(1):13-23, 2005. e-Pub 2005. PMID: 15589508.
Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, Huppertz B. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 191(6):2125-31, 2004. e-Pub 2004. PMID: 15592302.
Petrovic AG, Bose PK, Polavarapu PL. Vibrational circular dichroism of carbohydrate films formed from aqueous solutions. Carbohydr Res 339(16):2713-20, 2004. e-Pub 2004. PMID: 15519330.
Kaufmann P, Bose P, Prescher A. New insights into the soft-tissue anatomy anterior to the patella. Lancet 363(9409):586, 2004. e-Pub 2004. PMID: 14987881.
Borges M, Bose P, Frank HG, Kaufmann P, Potgens AJ. A two-colour fluorescence assay for the measurement of syncytial fusion between trophoblast-derived cell lines. Placenta 24(10):959-64, 2003. e-Pub 2003. PMID: 14580378.
Vinson JA, Mandarano M, Hirst M, Trevithick JR, Bose P. Phenol antioxidant quantity and quality in foods: beers and the effect of two types of beer on an animal model of atherosclerosis. J Agric Food Chem 51(18):5528-33, 2003. e-Pub 2003. PMID: 12926909.
Tare V, Gupta S, Bose P. Case studies on biological treatment of tannery effluents in India. J Air Waste Manag Assoc 53(8):976-82, 2003. e-Pub 2003. PMID: 12943317.
Tare V, Yadav AV, Bose P. Analysis of photosynthetic activity in the most polluted stretch of river Ganga. Water Res 37(1):67-77, 2003. e-Pub 2003. PMID: 12465789.
Bose P, Sharma A. Role of iron in controlling speciation and mobilization of arsenic in subsurface environment. Water Res 36(19):4916-26, 2002. e-Pub 2002. PMID: 12448536.
Bose P, Parmer R, Thompson FJ. Velocity-dependent ankle torque in rats after contusion injury of the midthoracic spinal cord: time course. J Neurotrauma 19(10):1231-49, 2002. e-Pub 2002. PMID: 12427331.
Wang DC, Bose P, Parmer R, Thompson FJ. Chronic intrathecal baclofen treatment and withdrawal: I. Changes in ankle torque and hind limb posture in normal rats. J Neurotrauma 19(7):875-86, 2002. e-Pub 2002. PMID: 12184857.
Gupta M, Mazumder UK, Chaudhuri I, Chaudhuri RK, Bose P, Bhattacharya S, Manikandan L, Patra S. Antimicrobial activity of Eupatorium ayapana. Fitoterapia 73(2):168-70, 2002. e-Pub 2002. PMID: 11978434.
Sinha S, Bose P, Jawed M, John S, Tare V. Application of neural network for simulation of upflow anaerobic sludge blanket (UASB) reactor performance. Biotechnol Bioeng 77(7):806-14, 2002. e-Pub 2002. PMID: 11835141.
Gaus G, Demir-Weusten AY, Schmitz U, Bose P, Kaufmann P, Huppertz B, Frank HG. Extracellular pH modulates the secretion of fibronectin isoforms by human trophoblast. Acta Histochem 104(1):51-63, 2002. e-Pub 2002. PMID: 11993851.
Green JS, Holden ST, Bose P, George DP, Bowsher WG. An investigation into the relationship between prostate size, peak urinary flow rate and male erectile dysfunction. Int J Impot Res 13(6):322-5, 2001. e-Pub 2001. PMID: 11918247.
Vinson JA, Su X, Zubik L, Bose P. Phenol antioxidant quantity and quality in foods: fruits. J Agric Food Chem 49(11):5315-21, 2001. e-Pub 2001. PMID: 11714322.
Green JS, Holden ST, Ingram P, Bose P, St George DP, Bowsher WG. An investigation of erectile dysfunction in Gwent, Wales. BJU Int 88(6):551-3, 2001. e-Pub 2001. PMID: 11678749.
Thompson FJ, Parmer R, Reier PJ, Wang DC, Bose P. Scientific basis of spasticity: insights from a laboratory model. J Child Neurol 16(1):2-9, 2001. e-Pub 2001. PMID: 11225952.
Vinson JA, Proch J, Bose P. Determination of quantity and quality of polyphenol antioxidants in foods and beverages. Methods Enzymol 335:103-14, 2001. e-Pub 2001. PMID: 11400359.
Bose PK, Polavarapu PL. Evidence for covalent binding between copper ions and cyclodextrin cavity: a vibrational circular dichroism study. Carbohydr Res 323(1-4):63-72, 2000. e-Pub 2000. PMID: 10782287.
Suri JC, Sen MK, Bose PP, Mehta C, Ojha UC. A case of motor neurone disease with sleep apnoea syndrome. Indian J Chest Dis Allied Sci 41(3):169-73, 1999. e-Pub 1999. PMID: 10534943.
Costantino L, Rastelli G, Gamberini MC, Vinson JA, Bose P, Iannone A, Staffieri M, Antolini L, Del Corso A, Mura U, Albasini A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem 42(11):1881-93, 1999. e-Pub 1999. PMID: 10354396.
Bose P, Fielding R, Vacca-Galloway LL. Effects of assisted feeding on Wobbler mouse motoneuron disease and on serotonergic and peptidergic sprouting in the cervical spinal ventral horn. Brain Res Bull 48(4):429-39, 1999. e-Pub 1999. PMID: 10357076.
Bose P, Vacca-Galloway LL. Increase in fiber density for immunoreactive serotonin, substance P, enkephalin and thyrotropin-releasing hormone occurs during the early presymptomatic period of motoneuron disease in Wobbler mouse spinal cord ventral horn. Neurosci Lett 260(3):196-200, 1999. e-Pub 1999. PMID: 10076901.
Bose P, Fielding R, Ameis KM, Vacca-Galloway LL. A novel behavioral method to detect motoneuron disease in Wobbler mice aged three to seven days old. Brain Res 813(2):334-42, 1998. e-Pub 1998. PMID: 9838183.
Seilacher A, Bose PK, Pfluger F. Triploblastic animals more than 1 billion years ago: trace fossil evidence from india. Science 282(5386):80-3, 1998. e-Pub 1998. PMID: 9756480.
Feneley MR, Green JS, Young MP, Bose P, Kirby RS, Peeling WB, Parkinson MC. Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications. Prostate Cancer Prostatic Dis 1(2):79-83, 1997. e-Pub 1997. PMID: 12496920.
Broor SL, Lahoti D, Bose PP, Ramesh GN, Raju GS, Kumar A. Benign esophageal strictures in children and adolescents: etiology, clinical profile, and results of endoscopic dilation. Gastrointest Endosc 43(5):474-7, 1996. e-Pub 1996. PMID: 8726761.
Suri JC, Naithani BK, Goel A, Bose PP, Sarbhai V. Management of tracheal stenosis: a report of two cases. Indian J Chest Dis Allied Sci 38(2):129-33, 1996. e-Pub 1996. PMID: 8822648.
Green JS, Bose P, Thomas DP, Thomas K, Clements R, Peeling WB, Bowsher WG. How complete is a transurethral resection of the prostate?. Br J Urol 77(3):398-400, 1996. e-Pub 1996. PMID: 8814845.
Broor SL, Raju GS, Bose PP, Lahoti D, Ramesh GN, Kumar A, Sood GK. Long term results of endoscopic dilatation for corrosive oesophageal strictures. Gut 34(11):1498-501, 1993. e-Pub 1993. PMID: 8244131.
Vinson JA, Staretz ME, Bose P, Kassm HM, Basalyga BS. In vitro and in vivo reduction of erythrocyte sorbitol by ascorbic acid. Diabetes 38(8):1036-41, 1989. e-Pub 1989. PMID: 2753234.
Bigoness WJ, Keef KM, Du Bose PB. Perceived goal-difficulty, locus of control, and performance ratings. Psychol Rep 63(2):475-82, 1988. e-Pub 1988. PMID: 3222414.
Vinson JA, Bose P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract. Am J Clin Nutr 48(3):601-4, 1988. e-Pub 1988. PMID: 3414575.
Reinstein L, Twardzik FG, Russo GL, Bose P. Electromyographic abnormalities in redundant nerve root syndrome of the cauda equina. Arch Phys Med Rehabil 65(5):270-2, 1984. e-Pub 1984. PMID: 6712456.
Bose PK, Jones GP. Choanal atresia. J Laryngol Otol 97(8):711-7, 1983. e-Pub 1983. PMID: 6886531.
Bose P, El Mikatti N. Foreign bodies in the respiratory tract. A review of forty-one cases. Ann R Coll Surg Engl 63(2):129-31, 1981. e-Pub 1981. PMID: 7247270.
Goh CW, Bose P. Child psychiatric problems in Singapore. A retrospective study of a year's new patients. Singapore Med J 21(1):467-73, 1980. e-Pub 1980. PMID: 7394545.
Goh CW, Bose P. A clinical profile of 100 child-patients with schizophrenia. Ann Acad Med Singap 8(3):252-61, 1979. e-Pub 1979. PMID: 44826.
Bose PK, Hanley JA. Gastric carcinoma--a ten years survey of 189 patients. J Ir Med Assoc 66(9):238-40, 1973. e-Pub 1973. PMID: 4708878.
Bhaskaran TR, Bose PC, Majumdar SK, Jha DN, Sahai S. Studies on different types of strainers used in small diameter tubewells. Indian J Med Res 61(2):304-16, 1973. e-Pub 1973. PMID: 4759007.
Roy BR, Bose PK. Spot test for detection of urea in foods and feeds. J Assoc Off Anal Chem 55(3):644, 1972. e-Pub 1972. PMID: 5044751.
Datta DD, Bose PC, Ghosh D. Thin layer chromatography and U. V. spectrphotometry of alcoholic extracts of Hydrastis canadensis. Planta Med 19(3):258-63, 1971. e-Pub 1971. PMID: 5546265.
Bose PK. "Rhustox" (homeopathic drug) for foot and mouth disease. Indian Vet J 46(8):735-6, 1969. e-Pub 1969. PMID: 5389563.
Bose P, Venkataraman GS. Recombination in Rhizobium leguminosarum. Experientia 25(7):772, 1969. e-Pub 1969. PMID: 5194835.
Ghosh D, Datta DD, Bose PC. Thin-layer chromatography and U. V. absorption of homeopathic drugs. I. Studies of lpecac mother tincture. J Chromatogr 32(4):774-6, 1968. e-Pub 1968. PMID: 4384604.
Banerjea JC, Bose P, Mukherjee SK. Absence of pulmonary artery. A case report with review of literature. Indian Heart J 18(1):75-88, 1966. e-Pub 1966. PMID: 5905966.
Gelfand HM, Bose PN, Sehgal PN, Mukherjee RN, Ramakrishnan SP. Epidemiological observations on the outbreak of acute haemorrhagic fever in Calcutta in 1963. Bull World Health Organ 35(1):86-7, 1966. e-Pub 1966. PMID: 20604284.
Das KC, Chakraborty DP, Bose PK. Antifungal activity of some constituents of Murraya koenigii Spreng. Experientia 21(6):340, 1965. e-Pub 1965. PMID: 5870511.
RAMAKRISHNAN SP, GELFAND HM, BOSE PN, SEHGAL PN, MUKHERJEE RN. THE EPIDEMIC OF ACUTE HAEMORRHAGIC FEVER, CALCUTTA, 1963: EPIDEMIOLOGICAL INQUIRY. Indian J Med Res 52:633-50, 1964. e-Pub 1964. PMID: 14195504.
CHATTERJEE A, BOSE PK, SAHA SK. [The chemistry of ferulin, the basic lactone of the Indian medicinal plant Ferula alliacea Boiss]. Arch Pharm Ber Dtsch Pharm Ges 295/67:248-55, 1962. e-Pub 1962. PMID: 13878420.
RAO KV, BOSE PK. Chemistry of Aegiceras majus Gaertn. IV. Some minor constituents. Ann Biochem Exp Med 21:355-8, 1961. e-Pub 1961. PMID: 14490326.
SEAL SC, GHOSAL SC, BOSE PN. Notes on the bamboo flowering, migration of rats and their unusual mortality in certain districts of north Assam. Calcutta Med J 48(6):195-9, 1951. e-Pub 1951. PMID: 14879249.
SEAL SC, GHOSAL SC, BOSE PN. Notes on the bamboo flowering, migration of rats and their unusual mortality in certain districts of North Assam. Calcutta Med J 48(5):149-55; contd, 1951. e-Pub 1951. PMID: 14870030.
BHADURI PN, BOSE PC. Cyto-genetical investigations in some common cucurbits, with special reference to fragmentation of chromosomes as a physical basis of speciation. J Genet 48(2):237-56, 1947. e-Pub 1947. PMID: 20266737.
BOSE PK, CHAUDHURI JC. Constitution of coumarins isolated from Ferula alliacea. Ann Biochem Exp Med 6(1):1-10, 1946. e-Pub 1946. PMID: 20286881.
BOSE P. Climate and tuberculosis. J Indian Med Assoc 15:47-50, 1945. e-Pub 1945. PMID: 21014661.
Bose PN. Anti-Malarial Operations in India. Ind Med Gaz 76(11):690-695, 1941. e-Pub 1941. PMID: 29013692.
Krishnan KV, Pai NG, Bose PN. Changes in Certain Chemical Constituents of the Blood in Kala-Azar. Ind Med Gaz 71(10):574-576, 1936. e-Pub 1936. PMID: 29013105.
Bose P. Accessory External Ear. Ind Med Gaz 57(4):139-140, 1922. e-Pub 1922. PMID: 29008375.
Bose P. A Case of Pulmonary Embolism. Ind Med Gaz 29(7):258-259, 1894. e-Pub 1894. PMID: 29001481.
Bose P. Selections from Cases Treated during 1872. Ind Med Gaz 8(12):323-324, 1873. e-Pub 1873. PMID: 28996911.

Invited Articles

Bose P. EXABS-115-MPN Current and Emerging Therapies for Systemic Mastocytosis. Clin Lymphoma Myeloma Leuk 23(Supplement 1):S14-S17, 2023. e-Pub 2023.
Bose P. EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S65-S66, 2022. e-Pub 2022. PMID: 36164235.
Bose P. Cases in the management of polycythemia vera: a patient with progressive leukocytosis. Clin Adv Hematol Oncol 20(Suppl 16(8)):1-12, 2022. e-Pub 2022. PMID: 36125942.
Bose P. A Young Woman with Thrombocytosis. Clin Lymphoma Myeloma Leuk 20(Suppl 1):S14-S17, 2020. e-Pub 2020. PMID: 32862851.
Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol 111(2):192-199, 2020. e-Pub 2020. PMID: 31630335.
Bose P. Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk 19(suppl 1):S36-S39, 2019. e-Pub 2019.
Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol 20(1):5, 2019. e-Pub 2019. PMID: 30675650.
Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. e-Pub 2019. PMID: 31597841.
Bose P, Verstovsek S. Accelerated Phase Myelofibrosis. Clin Lymphoma Myeloma Leuk 18(Suppl. 1):S40-S42, 2018. e-Pub 2018.
Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep 13(3):164-172, 2018. e-Pub 2018. PMID: 29796726.
Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18(1):1-12, 2018. e-Pub 2018. PMID: 29277359.
Bose P. Myelofibrosis with cytopenias. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S30-S31, 2017. e-Pub 2017.
Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 17S:S43-S52, 2017. e-Pub 2017. PMID: 28760302.
Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 18(3):17, 2017. e-Pub 2017. PMID: 28286924.
Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. e-Pub 2016. PMID: 27521306.
Bose P, Grant S. Rational combinations of targeted agents in AML. J Clin Med 4(4):634-664, 2015. e-Pub 2015. PMID: 26113989.
Bose P, Qubaiah O. A review of tumor lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36(3):299-326, 2011. e-Pub 2011. PMID: 21501203.

Review Articles

Tantravahi S, El Chaer F, Bose P. Current treatments, practical management, and emerging investigational therapies for myelofibrosis. Expert Rev Hematol:1-20, 2025. e-Pub 2025. PMID: 41391946.
Bose, P, Xiao, Z, Hasselbalch, H, Prchal, JT, Duan, M, Yacoub, A, Rampal, R, Kiladjian, JJ, Hobbs, GS, Tashi, T, Shimoda, K, Kirito, K, Gill, H, Hou, HA, Lee, SE, Huang, J, Li, B, Qin, A, Yu, LL, Mascarenhas, J, Mesa, RA. Highlights from MPN Asia 2025. Current hematologic malignancy reports 20(1), 2025. e-Pub 2025. PMID: 40646417.
Chifotides, H, Duminuco, A, Torre, E, Vetro, C, Harrington, P, Palumbo, GA, Bose, P. Emerging Therapeutic Approaches for Anemia in Myelofibrosis. Current hematologic malignancy reports 20(1), 2025. e-Pub 2025. PMID: 40317385.
Duan, M, Bose, P, Hunter, AM, Qin, A, Chang, L, Li, W, Wu, D, Rampal, R. Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera. Current hematologic malignancy reports 20(1), 2025. e-Pub 2025. PMID: 41060606.
Hou J, Klippel K, Bose P. Glutamate Excitotoxicity: A Key Secondary Injury Mechanism of Traumatic Brain Injury and Spinal Cord Injury. Front Biosci (Landmark Ed) 30(10):38904, 2025. e-Pub 2025. PMID: 41198536.
Bose PA, Sohag MMH, Rabbee MF, Zamee TM, Kona JU, Elora B, Zaki RM, Islam K, Baek KH. Pharmacological Overview of Bioactive Natural Products from Gynura procumbens (Lour.) Merr. Plants (Basel) 14(17), 2025. e-Pub 2025. PMID: 40941879.
Ray D, Bose P, Mukherjee S, Roy S, Kaity S. Recent drug delivery systems targeting the gut-brain-microbiome axis for the management of chronic diseases. Int J Pharm 680:125776, 2025. e-Pub 2025. PMID: 40425058.
Chifotides HT, Bose P. SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis. Clin Lymphoma Myeloma Leuk 25(1):1-12, 2025. e-Pub 2025. PMID: 39168723.
Bose P, Pitman R. Pediatric unsedated transnasal endoscopy: applications, equipment, and future directions. Front Pediatr 13:1585705, 2025. e-Pub 2025. PMID: 40416438.
Rahman MZ, Bose P, Ahamed T, Sultana P, Mukteruz-Zaman M, Sobur KA, Khatun MM, Islam MA. Exploring bovine brucellosis in Bangladesh: Current scenario and future outlook. J Adv Vet Anim Res 11(4):888-913, 2024. e-Pub 2024. PMID: 40013292.
Islam MA, Bose P, Rahman MZ, Muktaruzzaman M, Sultana P, Ahamed T, Khatun MM. A review of antimicrobial usage practice in livestock and poultry production and its consequences on human and animal health. J Adv Vet Anim Res 11(3):675-685, 2024. e-Pub 2024. PMID: 39605760.
Vachhani P, Loghavi S, Bose P. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis. Clin Lymphoma Myeloma Leuk 24(7):413-426, 2024. e-Pub 2024. PMID: 38341324.
Bose P. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices. Curr Hematol Malig Rep 19(3):111-119, 2024. e-Pub 2024. PMID: 38441783.
Goswami M, Bose PD. Gut microbial dysbiosis in the pathogenesis of leukemia: an immune-based perspective. Exp Hematol 133:104211, 2024. e-Pub 2024. PMID: 38527589.
McCullough MJ, Bose PG, Mock JR. Regulatory T cells: Supporting lung homeostasis and promoting resolution and repair after lung injury. Int J Biochem Cell Biol 170:106568, 2024. e-Pub 2024. PMID: 38518980.
Chiu CY, John TM, Matsuo T, Wurster S, Hicklen RS, Khattak RR, Ariza-Heredia EJ, Bose P, Kontoyiannis DP. Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections. J Fungi (Basel) 10(4), 2024. e-Pub 2024. PMID: 38667935.
Bose P, Kumaranchira Ramankutty K, Chakraborty P, Khatun E, Pradeep T. A concise guide to chemical reactions of atomically precise noble metal nanoclusters. Nanoscale 16(4):1446-1470, 2024. e-Pub 2024. PMID: 38032061.
Arora, S, Vachhani, P, Bose, P. Investigational drugs in early phase trials for myelofibrosis. Expert Opinion on Investigational Drugs 33(12):1231-1244, 2024. e-Pub 2024. PMID: 39604120.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol 15:20406207241229588, 2024. e-Pub 2024. PMID: 38380373.
Dumra H, Sainani R, Pratap N, Singh BP, Halder I, Shah J, Thakkar M, V MK, Abhyankar N, Bose PP, Gokalani R, Aggarwal V, Christopher DJ. Expert Recommendations on Optimizing the Diagnosis and Management of Gastroesophageal Reflux Disease Associated with Comorbidities in the Indian Population. J Assoc Physicians India 71(8):11-12, 2023. e-Pub 2023. PMID: 37651248.
Chifotides HT, Verstovsek S, Bose P. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444441.
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma 64(6):1063-1081, 2023. e-Pub 2023. PMID: 37081809.
Vachhani P, Verstovsek S, Bose P. Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother 24(8):901-912, 2023. e-Pub 2023. PMID: 37070147.
Lovell AR, Sawyers J, Bose P. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia. Expert Opinion on pharmacotherapy 24(11):1-10, 2023. e-Pub 2023. PMID: 37226798.
Chehade M, Furuta G, Klion A, Abonia JP, Aceves S, Bose P, Collins MH, Davis C, Dellon ES, Eickel G, Falk G, Gupta S, Hiremath G, Howard A, Jensen ET, Kesh S, Khoury P, Kocher K, Kodroff E, Kyle S, Mak N, McCoy D, Mehta P, Menard-Katcher P, Mukkada V, Paliana A, Rothenberg M, Sable K, Schmitt C, Scott M, Spergel J, Strobel MJ, Wechsler JB, Yang GY, Zicarelli A, Muir AB, Wright BL, Bailey DD. Enhancing diversity, equity, inclusion, and accessibility in eosinophilic gastrointestinal disease research: the consortium for eosinophilic gastrointestinal disease researchers' journey. Ther Adv Rare Dis 4:26330040231180895, 2023. e-Pub 2023. PMID: 37588777.
Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for Myelofibrosis Patients with Anemia. J Hematol Oncol 15(1):7, 2022. e-Pub 2022. PMID: 35045875.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol 40(4):491-504, 2022. e-Pub 2022. PMID: 35368098.
Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2022. PMID: 34840087.
Singh A, Amod A, Pandey P, Bose P, Pingali MS, Shivalkar S, Varadwaj PK, Sahoo AK, Samanta SK. Bacterial biofilm infections, their resistance to antibiotics therapy and current treatment strategies. Biomed Mater 17(2), 2022. e-Pub 2022. PMID: 35105823.
Bose P, Rangnekar A, Desikan P. NDM-beta-lactamase-1: Where do we stand?. Indian J Med Res 155(2):243-252, 2022. e-Pub 2022. PMID: 35946201.
Lovell AR, Jammal N, Bose P. Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Ther Adv Hematol 13:20406207221116577, 2022. e-Pub 2022. PMID: 35966045.
Bose P, Sunita P, Pattanayak SP. Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus. Curr Microbiol 78(11):3813-3828, 2021. e-Pub 2021. PMID: 34550435.
Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis. Clin Lymphoma Myeloma Leuk 21(10):641-649, 2021. e-Pub 2021. PMID: 34272171.
Bose P. Central pontine myelinolysis and the osmotic demyelination syndromes: an open and shut case?. Acta Neurol Belg 121(4):849-858, 2021. e-Pub 2021. PMID: 33713026.
Hazra A, Bose P, Sunita P, Pattanayak SP. Molecular epigenetic dynamics in breast carcinogenesis. Arch Pharm Res 44(8):741-763, 2021. e-Pub 2021. PMID: 34392501.
Agrahari AK, Bose P, Jaiswal MK, Rajkhowa S, Singh AS, Hotha S, Mishra N, Tiwari VK. Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications. Chem Rev 121(13):7638-7956, 2021. e-Pub 2021. PMID: 34165284.
Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev 10:22, 2021. e-Pub 2021. PMID: 33718939.
Bose P, Masarova L, Verstovsek S. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050168.
Bose P, Verstovsek S. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere 4(4):e424, 2020. e-Pub 2020. PMID: 32903304.
Bose P. Novel small molecule TRVA242 targets neuromuscular junction in amyotrophic lateral sclerosis. Neural Regen Res 15(6):1041-1042, 2020. e-Pub 2020. PMID: 31823882.
Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32183301.
Para C, Bose P, Pshezhetsky AV. Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression. J Clin Med 9(3), 2020. e-Pub 2020. PMID: 32106459.
Albatat M, Bergsland J, Arevalo H, Odland HH, Bose P, Halvorsen PS, Balasingham I. Technological and Clinical Challenges in Lead Placement for Cardiac Rhythm Management Devices. Ann Biomed Eng 48(1):26-46, 2020. e-Pub 2020. PMID: 31576502.
Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. e-Pub 2019. PMID: 31228096.
Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol 10:2040620719870052, 2019. e-Pub 2019. PMID: 31516686.
Bose P, Karsan N, Goadsby PJ. The Migraine Postdrome. Continuum (Minneap Minn) 24(4, Headache):1023-1031, 2018. e-Pub 2018. PMID: 30074547.
Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood 130(2):115-125, 2017. e-Pub 2017. PMID: 28500170.
Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 58:14-22, 2017. e-Pub 2017. PMID: 28380402.
Bose P, Abou Zahr A, Verstovsek S. Investigational Janus Kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs 26(6):723-734, 2017. e-Pub 2017. PMID: 28441920.
Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother 18(9):857-873, 2017. e-Pub 2017. PMID: 28446054.
Falchi L, Bose P, Newberry KJ, Verstovsek S. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. Br J Haematol 176(3):352-364, 2017. e-Pub 2017. PMID: 27984634.
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6:1924, 2017. e-Pub 2017. PMID: 29152232.
Bose P, Verstovsek S. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw 14(12):1613-1624, 2016. e-Pub 2016. PMID: 27956543.
Bose P, Goadsby PJ. The migraine postdrome. Curr Opin Neurol 29(3):299-301, 2016. e-Pub 2016. PMID: 26886356.
Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer 122(5):681-92, 2016. e-Pub 2016. PMID: 26717494.
Bhattacharjee S, Ghosh Roy S, Bose P, Saha A. Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis. Front Microbiol 7:457, 2016. e-Pub 2016. PMID: 27092119.
Bose P, Bathri R, Kumar L, Vijayan VK, Maudar KK. Role of oxidative stress & transient receptor potential in chronic obstructive pulmonary disease. Indian J Med Res 142(3):245-60, 2015. e-Pub 2015. PMID: 26458340.
Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid 10:23-38, 2015. e-Pub 2015. PMID: 25610345.
Bose P, Hou J, Thompson FJ. Traumatic Brain Injury (TBI)-Induced Spasticity: Neurobiology, Treatment, and Rehabilitation, 2015. e-Pub 2015. PMID: 26269896.
Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother 15(16):2443-59, 2014. e-Pub 2014. PMID: 25263936.
Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics 46(13):448-56, 2014. e-Pub 2014. PMID: 24824212.
Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer 133(9):2013-23, 2013. e-Pub 2013. PMID: 23417723.
Das S, Chattopadhyay S, Bose P. The anaesthesia gas supply system. Indian J Anaesth 57(5):489-99, 2013. e-Pub 2013. PMID: 24249882.
Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 22(6):723-38, 2013. e-Pub 2013. PMID: 23647051.
Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 18(11):1735-51, 2009. e-Pub 2009. PMID: 19780706.
Potgens AJ, Schmitz U, Bose P, Versmold A, Kaufmann P, Frank HG. Mechanisms of syncytial fusion: a review. Placenta 23 Suppl A:S107-13, 2002. e-Pub 2002. PMID: 11978067.

Editorials

Bose, P, Vachhani, P. Ruxolitinib for myelofibrosis. Cancer 130(24):4224-4226, 2024. PMID: 39396121.
Banerjee T, Bose P. Kidney-lung Crosstalk in Determining the Prognosis of Acute Kidney Injury Phenotypes in Acute Respiratory Distress Syndrome Patients. Indian J Crit Care Med 27(10):701-703, 2023. PMID: 37908423.
Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma 60(7):1603-1605, 2019. PMID: 30724681.
Desikan P, Panwalkar N, Bose P, Ansari K. Effect of transport temperature on the viability of Mycobacterium tuberculosis. Indian J Tuberc 66(1):1-2, 2019. PMID: 30797264.
Bose P, Konopleva MY. ORY-1001: Overcoming the differentiation block in AML. Cancer Cell 33(3):342-343, 2018. PMID: 29533778.
Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, Bose P, Yong VW. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology 7(10):e1478647, 2018. PMID: 30288344.
Bose P, Konopleva MY. T-PLL: another check on the venetoclax list?. Blood 130(23):2447-2448, 2017. PMID: 29217697.
Bose P, Verstovsek S. Ruxolitinib for Essential Thrombocythemia?. Oncoscience 4(11-12):148-149, 2017. PMID: 29344542.
Ravera F, Iniesta-Arandia I, Martin-Lopez B, Pascual U, Bose P. Gender perspectives in resilience, vulnerability and adaptation to global environmental change. Ambio 45(Suppl 3):235-247, 2016. PMID: 27878533.
Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res 38(8):862-5, 2014. PMID: 24996975.
Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget 3(12):1499-500, 2012. PMID: 23439314.
Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. Expert Rev Hematol 5(5):475-8, 2012. PMID: 23146050.

Abstracts

Rein L, Modena B, Siebenhaar F, DeAngelo D, Oh S, Ustun C, Akin C, Kirshenbaum A, Livideanu CB, George T, Patel J, Hunter A, Herrscher R, Manning M, Castells M, Yi CA, Dybedal I, Pilla A, Jolin H, Sun L, Exter B, Zhang J, Carden M, Bose P. SYMPTOM-FOCUSED RESULTS FROM SUMMIT PART 1: AN ONGOING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS. Hemasphere 8(S1), 2024. e-Pub 2024.
Bose P, Oh S, Kiladjian J, Takeuchi M, Gotlib J, Ritchie E, Shimomura T, Guglielmelli P, Hunter AM, Palandri F, Boyer F, Rambaldi A, Mori T, Ito T, Lamothe B, Yang Y, Cui Y, Seguy F, McBride A, Savona M, Mohan S. THE ACTIVIN RECEPTOR-LIKE KINASE-2 INHIBITOR ZILURGISERTIB (INCB000928) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS: PHASE 1/2 STUDY RESULTS. Hemasphere 8(S1), 2024. e-Pub 2024.
Harrison C, Maher K, Rampal RK, Bose P, Podoltsev N, Hong J, Wang X, Kye S, Mascarenhas J. PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY EVALUATING SAFETY AND EFFICACY OF SELINEXOR, AN XPO1 INHIBITOR, PLUS RUXOLITINIB IN JAKI-NAÏVE MYELOFIBROSIS. Hemasphere 8(S1), 2024. e-Pub 2024.
Gangat N, Foran JM, Halpern AB, Rampal RK, Bose P, Hexner E, Talpaz M, Michaelis L, Islam P, Swords R, Bhatt S, Buch A, Pelletier O, Savage W, Tefferi A. A PHASE 1B TRIAL OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA. Hemasphere 8(S1), 2024. e-Pub 2024.
Reiter A, Gotlib J, Radia D, Alvarez-Twose I, Deininger M, George T, Panse J, Pettit K, Vannucchi A, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic J, Zanotti R, Span L, Oh S, Yacoub A, Hexner E, Bose P, Lee S, Sperr W, Griffiths E, Butler M, Bidollari I, Lin H, Rylova S, Muñoz-González J, DeAngelo D. AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSIS FROM THE PHASE 2 PATHFINDER STUDY WITH 3-YEAR FOLLOW-UP. Hemasphere 8(S1), 2024. e-Pub 2024.
Rampal R, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee S, Gupta V, Lucchesi A, Kuykendall AT, Mesa RA, Kiladjian J, Talpaz M, Harris M, Wu M, Brown B, Harrison C, Mascarenhas J. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Watts JM, Vannucchi AM, Hunter A, McMahon B, Tantravahi SK, Iurlo A, Xicoy B, Palandri F, Searle E, Reeves B, Bose P, Diaz RA, Halpern AB, Chen X, Burke LM, Zhou F, Zheng F, Vachhani P. Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Braish J, Bose P, Pemmaraju N, Pierce S, Sasaki K, Estrov Z, Patel KP, Kantarjian HM, Masarova L. Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Masarova L, Huang M, Goel S, Bledsoe S, Pemmaraju N, Kadia TM, Bose P, Ishizawa J, Bravo GM, Lyu M, Sadeghi T, Assatiani E, Parmar S, Flowers C, Kantarjian HM. A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Urrutia S, Kantarjian HM, Ravandi-Kashani F, Jabbour E, Kanagal-Shamanna R, Loghavi S, Patel KP, Montalban-Bravo G, Short NJ, Daver NG, Borthakur G, Dinardo CD, Kadia TM, Masarova L, Bose P, Pemmaraju N, Garcia-Manero G, Sasaki K. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Arora S, Senapati J, Masarova L, Pemmaraju N, Bose <, Montalban Bravo . Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF). J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Mascarenhas J, Maher KR, Rampal R, Bose P, Podoltsev NA, Hong J, Wang X, Kye S, Harrison C. Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Vachhani P, Gupta V, Palandri F, Suthar P, Buckley S, Roman-Torres K, Bose P. Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia. J Clin Oncol 42(suppl 16), 2024. e-Pub 2024.
Mohan S, Oh S, Kiladjian J, Takeuchi M, Gotlib J, Ritchie EK, Shimomura T, Guglielmelli P, Hunter AM, Palandri F, Boyer F, Rambaldi A, Mori T, Ito T, Lamothe B, Yang Y, Cui Y, Seguy F, McBride A, Bose AP. Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis. Blood 142(Suppl 1), 2023. e-Pub 2023.
Gerds AT, Harrison CN, Kiladjian J, Mesa R, Komrokji RS, Bose P, Sanabria F, Marsousi N, Lai Y, Passamonti F. Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study. Blood 142(Suppl 1), 2023. e-Pub 2023.
Masarova L, Kantarjian HM, Pemmaraju N, Abbas HA, Bose P, Swaminathan M, Pierce S, Sasaki K, Yilmaz M, Short NJ, Daver N, Borthakur G, Garcia-Manero G, Ohanian M, Bhalla KN, DiNardo CD, M Kadia AT. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs). Blood 142(Suppl 1), 2023. e-Pub 2023.
Fiskus WC, Masarova L, Mill CP, Birdwell C, Das K, Davis J, Hou H, Alhamadani N, Philip K, Matthews A, Manshouri T, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Törngren M, N Bhalla AK. Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase. Blood 142(Suppl 1), 2023. e-Pub 2023.
Oh ST, Shammo J, Gupta V, McMullin MF, Bose P, Mesa RA, Lucchesi A, Buckley S, Suthar P, Roman-Torres K, Mascarenhas J, Ferrer Marin AF. Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib. Blood 142(Suppl 1), 2023. e-Pub 2023.
Bazinet A, Kantarjian HM, Borthakur G, Yilmaz M, Bose P, Jabbour E, Valero YA, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa GC, Jain N, Hammond DE, Bull-Linderman D, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Sasaki K, Garcia-Manero G, Ravandi F, M Kadia AT. Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. Blood 142(Suppl 1), 2023. e-Pub 2023.
Topping RP, Bose P, Mascarenhas J, Rampal R, Stein BL, Quill TA, Mesa RA. Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool. Blood 142(Suppl 1), 2023. e-Pub 2023.
Masarova L, Huang M, Bledsoe S, Pemmaraju N, Kadia TM, Bose P, Ishizawa J, Montalban-Bravo G, Lyu M, Zeng K, Sadeghi T, Asatiani E, Parmar S, Flowers CR, M Kantarjian AH. A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib. Blood 142(Suppl 1), 2023. e-Pub 2023.
Jain N, Thompson P, Jain A, Burger JA, Ferrajoli A, Senapati J, Takahashi K, Swaminathan M, Estrov Z, Borthakur G, Bose P, Kadia TM, Pemmaraju N, Sasaki K, Bansal D, Konopleva MY, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel KP, Wang W, Wang SA, Jorgensen JL, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, G Wierda AW. Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/TP53 Mutation: Six-Year Follow-up Analyses. Blood 142(Suppl 1), 2023. e-Pub 2023.
Tashi T, Hermine O, Castells M, Guilarte M, Sabato V, Maurer M, Panse J, Alvarez-Twose I, Cabral R, Bird R, Barete S, Bouillet L, Hermans M, Daele PV, González-De-Olano D, Griffiths EA, Jurcic J, Dybedal I, Damaj GL, Schafhausen P, Elena C, Teh T, Vachhani P, Labe C, Venugopal S, He K, Muñoz-González J, Lampson B, Scherber R, Bose P, Grattan C, Pongdee T, George TI, Bulai Livideanu AC. Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial. Blood 142(Suppl 1), 2023. e-Pub 2023.
Fiskus WC, Bose P, Masarova L, Mill CP, Birdwell C, Davis J, Das K, Hou H, Manshouri T, Philip K, Alhamadani N, Matthews A, Loghavi S, N Bhalla AK. Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML. Blood 142(Suppl 1), 2023. e-Pub 2023.
Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee S, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Alvarez-Larran A, Mesa R, Kiladjian J, Talpaz M, Harris M, Kays S, Jegg A, Li Q, Brown B, Harrison CN, Mascarenhas J. Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study. Blood 142(Suppl 1), 2023. e-Pub 2023.
Harrison CN, Bose P, Ellis MH, Gupta V, Kiladjian J, Mascarenhas J, Mathews V, Passamonti F, Koschmieder AS. Consensus-Based Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice with a Focus on Patients with Cytopenias: Systematic Literature Review and Clinical Practice Recommendations from a Global Consensus Group. Blood 142(Suppl 1), 2023. e-Pub 2023.
Watts JM, Vannucchi AM, Hunter AM, McMahon B, Tantravahi SK, Iurlo A, Xicoy B, Palandri F, Searle E, Reeves BN, Bose P, Ayala R, Halpern AB, Chen X, Burke LM, Zhou F, Zheng F, Vachhani AP. Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study. Blood 142(Suppl 1), 2023. e-Pub 2023.
Urrutia S, Chien KS, Li Z, Borthakur G, Valero YA, Kadia TM, Kornblau SM, Daver N, Ravandi F, Bose P, Yilmaz M, Ohanian M, Kanagal-Shamanna R, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero AG. Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria. Blood 142(Suppl 1), 2023. e-Pub 2023.
Bose P, Oh ST, Modena B, Hunter AM, Akin C, Castells M, Manning M, Herrscher R, Siebenhaar F, DeAngelo DJ, George TI, Exter B, Zhang J, Pilla A, Jolin H, Easton R, AM Rein AL. Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood 142(Suppl 1), 2023. e-Pub 2023.
Arora S, Senapati J, Pemmaraju N, Bose P, Masarova L, Montalban-Bravo G, Maiti A, Kadia TM, Jabbour E, Garcia-Manero G, Kantarjian HM, Daver AN. Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 142(Suppl 1), 2023. e-Pub 2023.
Maher K, Rampal RK, Bose P, Podoltsev NA, Harrison CN, Hong J, Wang X, Chamoun K, Mascarenhas J. A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034). Blood 142(Suppl 1), 2023. e-Pub 2023.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Swaminathan M, Takahashi K, Estrov Z, Konopleva MY, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Valero YA, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, MD, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, G Wierda AW. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. Blood 142(Suppl 1), 2023. e-Pub 2023.
Komrokji RS, Gerds AT, Harrison CN, Kiladjian J, Mesa R, Bose P, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Passamonti F. Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study. Blood 142(Suppl 1), 2023. e-Pub 2023.
Rein LA, Chaer FE, Yuda J, Shimoda K, McCloskey J, Takami A, Haque T, Ichii M, Shirane S, Fukaya M, Scandura JM, Bradley T, Vachhani P, Tabayashi T, Green S, Cheung S, Bose P, Khurana S, O'Connell CL, Amanam I, Ross DM, Kabir S, Seki M, Wade M, Peddagali V, Li Z, Shah J, K Rampal AR. Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients. Blood 142(Suppl 1), 2023. e-Pub 2023.
Braish J, Bose P, Pemmaraju N, Pierce S, Sasaki K, Patel KP, Kantarjian H, Masarova AL. Deeper Insights into Splicing Mutations in Myelofibrosis. Blood 142(Suppl 1), 2023. e-Pub 2023.
Bewersdorf JP, Derkach A, Masarova L, Pemmaraju N, Stein EM, Mauro M, Rampal R, Bose P. A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 142(Suppl 1), 2023. e-Pub 2023.
Jason Gotlib MD, MS, Mariana Castells MD, PhD, Hanneke Oude Elberink MD, PhD, Dr med FSP, Karin Hartmann MD, Sigurd Broesby-Olsen MD, Tracy I George MD, Jens Panse MD, Iván Alvarez-Twose MD, PhD, Radia MRCPI DH, FRCPath, Tsewang Tashi MD, Cristina Bulai Livideanu MD, MSc, Vito Sabato MD, PhD, Paul Van Daele MD, PhD, Sonia Cerquozzi MD, Ingunn Dybedal MD, PhD, Andreas Reiter MD, Celalettin Ustun MD, Philippe Schafhausen MD, Prithviraj Bose MD, Daniel J DeAngelo MD, PhD, Lindsay Rein MD, Pankit Vachhani MD, Massimo Triggiani MD, PhD, MBChB MR, BSC, MRCP, FRCPath, Butt MBChB NM, MRCP, FRCPath, MD, Stephen T Oh MD, PhD, Friederike Wortmann MD, Johanna Ungerstedt MD, PhD, Minakshi Taparia MD, Andrew T Kuykendall MD, Cecilia Arana Yi MD, MSHS, Mattias Mattsson MD, PhD, William Shomali MD, Matthew P Giannetti MD, Ilda Bidollari MD, MBA, PhD HL, Robyn Scherber MD, Maria Roche MS, Cem Akin MD, PhD, Marcus Maurer MD. Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-524, 2023. e-Pub 2023.
Jason Gotlib MD, MS, Andreas Reiter MD, Radia MRCPI DH, FRCPath, Michael W Deininger MD, PhD, Tracy I George MD, Jens Panse MD, Alessandro M Vannucchi MD, CRIMM, Uwe Platzbecker MD, Iván Alvarez-Twose MD, PhD, Andrzej Mital MD, PhD, Olivier Hermine MD, PhD, Md ID, PhD, Elizabeth O Hexner MD, Lambert Span MD, Phd, Ruben Mesa MD, FACP, Prithviraj Bose MD, Kristen M, Pettit MD, Stephen T Oh MD, PhD, PhD HL, PhD SD, Muñoz-González PhD JI, DeAngelo Md DJ, PhD. Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-295, 2023. e-Pub 2023.
Justin Watts MD, Anthony Hunter MD, Alessandra Iurlo MD, PhD, Blanca Xicoy MD, Francesca Palandri MD, PhD, Brandi Reeves MD, Alessandro Vannucchi MD, Prithviraj Bose MD, Rosa Diaz MD, Anna Halpern MD, PhD XC, Lea Burke MS, PhD FZ, Fred Zheng MD, Pankit Vachhani MD. Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-559, 2023. e-Pub 2023.
Prithviraj Bose MD, Sanjay Mohan MD, MSCI, Stephen Oh MD, PhD, Jason Gotlib MD, MS, Ellen Ritchie MD, Taizo Shimomura MD, PhD, Haris Ali MD, Francoise Boyer MD, Paola Guglielmelli MD, PhD, Anthony Hunter MD, PhD BL, PhD YC, MSc FS, Amanda McBride MD, PhD, Francesca Palandri MD, PhD, Masahiro Takeuchi MD, PhD, Jean-Jacques Kiladjian MD, PhD. Phase I/II Study of the Activin Receptor-like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-548, 2023. e-Pub 2023.
Pankit Vachhani MD, Bart Scott MD, Prithviraj Bose MD, Sarah Buckley MD, Karisse Roman-Torres MS, Marta Sobas MD, PhD. Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-339, 2023. e-Pub 2023.
Aaron T Gerds MD, Claire Harrison MD, PhD JK, Ruben Mesa MD, Alessandro M Vannucchi MD, Rami Komrokji MD, Prithviraj Bose MD, Marina Kremyanskaya MD, Mead PhD AJ, Jason Gotlib MD, Fabian Sanabria MD, PharmD NM, Ana Carolina Giuseppi MD, PhD HJ, Jeanne M Palmer MD, Kelly McCaul MD, Vincent Ribrag MD, Francesco Passamonti MD. Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study. Clin Lymphoma Myeloma Leuk 23(Supplement 1):MPN-404, 2023. e-Pub 2023.
Bewersdorf JP, Verstovsek S, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 41(16_suppl):TPS7086, 2023. e-Pub 2023.
Watts J, Hunter A, Iurlo A, Xicoy B, Palandri F, Reeves B, Vannucchi A, Bose P, Diaz R, Halpern A, Chen X, Seguy F, Zhou F, Zheng F, Vachhani P. Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study. J Clin Oncol 41(16_suppl):7069, 2023. e-Pub 2023.
Kremyanskaya M, Harrison C, Bose P, Gupta V, Rampal RK, Lambert J, Talpaz M, Vannucchi A, Kuykendall A, Kiladjian J, Verstovsek S, Mesa R, Colak G, Klein S, Alvero C, Mascarenhas J. UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS. Hemasphere 7(S1):P1018, 2023. e-Pub 2023.
Mascarenhas J, Jain T, Otoukesh S, Gerds AT, Lucchesi A, Sosa IR, Laribi K, Mishchenko E, Radinoff A, Benevolo G, Vannucchi AM, Boyer F, Quittet P, Radsak M, Machet A, Bose P, Huang Z, Qamoos H, McGreivy J, Rothbaum WP, Verstovsek S, Passamonti F. AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX. Hemasphere 7(S1):S210, 2023. e-Pub 2023.
Gotlib J, Reiter A, Radia D, Deininger M, George T, Panse J, Vannucchi A, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Span L, Mesa R, Bose P, Pettit K, Oh S, Lin H, Dimitrijevic S, Muñoz-González J, DeAngelo DJ. AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP. Hemasphere 7(S1):P1023, 2023. e-Pub 2023.
Bose P, Mohan S, Oh S, Gotlib J, Ritchie E, Shimomura T, Ali H, Boyer F, Guglielmelli P, Hunter A, Lamothe B, Cui Y, Seguy F, McBride A, Palandri F, Takeuchi M, Kiladjian J. Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). J Clin Oncol 41(16_suppl):7017, 2023. e-Pub 2023.
Bose P, Gagelmann N, Gupta V, McLornan D, Vachhani P, Al-Ali H, Ali H, Treskes P, Buckley S, Roman-Torres K, Scott B. Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias. J Clin Oncol 41(16_suppl):7068, 2023. e-Pub 2023.
Bose P, Masarova L, Pemmaraju N, Dobbins M, Jain N, Abbas H, Kornblau S, Maiti A, Veletic I, Manshouri T, Bledsoe S, Richie MA, Hall-Moore N, Zhou L, Wang X, Kantarjian H, Estrov Z, Verstovsek S. A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 7(S1):P1025, 2023. e-Pub 2023.
Gerds A, Harrison C, Kiladjian J, Mesa R, Vannucchi A, Komrokji R, Bose P, Kremyanskaya M, Mead A, Gotlib J, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer J, McCaul K, Ribrag V, Verstovsek S, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study. Hemasphere 7(S1):S167, 2023. e-Pub 2023.
Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia D, Tashi T, Livideanu CB, Sabato V, Daele PV, Cerquozzi S, Dybedal I, Reiter A, Ustun C, Schafhausen P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Rafferty M, Butt N, Oh S, Wortmann F, Ungerstedt J, Taparia M, Kuykendall AT, Yi CA, Mattsson M, Shomali W, Giannetti M, Bidollari I, Lin H, Scherber R, Roche M, Akin C, Maurer M. REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL. Hemasphere 7(S1):P1017, 2023. e-Pub 2023.
Castells M, Gotlib J, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Livideanu CB, Sabato V, Daele PV, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Schwartz L, Bose P, Triggiani M, Shomali W, Giannetti M, Bidollari I, Lin H, Scherber R, Roche M, Akin C, Maurer M. Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double Blinded Placebo-Controlled PIONEER Study. J Allergy Clin Immunol 151(2, Supplement), 2023. e-Pub 2023.
Akin C, Siebenhaar F, Gotlib J, Castells M, Barete S, Alvarez-Twose I, Livideanu CB, Sabato V, Daele PV, Pongdee T, Ward B, Vadas P, Bose P, Vachhani P, Triggiani M, Bonadonna P, Hartmann K, Oh S, Guilarte M, Kuykendall AT, Yi CA, Ogbogu P, Broesby-Olsen S, Gaudy C, Giannetti M, Lin H, Scherber R, Roche M, Maurer M, Elberink HO. Avapritinib Improved Symptoms and Quality of Life in Patients with Indolent Systemic Mastocytosis in the PIONEER Study. J Allergy Clin Immunol 151(2, Supplement), 2023. e-Pub 2023.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton E, Horny H, Tugnait M, Lin H, Dimitrijević S, Munoz-Gonzalez JI, Bidollari I, Deininger MW, Gotlib AJ. An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety. Blood 140(Suppl 1), 2022. e-Pub 2022.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Ayala A, Hernandez JA, Kadia TM, Bose P, Pemmaraju N, Short N, G Wierda AW. Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year. Blood 140(Suppl 1), 2022. e-Pub 2022.
Akin C, Siebenhaar F, Deininger MW, DeAngelo DJ, George TI, Castells M, Giannetti M, Gotlib J, Sachs J, Pilla A, Jolin HA, PharmD, Bose P. Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood 140(Suppl 1), 2022. e-Pub 2022.
Abuasab T, Verstovsek S, Borthakur G, Kanagal-Shamanna R, Patel K, Takahashi K, Masarova L, Bose P, Villarreal J, Pierce SA, Montalban-Bravo G, Garcia-Manero G, Short N, DiNardo CD, Daver N, Ravandi F, Kantarjian H, Yilmaz AM. The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms. Blood 140(Suppl 1), 2022. e-Pub 2022.
Bewersdorf JP, Verstovsek S, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal RK, Bose AP. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 140(Suppl 1), 2022. e-Pub 2022.
Masarova L, Bose P, Pemmaraju N, Richie MA, Borthakur G, Estrov ZE, Kantarjian H, Patel KP, Verstovsek AS. Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years. Blood 140(Suppl 1), 2022. e-Pub 2022.
Scandura J, Verstovsek S, Kremyanskaya M, Talpaz M, Rampal RK, Vannucchi A, Gupta V, Palandri F, Patriarca A, Bose P, Chen D, Zavidij O, Cui J, Chang T, Taverna P, Mascarenhas J, N Harrison AC. Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib. Blood 140(Suppl 1), 2022. e-Pub 2022.
Reville PK, Kantarjian H, Borthakur G, Yilmaz M, Daver N, Short N, DiNardo CD, Kornblau SM, Pemmaraju N, Jain N, Alvarado Y, Bose P, Jabbour E, Chien KS, Abbas HA, Masarova L, Wang SA, S Tidwell RS, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, M Kadia AT. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 140(Suppl 1), 2022. e-Pub 2022.
DeAngelo DJ, Pullarkat VA, Piris-Villaespesa M, George TI, Patel JL, Ustun C, Bose P, Heaney ML, Sachs J, Sun L, Pilla A, Exter B, Jolin HA, PharmD, Tashi T. Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood 140(Suppl 1), 2022. e-Pub 2022.
Oh ST, Mesa R, Harrison CN, Bose P, Gerds AT, MD, Heaney ML, Gupta V, Scott BL, Kiladjian J, Lucchesi A, Buckley S, Tyavanagimatt S, Roman-Torres K, Mascarenhas J, Verstovsek AS. Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis. Blood 140(Suppl 1), 2022. e-Pub 2022.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Konopleva M, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Alvarado Y, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood 140(Suppl 1), 2022. e-Pub 2022.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short N, Daver N, Issa GC, Jain N, Linderman DB, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, M Kadia AT. A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up. Blood 140(Suppl 1), 2022. e-Pub 2022.
Harrison CN, Kremyanskaya M, Bose P, Gupta V, Rampal RK, Lambert J, Talpaz M, Vannucchi A, Kuykendall A, Kiladjian J, Verstovsek S, Mesa R, Colak G, Klein S, Dutta S, Mascarenhas AJ. Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study. Blood 140(Suppl 1), 2022. e-Pub 2022.
Gener-Ricos G, Haddad F, Sasaki K, Issa GC, Skinner J, Takahashi K, Masarova L, Burger JA, Borthakur G, Bose P, Garcia-Manero G, Jabbour E, Kantarjian AH. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood 140(Suppl 1), 2022. e-Pub 2022.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. e-Pub 2022. PMID: 36163821.
Oh S, Mesa R, Harrison C, Bose P, Gerds A, Gupta V, Swami A, Tyavanagimatt S, Buckley S, Roman-Torres K, Verstovsek S. MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S327, 2022. e-Pub 2022. PMID: 36163989.
Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian JJ, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S335-S336, 2022. e-Pub 2022. PMID: 36164005.
Lachowiez C, Borthakur G, Loghavi S, Zeng Z, Kadia T, Masarova L, Takahashi K, Tippett G, Garcia J, Bose P, Jabbour E, Ravandi F, Daver N, Manero GG, Vyas P, Kantarjian H, Konopleva M, DiNardo C. A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S240-S241, 2022. e-Pub 2022.
Harrison C, Bose P, Mesa R, Gerds A, Oh S, Kiladijan JJ, Garcia-Gutierrez V, Vannucchi A, Scheid C, Sobas M, Verstovsek S, Buckley S, Roman-Torres K, Mascarenhas J. MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S326-S327, 2022. e-Pub 2022. PMID: 36163987.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S334, 2022. e-Pub 2022. PMID: 36164003.
Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S271, 2022. e-Pub 2022.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S239-S240, 2022. e-Pub 2022.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S334-S335, 2022. e-Pub 2022. PMID: 36164004.
Masarova L, Bose P, Pemmaraju N, Chifotides H, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER. Hemasphere 6(S1), 2022. e-Pub 2022.
DeAngelo DJ, Pullarkat V, Piris-Villaespesa M, George TI, Patel JL, Ustun C, Bose P, Heaney ML, Pilla A, Massaro M, Exter B, Jolin HA, Mikhak Z, Tashi T. A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS. Hemasphere 6(S1), 2022. e-Pub 2022.
Venugopal S, Song H, Young C, Cutherell MA, Baganz JA, Zatorsky S, Woodman SE, Pemmaraju N, Bose P, Masarova L, Zhou L, Pierce S, Kantarjian H, Verstovsek S. OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES. Hemasphere 6(S1), 2022. e-Pub 2022.
Harrison C, Bose P, Mesa R, Gerds A, Oh S, Kiladjian J, García-Gutierrez V, Vannucchi A, Scheid C, Sobas M, Verstovsek S, Buckley S, Roman-Torres K, Mascarenhas J. RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA. Hemasphere 6(S1), 2022. e-Pub 2022.
Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian J, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY. Hemasphere 6(S1), 2022. e-Pub 2022.
Curto-Garcia N, Kremyanskaya M, Mascarenhas J, Palandri F, Vannucchi AM, Verstovsek S, Harrison C, Bose P, Schiller GJ, Rampal R, Drummond MW, Gupta V, Patriarca A, Granacher N, Scandura J, Prejzner W, Teichmann LL, Hoffman R, Colak G, Ren Z, Bobba S, Cui J, Efuni S, Talpaz M, Mead AJ. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis—update of clinical and translational data from the ongoing MANIFEST trial. Br J Haematol 197(S1), 2022. e-Pub 2022.
Mesa R, Palmer J, Bose P, Oh S, Rampal R, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Symptom Burden in Patients with Myelofibrosis who Have Moderate or Severe Thrombocytopenia: a Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study. J Natl Compr Canc Netw 20(3.5), 2022. e-Pub 2022.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva AM. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138(Supplement 1), 2021. e-Pub 2021.
Sasaki K, Jabbour EJ, Issa GC, Naqvi K, Skinner J, Anderson K, Dellasala SE, Yilmaz M, Ferrajoli A, Bose P, Thompson PA, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger JA, Borthakur G, Pemmaraju N, Haddad F, Khouri MR, Paul S, Pierce SA, Cortes JE, Kantarjian AH. Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 138(Supplement 1), 2021. e-Pub 2021.
Thompson PA, Wang Y, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, G Wierda AW. Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 138(Supplement 1), 2021. e-Pub 2021.
Gotlib J, George TI, Deininger MW, Tashi T, Pullarkat VA, Bose P, Payumo F, Pilla A, Jolin H, Sachs J, J DeAngelo AD. A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). Blood 138(Supplement 1), 2021. e-Pub 2021.
Bose P, Manshouri T, Bledsoe SD, Jain N, Masarova L, Pemmaraju N, Hall N, Richie MA, Wang X, Kantarjian H, Estrov ZE, Verstovsek AS. A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis. Blood 138(Supplement 1), 2021. e-Pub 2021.
Mascarenhas J, Bose P, Kiladjian J, Mesa RA, Gerds AT, Gupta V, Harrison CN, Yacoub A, Gutierrez VG, Vannucchi AM, Scheid C, Tenza PV, Buckley SA, Roman-Torres K, Oh ST, Sobas M, Lavie D, Verstovsek S. A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia. Blood 138(Supplement 1), 2021. e-Pub 2021.
Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, E Cortes AJ. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood 138(Supplement 1), 2021. e-Pub 2021.
Jain N, MD, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour EJ, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, G Wierda AW. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. Blood 138(Supplement 1), 2021. e-Pub 2021.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver N, Jabbour EJ, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Nguyen-Cao MM, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian H, Verstovsek AS. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Blood 138(Supplement 1), 2021. e-Pub 2021.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov ZE, Kantarjian H, Verstovsek AS. Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils. Blood 138(Supplement 1), 2021. e-Pub 2021.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Jabbour EJ, Short NJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch JS, Kantarjian H, Konopleva AM. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood 138(Supplement 1), 2021. e-Pub 2021.
Mohamed SF, Assi R, Ning J, Xiao L, Naveen Pemmaraju EJJ, Kadia TM, Jain N, DiNardo CD, Yilmaz M, Maiti A, Issa GC, Short NJ, Bose P, Masarova L, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian H, Daver AN. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood 138(Supplement 1), 2021. e-Pub 2021.
Kremyanskaya M, Mascarenhas J, Palandri F, Vannucchi A, Verstovsek S, Harrison CN, Bose P, Schiller GJ, Rampal R, Drummond MW, Gupta V, Patriarca A, Granacher N, Scandura J, Prejzner W, Teichmann LL, Curto-Garcia N, Hoffman R, Colak G, Ren Z, Bobba S, Cui J, Efuni S, Talpaz AM. Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis – Update of Clinical and Translational Data from the Ongoing Manifest Trial. Blood 138(Supplement 1), 2021. e-Pub 2021.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour EJ, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Issa GC, Jain N, Ferrajoli A, Burger JA, Linderman DB, Daver N, DiNardo CD, Konopleva M, Garcia-Manero G, Sasaki K, Ravandi F, M Kadia AT. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood 138(Supplement 1), 2021. e-Pub 2021.
Palmer JM, Mesa RA, Oh ST, Rampal R, Buckley SA, Roman-Torres K, Verstovsek S, Mascarenhas J, Vannucchi AM, Kiladjian J, Harrison CN, Bose P, Craig AR, T Gerds AA. The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study. Blood 138(Supplement 1), 2021. e-Pub 2021.
Kremyanskaya M, Mascarenhas J, Patriarca A, Gupta V, Devos T, Harrison C, Passamonti F, Rampal R, Mead A, Scandura J, Hobbs G, Talpaz M, Granacher N, Somervaille T, Hoffman R, Bose P, Colak G, Shao J, Cui J, Bobba S, Luptakova K, Verstovsek S, Palandri F. CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY. Hemasphere 5(S1), 2021. e-Pub 2021.
Masarova L, Bose P, Pemmaraju N, Chifotides H, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. OVERALL AND CAUSE SPECIFIC CHANGES IN MORTALITY OF PATIENTS WITH MYELOFIBROSIS OVER THE LAST 3 DECADES. Hemasphere 5(S1), 2021. e-Pub 2021.
Verstovsek S, Kremyanskaya M, Mascarenhas J, Talpaz M, Harrison C, Rampal R, Patriarca A, Gupta V, Granacher N, Somervaille T, Schiller G, Drummond M, Foltz L, Lambert J, Prejzner W, Colak G, Keller P, Shao J, Luptakova K, Hoffman R, Bose P, Vannucchi A. PELABRESIB (CPI-0610) IMPROVED ANEMIA ASSOCIATED WITH MYELOFIBROSIS: INTERIM RESULTS FROM MANIFEST PHASE 2 STUDY. Hemasphere 5(S1), 2021. e-Pub 2021.
Reiter A, DeAngelo DJ, Radia D, Deininger MW, George TI, Panse J, Vannucchi AM, Jentzsch M, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh S, Sen J, Lin H, Mar BG, Gotlib J. EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY. Hemasphere 5(S1), 2021. e-Pub 2021.
DeAngelo DJ, Reiter A, Radia D, Deininger MW, George TI, Panse J, Vannucchi AM, Jentzsch M, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh S, Sen J, Lin H, Mar BG, Gotlib J. PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). Clin Cancer Res, 2021. e-Pub 2021.
Bose P, Verstovsek S, Kremyanskaya M, Mascarenhas J, Talpaz M, Harrison C, Rampal R, Patriarca A, Gupta V, Granacher N, Somervaille T, Schiller G, Drummond M, Foltz L, Lambert J, Prejzner W, Colak G, Keller P, Shao J, Luptakova K, Hoffman R, Vannucchi A. Pelabresib (CPI-0610) Improved Anemia Associated With Myelofibrosis: Interim Results From Ongoing MANIFEST Phase 2 Study. Clin Lymphoma Myeloma Leuk 21(S1):S361-2, 2021. e-Pub 2021.
Masarova L, Bose P, Pemmaraju N, Daver N, Sasaki K, Chifotides H, Zhou L, Kantarjian H, Estrov Z, Verstovsek S. Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center. Clin Lymphoma Myeloma Leuk 21(S1):S361, 2021. e-Pub 2021.
Gupta V, Kremyanskaya M, Mascarenhas J, Palandri F, Patriarca A, Devios T, Harrison C, Passamonti F, Rampal R, Mead A, Scandura J, Hobbs G, Talpaz M, Granacher N, Somervaille T, Hoffman R, Bose P, Colak G, Shao J, Cui J, Bobba S, Luptakova K, Verstovsek S. Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study. Clin Lymphoma Myeloma Leuk 21(S1):S362, 2021. e-Pub 2021.
Lachowiez CA, Borthakur G, Loghavi S, Zeng Z, Kadia TM, Masarova L, Takahashi K, Tippett GD, Smith S, Garcia JS, Bose P, Jabbour E, Ravandi F, Daver NG, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian HM, Konopleva M, Dinardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. J Clin Oncol 39(suppl 15), 2021. e-Pub 2021.
Chien KS, Borthakur G, Naqvi K, Daver N, Bravo GM, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Sheppard K, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero AG. Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome. Blood 136, 2020. e-Pub 2020.
Chien KS, Borthakur G, Naqvi K, Daver N, Bravo GM, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Sheppard K, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero AG. Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood 136, 2020. e-Pub 2020.
Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi AF. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 136, 2020. e-Pub 2020.
Morita K, Kantarjian HM, Bravo GM, Sasaki K, Daver N, Jabbour E, Alvarado Y, Chien KS, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva M, Rausch CR, Gasior Y, Garcia-Manero AG. A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 136, 2020. e-Pub 2020.
Kim K, Maiti A, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, DiNardo CD, Konopleva AM. Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood 136, 2020. e-Pub 2020.
Maiti A, Konoplev S, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, Konopleva AM. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood 136, 2020. e-Pub 2020.
Rivera D, Verstovsek S, Bose P, Pemmaraju N, Zhou L, Pierce SA, Kantarjian HM, Estrov ZE, Masarova AL. Outcomes of Patients with Myelofibrosis and Favorable Karyotype. Blood 136, 2020. e-Pub 2020.
Venugopal S, Verstovsek S, Bose P, Pemmaraju N, Zhou L, Pierce SA, Kantarjian HM, Estrov ZE, Masarova AL. Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms. Blood 136, 2020. e-Pub 2020.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov ZE, Kantarjian HM, Verstovsek S. Improved Survival of Patients with Myelofibrosis in the Last Decade. Blood 136, 2020. e-Pub 2020.
Verstovsek S, Mascarenhas J, Kremyanskaya M, Hoffman R, Rampal RK, Gupta V, Talpaz M, Granacher N, Leber B, Kiladjian J, Vannucchi A, Bose P, McMullin MF, Sirhan S, Ribrag V, Luptakova K, Christo J, Wang J, Mertz JA, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Harrison AC. CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Talpaz M, Rampal RK, Verstovsek S, Harrison C, Drummond MW, Kiladjian J, Vannucchi A, Kremyanskaya M, Schiller GJ, Patriarca A, Gorkom GV, Bose P, Hoffman R, Luptakova K, Christo J, Wang J, Mertz JA, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Mascarenhas AJ. CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study. Blood 136, 2020. e-Pub 2020.
Bravo GM, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Short NJ, Issa GC, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Masarova L, Kadia TM, Paul S, Nichols D, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Bose P, Khouri R, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour AE. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Maiti A, DiNardo CD, Ravandi F, Pemmaraju N, Borthakur G, Bose P, Issa GC, Kadia TM, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano KS, Pierce SA, Kantarjian HM, Daver N, Konopleva AM. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 136, 2020. e-Pub 2020.
Fiskus W, Mill CP, Birdwell C, Lara BH, Bose P, Masarova L, Kadia TM, Khoury JD, Manshouri T, Verstovsek S, N Bhalla AK. Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells. Blood 136, 2020. e-Pub 2020.
Gotlib J, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny H, Tugnait M, Schmidt-Kittler O, Evans EK, Lin H, Mar BG, Deininger MW, J DeAngelo AD. Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. Blood 136, 2020. e-Pub 2020.
Rausch CR, DiPippo A, Bose P, Kontoyiannis DP. Breakthrough Invasive Fungal Infections (bIFI) Are Uncommon in Patients with Newly Diagnosed Acute Leukemia Receiving Primary Antifungal Prophylaxis. Blood 136, 2020. e-Pub 2020.
Thompson PA, Ferrajoli A, Jain N, Wang Y, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, Keating MJ, G Wierda AW. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood 136, 2020. e-Pub 2020.
Maiti A, DiNardo CD, Wang SA, Jorgensen JL, Kadia TM, Daver N, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano K, Pierce SA, Kantarjian HM, Konopleva M, Ravandi AF. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Morita K, Bravo GM, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Kantarjian HM, Garcia-Manero AG. Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 136, 2020. e-Pub 2020.
Reville PK, Kantarjian HM, Borthakur G, Yilmaz M, Montalban-Bravo G, DiNardo CD, Andreeff M, MD, Daver N, Jain N, Kornblau SM, Jabbour E, Short NJ, Alvarado Y, Ohanian M, Bose P, Masarova L, Wang SA, S Tidwell RS, Estrov ZE, Garcia-Manero G, Konopleva M, Ravandi F, M Kadia AT. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 136, 2020. e-Pub 2020.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, G Wierda AW. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood 136, 2020. e-Pub 2020.
Short NJ, Kadia TM, DiNardo CD, Pemmaraju N, Borthakur G, Garcia-Manero G, Jabbour E, Sasaki K, Issa GC, Montalban-Bravo G, Bose P, Burger JA, Miller D, Alexander-Williams L, Ravandi F, Konopleva M, Kantarjian HM, Daver AN. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver N, Jabbour E, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Nguyen-Cao M, Richie MA, Dobbins MH, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek AS. Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala SE, Yilmaz M, Ferrajoli A, Bose P, Thompson PA, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger JA, Borthakur G, Pemmaraju N, Shilpa Paul RK, Pierce SA, Cortes JE, M Kantarjian AH. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood 136, 2020. e-Pub 2020.
Gotlib J, Radia DH, George TI, Robinson WA, Quiery AT, Jr, Drummond MW, Bose P, Hexner EO, Winton E, Horny H, Tugnait M, Schmidt-Kittler O, Evans EK, Lin H, Mar BG, Deininger MW, DeAngelo DJ. AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY. Hemasphere 4(S1), 2020. e-Pub 2020.
Verstovsek S, Mascarenhas J, Kremyanskaya M, Hoffman R, Rampal R, Gupta V, Talpaz M, Granacher N, Leber B, Kiladjian J, Vannucchi A, Bose P, McMullin M, Sirhan S, Ribrag V, Kabir S, Mertz J, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Harrison C. CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY. Hemasphere 4(S1), 2020. e-Pub 2020.
Talpaz M, Rampal R, Verstovsek S, Harrison C, Drummond M, Kiladjian J, Vannucchi A, Kremyanskaya M, Schiller G, Patriarca A, Gorkom GV, Bose P, Hoffman R, Kabir S, Mertz J, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Mascarenhas J. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY. Hemasphere 4(S1), 2020. e-Pub 2020.
DiNardo C, Lachowiez C, Borthakur G, Loghavi S, Zeng Z, Kadia T, Masarova L, Takahashi K, Naqvi K, Bose P, Jabbour E, Ravandi F, Daver N, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian H, Konopleva M. PHASE IB/II STUDY OF THE IDH1-MUTANT INHIBITOR IVOSIDENIB WITH THE BCL2 INHIBITOR VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED HEMATOLOGIC MALIGNANCIES. Hemasphere 4(S1), 2020. e-Pub 2020.
Maiti A, DiNardo C, Kadia T, Rausch C, Pemmaraju N, Daver N, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Thompson P, Pierce S, Garcia-Manero G, Ravandi F, Welch J, Qiao W, Ning J, Kantarjian H, Konopleva M. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Hemasphere 4(S1), 2020. e-Pub 2020.
Lachowiez CA, Borthakur G, Loghavi S, Zeng Z, Kadia TM, Masarova L, Takahashi K, Tippett GD, Naqvi K, Bose P, Jabbour E, Ravandi F, Daver NG, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian HM, Konopleva M, Dinardo CD, Halpern AB. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. J Clin Oncol 38 (suppl), 2020. e-Pub 2020.
Kadia TM, Garcia-Manero G, Yilmaz M, Dinardo CD, Konopleva M, Montalban-Bravo G, Borthakur G, Jabbour E, Jain N, Andreeff M, Short NJ, Issa GC, Ohanian M, Bose P, Daver NG, Wang SA, Tidwell R, Estrov Z, Ravandi F, Kantarjian HM. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 38 (suppl), 2020. e-Pub 2020.
Maiti A, MBBS, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian M, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz ME, MD, Jain N, MD, Kornblau SM, MD, Bravo GM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD, DiNardo CD, MD, MSc. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134:738, 2019. e-Pub 2019.
Jain N, MD, Thompson PA, MBBS, Burger JA, MD, PhD, Ferrajoli A, MD, Takahashi K, MD, Estrov ZE, MD, Borthakur GM, MD, Bose P, MD, Kadia TM, MD, Pemmaraju N, MD, Sasaki K, MD, Garg N, MD, Wang X, MS, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Lopez W, RN, Ayala A, RN, Plunkett W, PhD, Gandhi V, PhD, Kantarjian HM, MD, O'Brien S, MD, Keating MJ, MBBS, Wierda WG, MD, PhD. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134:357, 2019. e-Pub 2019.
Taylor F, Shields A, Li S, Yip C, Padilla B, Green T, Radia D, Deininger M, Gotlib JR, Bose P, Drummond MW, Hexner E, Robinson W, Quiery, Jr A, Winton EF, DeAngelo DJ, Mar B. PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS, 2019. e-Pub 2019.
Pemmaraju N, MD, Carter BZ, PhD, Kantarjian HM, MD, Cortes JE, MD, Bose P, MD, Kadia TM, MD, Garcia-Manero G, MD, Bueso-Ramos CE, MD, PhD, DiNardo CD, MD, MSc, Bledsoe S, Daver NG, MD, Popat U, MD, Konopleva MY, MD, PhD, Ohanian M, DO, Pierce SA, BSN, BA, Zhou L, Estrov ZE, MD, Borthakur GM, MD, Mak PY, Jain N, MD, Jabbour E, Verstovsek S, MD, PhD. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 134:555, 2019. e-Pub 2019.
Fiskus W, BSc, PhD, Mill CP, PhD, BA, Karkhanis V, PhD, Lara BH, Bose P, MD, Masarova L, MD, Kadia TM, MD, Shao N, Bhalla I, Maher JV, Khoury JD, MD, Sharma S, MD, Manshouri T, PhD, Verstovsek S, MD, PhD, Bhalla KN, MD. Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells. Blood 134:1274, 2019. e-Pub 2019.
Thompson PA, MBBS, Keating MJ, MBBS, Jain N, MD, Ferrajoli A, MD, Kadia TM, MD, Bose P, MD, Wierda WG, MD, PhD. Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 134:358, 2019. e-Pub 2019.
Kantarjian HM, MD, Richard-Carpentier G, MD, Borthakur GM, MD, Ravandi F, MD, Naqvi K, MD, MPH, Sasaki K, MD, Kadia TM, MD, Verstovsek S, MD, PhD, Garcia-Manero G, MD, DiNardo CD, MD, MSc, Pemmaraju N, MD, Daver NG, MD, Bose P, MD, Pierce SA, BSN, BA, Dara S, MBBS, Jabbour E, Shoukier M, Cortes JE, MD. Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood 134:2941, 2019. e-Pub 2019.
Masarova L, MD, Verstovsek S, MD, PhD, Bose P, MD, Pemmaraju N, MD, Cortes JE, MD, Jabbour E, MD, Ohanian M, DO, Zhou L, Pierce SA, BSN, BA, Gergis R, Borthakur GM, MD, Kadia TM, MD, DiNardo CD, MD, MSc, Ravandi F, MD, Konopleva MY, MD, PhD, Naqvi K, MD, MPH, Sasaki K, MD, Estrov ZE, MD, Garcia-Manero G, MD, Bueso-Ramos CE, MD, PhD, Kantarjian HM, MD, Daver NG, MD. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134:1656, 2019. e-Pub 2019.
Samra B, MD, Richard-Carpentier G, MD, Ravandi F, MD, Kadia TM, MD, Guerra VA, MD, Daver NG, MD, DiNardo CD, MD, MSc, Issa GC, MD, Bose P, MD, Yilmaz M, MD, Ohanian M, DO, Borthakur GM, MD, Garcia-Manero G, MD, Pierce SA, BSN, BA, Cortes JE, MD, Kantarjian HM, MD, Short NJ. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood 134:3834, 2019. e-Pub 2019.
Rozovski U, MD, Harris DM, PhD, Li P, PhD, Liu Z, BS, Manshouri T, PhD, Veletic I, MD, Jain P, MBBS, MD, DM, PhD, Ferrajoli A, MD, Burger JA, MD, PhD, Bose P, MD, Thompson PA, MBBS, Jain N, MD, Verstovsek S, MD, PhD, Wierda WG, MD, PhD, Keating MJ, MBBS, Estrov ZE, MD. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood 134:3018, 2019. e-Pub 2019.
Rozovski U, MD, Harris DM, PhD, Li P, PhD, Liu Z, BS, Manshouri T, PhD, Veletic I, MD, Jain P, MBBS, MD, DM, PhD, Ferrajoli A, MD, Burger JA, MD, PhD, Bose P, MD, Thompson PA, MBBS, Jain N, MD, Verstovsek S, MD, PhD, Wierda WG, MD, PhD, Keating MJ, MBBS, Estrov ZE, MD. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood 134:3024, 2019. e-Pub 2019.
Mascarenhas J, MD, Kremyanskaya M, Hoffman R, MD, Bose P, MD, Talpaz M, MD, Harrison CN, Professor, Gupta V, MD, FRCP, FRCPath, Leber B, MD, Sirhan S, MD, Kabir S, MD, Senderowicz A, MD, Shao J, MS, Mertz J, PhD, Trojer P, PhD, Verstovsek S, MD, PhD. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood 134:670, 2019. e-Pub 2019.
Yilmaz M, MD, Kantarjian HM, MD, Wang X, MS, Khoury JD, MD, Ravandi F, MD, Jorgensen JL, MD, PhD, Short NJ, MD, Loghavi S, MD, Cortes JE, MD, Garcia-Manero G, MD, Kadia TM, MD, Sasaki K, MD, Konopleva MY, MD, PhD, Takahashi K, MD, Wierda WG, MD, PhD, Jain N, MD, Verstovsek S, MD, PhD, Estrov ZE, MD, Bose P, MD, Pierce SA, BSN, BA, Garris R, MSc, O'Brien SM, MD, Jabbour E, MD. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134:1297, 2019. e-Pub 2019.
Jain N, MD, Keating MJ, MBBS, Thompson PA, MBBS, Burger JA, MD, PhD, Ferrajoli A, MD, Estrov ZE, MD, Borthakur GM, MD, Takahashi K, MD, Bose P, MD, Fowler NH, MD, Kadia TM, MD, Daver NG, MD, Konopleva MY, MD, PhD, Alvarado Y, MD, Yilmaz M, MD, DiNardo CD, MD, MSc, Ohanian M, DO, Pemmaraju N, MD, Jabbour E, Sasaki K, MD, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Garg N, MD, Wang X, MS, Sondermann K, BA, Cruz N, RN, Wei C, PhD, Ayala A, RN, Plunkett W, PhD, Kantarjian HM, MD, Gandhi V, PhD, Wierda WG, MD, PhD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 134:359, 2019. e-Pub 2019.
Guerra VA, MD, Kantarjian HM, MD, Cortes JE, MD, Garcia-Manero G, MD, Masarova L, MD, Pemmaraju N, MD, Jabbour E, Kadia TM, MD, DiNardo CD, MD, MSc, Zhou L, Pierce SA, BSN, BA, Borthakur GM, MD, Wierda WG, MD, PhD, Ferrajoli A, MD, Sasaki K, MD, Takahashi K, MD, Naqvi K, MD, MPH, Alvarado Y, MD, Ohanian MN, DO, Jain N, MD, Bose P, MD, Ravandi F, MD, Konopleva MY, MD, PhD, Estrov ZE, MD, Verstovsek S, MD, PhD, Daver NG, MD. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 134:4237, 2019. e-Pub 2019.
Rampal RK, MD, PhD, Verstovsek S, MD, PhD, Devlin SM, PhD, King AC, PharmD, BCOP, Stein EM, MD, Pemmaraju N, MD, Mauro MJ, MD, Kadia TM, MD, Montalban-Bravo G, MD, Alvarez K, RN, Ard N, Goodman T, Taylor B, Bose P, MD. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood 134:4163, 2019. e-Pub 2019.
Chien KS, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Daver NG, MD, Cortes JE, MD, DiNardo CD, MD, MSc, Jabbour E, MD, Andreeff M, MD, PhD, Alvarado Y, MD, Bose P, MD, Jain N, MD, Sheppard K, BSN, RN, Klingner-Winton C, Pierce SA, BSN, BA, Dong XQ, Soltysiak K, PhD, Kantarjian HM, MD, Garcia-Manero G, MD. Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood 134:4240, 2019. e-Pub 2019.
Maiti A, MBBS, DiNardo CD, MD, MSc, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian MN, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz ME, MD, Jain N, MD, Kornblau SM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, MD, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134:2637, 2019. e-Pub 2019.
Jain N, MD, Keating MJ, MBBS, Thompson PA, MBBS, Ferrajoli A, MD, Burger JA, MD, PhD, Borthakur GM, MD, Takahashi K, MD, Estrov ZE, MD, Fowler NH, MD, Kadia TM, MD, Konopleva MY, MD, PhD, Alvarado Y, MD, Yilmaz M, MD, DiNardo CD, MD, MSc, Bose P, MD, Ohanian M, DO, Pemmaraju N, MD, Jabbour E, Sasaki K, MD, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Garg N, MD, Wang X, MS, Sondermann K, BA, Cruz N, RN, Wei C, PhD, Ayala A, RN, Plunkett W, PhD, Kantarjian HM, MD, Gandhi V, PhD, Wierda WG, MD, PhD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134:34, 2019. e-Pub 2019.
Maiti A, MBBS, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian M, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz M, MD, Jain N, MD, Kornblau SM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, MD, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Patel KP, MBBS, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD, DiNardo CD, MD, MSc. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134:645, 2019. e-Pub 2019.
Bose P, McCue D, Wurster S, Wiederhold NP, Kadia TM, Borthakur G, Ravandi-Kashani F, Masarova L, Konopleva M, Estrov Z, Takahashi K, Yilmaz M, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study. Open Forum Infect Dis 6(suppl 2):S718, 2019. e-Pub 2019.
Lee LW, Ching T, Patel K, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Burger J, Keating M, Bose P, Wierda WG, Kirsch I. Assessment of immunoglobulin heavy chain variable region (IGHV) mutation status with a next-generation sequencing (NGS) immunosequencing assay for minimal residual disease (MRD), 2019. e-Pub 2019.
Jain N, Thompson PA, Burger JA, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Jorgensen J, Wang S, Plunkett W, Gandhi V, Kantarjian H, O’Brien S, Keating M, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-line Treatment of patients with CLL with Mutated IGHV and without TP53 Aberrations, 2019. e-Pub 2019.
Radia D, Deininger MW, Gotlib J, Bose P, Drummond MW, Hexner EO, Robinson WA, Quiery AT, George TI, Horny H, Oren R, Shi H, Schmidt-Kittler O, Mar B, DeAngelo D. AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Rampal R, Verstovsek S, Devlin S, Stein E, Kadia T, Mauro M, Pemmaraju N, Montalban-Bravo G, King A, Alvarez K, Ard N, Goodman T, Taylor B, Bose P. EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Kremyanskaya M, Hoffman R, Mascarenhas J, Bose P, Gupta V, Schiller GJ, Liew E, Lebedinsky C, Senderowicz AM, Mertz J, Trojer P, Verstovsek S. A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF). J Clin Oncol 37(suppl), 2019. e-Pub 2019.
DiNardo C, Takahashi K, Kadia T, Loghavi S, Naqvi K, Bose P, Daver N, Tippett GD, Borthakur G, Cortes J, Chan S, Quek L, Vyas P, Kantarjian H, Konopleva M. A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES. Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Hoffman R, Mascarenhas J, Kremyanskaya M, Bose P, Gupta V, Schiller G, Liew E, Godfrey A, Mertz J, Piel J, Trojer P, Lebedinsky C, Senderowicz A, Kabir S, Supko J, Verstovsek S. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS. Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Naqvi K, Jabbour E, Skinner JA, Anderson KN, Yilmaz M, Jain N, Ferrajoli A, Bose P, Thompson PA, Alvarado Y, Takahashi K, Burger JA, Borthakur G, Estrov Z, Pemmaraju N, Paul S, Dellasala S, Cortes JE, Kantarjian HM. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). J Clin Oncol 37(suppl), 2019. e-Pub 2019.
Naqvi K, Jabbour E, Skinner J, Anderson K, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Dellasala S, Paul S, Cortes J, Kantarjian H. FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP). Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Bose P, Pemmaraju N, Daver N, Jabbour E, Bledsoe S, Kadia T, Estrov Z, Kornblau S, Borthakur G, Masarova L, Huynh-Lu J, Henriquez M, Richie MA, Sun J, Zhou L, Pierce S, Wang X, Pike A, Kantarjian H, Verstovsek S. SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA. Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Bose P, Verstovsek S, Naqvi K, Jabbour E, DiNardo C, Alvarado Y, Pemmaraju N, Daver N, Kadia T, Short N, Jain N, Benton C, Takahashi K, Estrov Z, Cortes J, Nogueras-Gonzalez G, Huang X, Villareal J, Pierce S, Wilson L, Tse S, Kantarjian H, Ravandi F. PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML). Hemasphere 3(suppl 1), 2019. e-Pub 2019.
Maiti A, Ravandi F, Cortes JE, Jabbour E, Marx K, Daver NG, Garcia-Manero G, Konopleva M, Benton CB, Masarova L, Dinardo CD, Bose P, Naqvi K, Pierce SA, Kantarjian HM, Short NJ. Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP). J Clin Oncol 37(suppl), 2019. e-Pub 2019.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, Alvarado Y, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Kadia TM, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour EJ, Verstovsek S. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 132, 2018. e-Pub 2018.
Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, Estrov ZE, Kadia TM, Takahashi K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Kadia TM, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Bhalla KN, Pemmaraju N, Jain N, Malla R, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood 132, 2018. e-Pub 2018.
Tallis E, Kantarjian HM, Major CK, Vazquez M, Borthakur G, Bose P, Ravandi F, Garcia-Manero G, Kadia TM, Wierda WG, Ferrajoli A, Pemmaraju N, Daver NG, DiNardo CD, Konopleva MY, Kornblau SM, Champlin RE, Jabbour EJ, Pierce SA, Cortes JE. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood 132, 2018. e-Pub 2018.
Richard-Carpentier G, Kantarjian HM, Ravandi F, Kadia TM, Borthakur G, Garcia-Manero G, DiNardo CD, Wierda WG, Daver NG, Pemmaraju N, Bose P, Konopleva MY, Andreeff M, Verstovsek S, Krause HM, Aung FM, Cortes JE. Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Jabbour EJ, Konopleva MY, Daver NG, Borthakur G, DiNardo CD, Bose P, Patel P, Komrokji RS, Shastri A, Roboz GJ, Miller RM, Arbe-Barnes S, Reilly M, McGuirk P, Kearney T, Keogh B, Kantarjian HM. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood 132, 2018. e-Pub 2018.
Alfayez M, Kantarjian HM, Short NJ, Assi R, Khouri M, Ravandi F, Paul S, Rausch CR, Nasnas P, Borthakur G, DiNardo CD, Kadia TM, Daver NG, Garcia-Manero G, Naqvi K, Bose P, O'Brien SM, Cortes JE, Jabbour EJ. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood 132, 2018. e-Pub 2018.
Rausch CR, Paul S, Bravo GM, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132, 2018. e-Pub 2018.
Alfayez M, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Cortes JE, Kadia TM. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
Gotlib JR, Radia D, DeAngelo DJ, Bose P, Drummond MW, Hexner EO, Robinson WA, Conlan MG, Oren RG, Shi H, Deininger MW. Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood 132, 2018. e-Pub 2018.
Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju N, Kadia TM, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood 132, 2018. e-Pub 2018.
Rampal RK, Verstovsek S, Devlin SM, Stein EM, Kadia TM, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi R, Sun B, Mill CP, Nowak AJ, Kornblau SM, Bose P, Kadia TM, DiNardo CD, Masarova L, Horrigan S, Khoury JD, Sharma S, Verstovsek S, Bhalla KN. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood 132, 2018. e-Pub 2018.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132, 2018. e-Pub 2018.
Masarova L, Verstovsek S, Cortes JE, Pemmaraju N, Bose P, Ohanian MN, Zhou L, Pierce SA, Gergis R, Borthakur G, Estrov ZE, Garcia-Manero G, Kantarjian HM, Daver NG. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132, 2018. e-Pub 2018.
Masarova L, Bose P, Pemmaraju N, Estrov ZE, Zhou L, Pierce SA, Cortes JE, Kantarjian HM, Verstovsek S. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132, 2018. e-Pub 2018.
Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132, 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Kadia TM, Garcia-Manero G, Patel K, Loghavi S, Sasaki K, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132, 2018. e-Pub 2018.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov ZE. CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB. Blood 132, 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, Konopleva MY, Garcia-Manero G, Takahashi K, DiNardo CD, Bose P, Andreeff M, Ravandi F, Cortes JE. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
Rozovski U, Li P, Harris DM, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov ZE. Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage. Blood 132, 2018. e-Pub 2018.
Masarova L, Verstovsek S, Cortes J, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Daver N. PHASE 2 STUDY OF RUXOLITINIB IN COMBINATION WITH 5-AZACITIDINE IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 2(suppl 1), 2018. e-Pub 2018.
Sanchez-Petitto G, Garcia-Manero G, Short NJ, Naqvi K, Andreeff M, Takahashi K, Kornblau S, Bose P, Estrov Z, Konopleva M, Patel A, Islam R, Alvarado Y, Dinardo CD, Kantarjian HM, Jabbour E. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Garcia-Manero G, Bose P, Alvarado Y, Borthakur G, Daver N, Ravandi-Kashani F, Jabbour E, Takahashi K, Andreeff M, Kadia T, DiNardo C, Cortes J, Kornblau S, Naqvi K, Benton C, Ohanian M, Konopleva M, Estrov Z, Montalban-Bravo G, Pierce S, Bodden K, Kantarjian H. A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME. Hemasphere 2(suppl 1), 2018. e-Pub 2018.
Ghorab A, Kantarjian HM, Jain P, Kanagal-Shamanna R, Jabbour E, Sasaki K, Kadia TM, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Boddu P, Borthakur G, Naqvi K, Wierda WG, Bose P, Jabbour E, Estrov Z, Burger JA, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Kantarjian HM, Andreeff M, Konopleva M. Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Hu B, Patel K, Chen H, Wang X, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros L, Yin CC, Zuo Z, Ok C, Loghavi S, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Wierda WG. Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. Blood 130, 2017. e-Pub 2017.
Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130, 2017. e-Pub 2017.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells. Blood 130, 2017. e-Pub 2017.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes J, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, 2017. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Takahashi K, Garg N, Wang X, Gandhi V, Plunkett W, Kanagal-Shamanna R, Patel K, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 130, 2017. e-Pub 2017.
Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 130, 2017. e-Pub 2017.
Hu B, Patel K, Wang X, H-C C, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood 130, 2017. e-Pub 2017.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 130, 2017. e-Pub 2017.
Yilmaz M, Kantarjian HM, Wang X, KC D, Khoury JD, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda W, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 130, 2017. e-Pub 2017.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2017. e-Pub 2017.
Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda W. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood, 2017. e-Pub 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib. Blood 130, 2017. e-Pub 2017.
Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, Huynh-Lu J, Nguyen-Cao M, Wang X, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood 130, 2017. e-Pub 2017.
Falchi L, Chihara D, Bose P, Estrov Z, Kantarjian HM, Ravandi F, Verstovsek S. Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes. Blood 130, 2017. e-Pub 2017.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, KC D, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M, Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 130, 2017. e-Pub 2017.
Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 130, 2017. e-Pub 2017.
Bose P, Pemmaraju N, Schroeder K, Ferrajoli A, Jabbour EJ, Daver N, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood 130, 2017. e-Pub 2017.
Bose P, Chen L, Cruz N, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll M, Jain N, Wierda WG, Keating MJ, Gandhi V. A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL). Blood 130, 2017. e-Pub 2017.
Naqvi K, Cortes JE, Skinner J, Jabbour EJ, Pemmaraju N, Bose P, Thompson PA, Borthakur G, Estrov Z, Kantarjian HM. Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Blood 130, 2017. e-Pub 2017.
Boddu P, Mansurov A, Masarova L, Bose P, Patel KP, Estrov Z, Kantarjian HM, Verstovsek S. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood 130, 2017. e-Pub 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. Blood 130, 2017. e-Pub 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130, 2017. e-Pub 2017.
Naqvi K, Cortes J, Skinner J, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson P, Kantarjian H. Therapy with Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Clin Lymphoma Myeloma Leuk 17(Suppl 2):S317, 2017. e-Pub 2017.
Masarova L, Bose P, Abou Zahr A, Cortes J, Kantarjian H, Verstovsek S. Do We Need to Re-Define Accelerated Phase of Myelofibrosis? Correlation between Blast Percentage in Myelofibrosis and Outcomes. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S352, 2017. e-Pub 2017.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. JAK2 V617F Acute Lymphoblastic Leukemia Secondary to Myeloproliferative Neoplasms (MPNs) or After Lenalidomide Exposure: Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S254, 2017. e-Pub 2017.
Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes JE, Kantarjian HM, Verstovsek S. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. J Clin Oncol 35, 2017. e-Pub 2017.
Garcia-Manero G, Daver N, Montalban-Bravo G, Jabbour E, DiNardo C, Kornblau S, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes J, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez G, Bueso-Ramos C, Gasior Y, Bayer V, Pierce S, Yang H, Colla S, Kantarjian H. AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS). Haematologica (Roma) 102:183, 2017. e-Pub 2017.
Naqvi K, Kadia T, Borthakur G, Takahashi K, Bose P, Daver N, Alvarado Y, Ohanian M, DiNardo C, Jabbour E, Garcia-Manero G, Kantarjian H, Patel A, Ravandi F. PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR. Haematologica (Roma) 102:375, 2017. e-Pub 2017.
Bose P, Nazha A, Komrokji R, Savona M, Patel K, Pierce S, Al Ali N, Sochacki A, Shaver A, Daver N, DiNardo C, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Sekeres M, Maciejewski J, Verstovsek S. MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM -. Haematologica (Roma) 102:118, 2017. e-Pub 2017.
Naqvi K, Cortes JE, Skinner JA, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson PA, Kantarjian HM. Early Results of Lower Dose Dasatinib, 50mg Daily, in Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase. J Clin Oncol 35. e-Pub 2017.
Boddu P, Jorgensen JL, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour E, Garcia-Manero G, Cortes JE, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces risk of relapse. J Clin Oncol 35. e-Pub 2017. PMID: 28919634.
Assi R, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Kadia TM, DiNardo CD, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). J Clin Oncol 35. e-Pub 2017.
Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G. Updated results from Phase 2 Study of Guadecitabine for Patients with Higher Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia. J Clin Oncol 35. e-Pub 2017.
Masarova L, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. J Clin Oncol 35. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Gandhi V, Plunkett W, Lopez W, Kantarjian HM, O’Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV and Non-del(17p). J Clin Oncol 35. e-Pub 2017.
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes J, DiNardo C, Jabbour E, Kadia T, Kornblau S, Ohanian M, Alfonso A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Initial results of a Phase 2 Study of Guadecitabine (SGI-110), A Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128, 2016. e-Pub 2016.
Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 128, 2016. e-Pub 2016.
Strati P, Bose P, Gaw K, Zhou L, Pierce S, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S. Immature Platelet Fraction Is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells. Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda WG, Keating M, Estrov Z. Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo. Blood 128, 2016. e-Pub 2016.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128, 2016. e-Pub 2016.
Ohanian M, Kantarjian H, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt J, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-dose Ara-C in Multiply Relapsed/ Refractory FLT3+ AML. Blood 128, 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin C, Khouri MR, Cortes JE, Garris R, O'Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood 128, 2016. e-Pub 2016.
Sasaki K, Jabbour E, O'Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Acute Lymphoblastic Leukemia (ALL) by Age Group over 35 Years: A Single Institution Experience. Blood 128, 2016. e-Pub 2016.
Pemmaraju N, Carter BZ, Kantarjian H, Cortes J, Kadia T, Garcia-Manero G, DiNardo C, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle C, Salinas K, Mak PY, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri RB, Alvarado Y, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Garris R, Schroeder H, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O'Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128, 2016. e-Pub 2016.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128, 2016. e-Pub 2016.
Khan M, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo C, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine as Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) as Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128, 2016. e-Pub 2016.
Abaza Y, Kantarjian H, Jabbour E, Thomas D, Kadia T, Borthakur G, Burger J, Wierda W, Jain N, Faderl S, O'Brien S, Konopleva M, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose P, Thompson P, Kelly M, Garris R, Garcia-Manero G, Cortes J, Ravandi F. Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated Adult T-cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128, 2016. e-Pub 2016.
Jain P, Wang S, Kantarjian H, Sarwari N, Patel KP, Bose P, Pierce S, Kadia TM, Daver N, Pemmaraju N, Cortes J, Verstovsek S. Aleukemic mast cell leukemia (aMCL) – clinical characteristics and outcomes. Blood 128, 2016. e-Pub 2016.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Cytogenetic risk stratification in primary versus post-essential thrombocythemia / post-polycythemia vera myelofibrosis. Blood 128. e-Pub 2016.
Masarova L, Popat U, Bose P Champlin R, Cortes J, Kantarjian H, Verstovsek S. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. Blood 128, 2016. e-Pub 2016.
Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa G, Daver N, Jabbour E, DiNardo C, Bueso-Ramos C, Patel K, Kornblau S, Konopleva M, Borthakur G, Kadia T, Cortes J, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian H. Archetypes of AML defined using whole exome sequencing and clinical characteristics in a diverse group of patients. Blood 128, 2016. e-Pub 2016.
Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128, 2016. e-Pub 2016.
Bose P, Daver N, Jabbour EJ, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek S. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128, 2016. e-Pub 2016.
Masarova L, Bose P, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Therapy-Related Myelofibrosis does not appear to exist. Clin Lymphoma Myeloma Leuk 16(S2), 2016. e-Pub 2016.
Masarova L, Bose P, Daver N, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis and deletion 13q. Clin Lymphoma Myeloma Leuk 16(S2), 2016. e-Pub 2016.
Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, MKadia T, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DDiNardo C, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22):3975, 2016. e-Pub 2016.
Masarova L, Bose P, Pemmaraju N, Daver NG, Newberry K, Cortes JE, Kantarjian HM, Verstovsek S. Does therapy-related myelofibrosis exist? Analysis of 1100 myelofibrosis cases from a single institution. J Clin Oncol 34, 2016. e-Pub 2016.
Alhuraiji A, Masarova L, Bose P, Daver NG, Cortes JE, Pierce S, Kantarjian HM, Verstovsek S. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. J Clin Oncol 34, 2016. e-Pub 2016.
Masarova L, MD, Bose P, MD, pemmaraju N, MD, Newberry KJ, PhD, Bueso-Ramos CE, PhD MD, Cortes JE, MD, Kantarjian HM, MD, Verstovsek S, MD, PhD. Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis. Blood 128(22):4265, 2016. e-Pub 2016.
Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes JE, Kantarjian HM, Verstovsek S. Do Patients with Post-Essential Thrombocythemia and post-Polycthemia Vera Differ from Patients with Primary Myelofibrosis?. Blood 126(23), 2015. e-Pub 2015.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
Yilmaz M, Kantarjian HM, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Takahashi K, Wierda WG, Jain N, Verstovsek S, Estrov Z, Bose P Pierce S, Jabbour E. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood 126(23), 2015. e-Pub 2015.
KC B, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23), 2015. e-Pub 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Bravo Montalban G, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23), 2015. e-Pub 2015.
Holkova B, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Singh AG, Dean A, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 124(21), 2014. e-Pub 2014.
Zeidner JF, Foster MC, Blackford A, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy Y, Tibes R, Gojo I, Gocke CD, Greer JM, Cain JM, Little RF, Wright JJ, Doyle L, Smith B, Karp JE. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 32, 2014. e-Pub 2014.
Holkova B, Kmieciak M, Bose P, Barr PM, Tombes MB, Shrader E, Cebula E, Pierce E, Herr MM, Sankala H, Feng C, Fisher RI, Grant S, Friedberg JW. Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood 122, 2013. e-Pub 2013.
Holkova B, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis – One Year Update. Blood 120(21), 2012. e-Pub 2012.
Zeidner JF, Gerber JM, Blackford A, Litzow M, Foster M, Morris L, Gojo I, Lancet J, Bose P, Tibes R, Strickland S, Greer J, Drye M, Meads K, Doyle L, Little RF, Wright JJ, Karp JE. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012. e-Pub 2012.
Holkova B, Shea TC, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 120(21), 2012. e-Pub 2012.
Holkova B, Perkins E, Bose P, Sullivan D, Baz RC, Tombes MB, Shrader E, Ramakrishnan V, Wan W, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms – Update of the “Bolus” Infusion Schedule of Alvocidib. Blood 120(21), 2012. e-Pub 2012.
Li J, Gatesman ML, Newland AM, Sabo R, Bose P. FLAG ± Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience. Blood 120(21), 2012. e-Pub 2012.
Bose P, Holter JL, Selby GB. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Blood 112(11):1338, 2008. e-Pub 2008.
Bose P, Nakadar S, Ali AY, Reyes MP. Daptomycin-induced rhabdomyolysis. J Gen Int Med 22(S1):240, 2007. e-Pub 2007.
Bose P, Al-Romaihi D, Movva K. Hypokalemic periodic paralysis: Not always familial. J Gen Int Med 22(S1):211, 2007. e-Pub 2007.
Bose P, Thompson JA. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. J Gen Int Med 21(S4):237, 2006. e-Pub 2006.
Bose P, Shah V. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. J Gen Int Med 21(S4):231, 2006. e-Pub 2006.

Book Chapters

Bose, P, Verstovsek, S. JAK Inhibitors for the Management of Myeloproliferative Neoplasms, 567-576, 2023.
Pasca, S, Chifotides, H, Verstovsek, S, Bose, P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN, 83-124, 2022.
Bose P, Masarova L, Amin H, Verstovsek S. Philadelphia Chromosome Negative Myeloproliferative Neoplasms. In: MD Anderson Manual of Medical Oncology. 4. McGraw Hill, 2022.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice, 2020.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice. BMJ Publishing Group Limited, 2018.
Bose P, Verstovsek S. Polycythemia vera. In: BMJ Best Practice, 2016.
Dai Y, Bose P, Grant S. Cell cycle regulation and hematologic disorders. In: Williams Hematology. 9. Mc-Graw Hill, 2015.
Bose P, Grant S. Bcl-2 family: translational aspects. In: Targeted Therapy of Acute Myeloid Leukemia. Springer, 67-94, 2015.
Batalo MS, Bose P, Holkova B, Grant S. Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition. In: Resistance to Proteasome Inhibitors in Cancer. Springer, 149-179, 2014.
Bose P, Vachhani P. Can we cure CML without transplantation?. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova, 279-326, 2014.
Ustun C, Warlick E, Bose P, Radich JP, Goldman JM. Summary of treatment and recommended follow-up of CML patients. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova, 183-190, 2014.
Park H, Poklepovic A, Bose P. Emerging therapeutic options for metastatic exocrine pancreatic cancer. In: Pancreas: Anatomy, Diseases and Health Implications. Nova, 159-172, 2012.
Poklepovic A, Bose P. Molecularly Targeted Therapy: Imatinib and Beyond. In: Gastrointestinal Stromal Tumor. InTech, 47-60, 2012.
Bose P, Verstovsek S. Polycythemia vera. In: Cancer Consult: Uncertainties and Controversies in the Diagnosis & Management of Cancer. 2nd. Wiley-Blackwell Health Sciences, John Wiley and Sons.

Letters to the Editor

Bharathi, V, Jen, WY, Venugopal, S, Thakral, B, Daver, N, Chien, K, Bose, P, Masarova, L, Pemmaraju, N, Tang, G, Jain, N. Durable complete remission with imatinib monotherapy in a patient with FIP1L1-PDGFRA rearranged myeloid neoplasm with extramedullary involvement. Leukemia and Lymphoma 67: 225-228, 2026.
Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110: 1628-1633, 2025.
Srinivasan T, Mallik N, Ahluwalia J, Bose P, Srinivasan R, Mallik M, Khadwal A, Sachdeva MUS. Myeloid sarcoma or mixed phenotype acute leukemia? Multiparametric flow cytometry to the rescue in an unusual diagnostic dilemma. Cytometry B Clin Cytom 108: 329-331, 2025.
Sreedharanunni S, Kaur P, Raina S, Bose P, Kumar A, Sharma P, Naseem S, Jain A, Khadwal A, Sachdeva MUS. Flow Cytometric Intracellular 5-Methyl Cytosine Expression and Its Correlation With Cytogenetics and Measurable Residual Disease in Adult B-Lineage Acute Lymphoblastic Leukemia. Int J Lab Hematol 47: 349-353, 2025.
Koschmieder, S, Bose, P, Ellis, M, Gupta, V, Kiladjian, JJ, Mascarenhas, J, Mathews, V, Passamonti, F, Harrison, C. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias. Leukemia 38: 1831-1838, 2024.
Ramani S, Parashar R, Roy N, Kullu A, Gaitonde R, Ananthakrishnan R, Arora S, Mishra S, Pitre A, Saluja D, Srinivasan A, Uppal A, Bose P, Yellappa V, Kumar S. How to work with intangible software in public health systems: some experiences from India. Health Res Policy Syst 20: 52, 2022.
Blough MD, Kumar M, Bose P, Cairncross JG. In the beginning: PDGFA and the genesis of GBM. Neuro Oncol 23: 697-698, 2021.
Sreedharanunni S, Varma N, Sachdeva MUS, Naseem S, Malhotra P, Bansal D, Sood A, Bose P, Varma S. Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. Eur J Haematol 99: 194-195, 2017.
Bose P, Pleasance ED, Jones M, Shen Y, Ch'ng C, Reisle C, Schein JE, Mungall AJ, Moore R, Ma Y, Sheffield BS, Thomson T, Rasmussen S, Ng T, Yip S, Lee CW, Ho C, Laskin J, Marra MA, Jones SJ. Integrative genomic analysis of ghost cell odontogenic carcinoma. Oral Oncol 51: e71-5, 2015.
Goel V, Bose PD, Sarma MP, Hazam RK, Das BC, Gondal R, Kar P. Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues. Indian J Med Res 137: 1208-9, 2013.
Bose P, Holter JL, Selby GB. More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia (author reply). N Engl J Med 361: 931-932, 2009.
Bose P, Bowsher WG. Length of postoperative hospital stay after transurethral resection of the prostate. Ann R Coll Surg Engl 79: 468, 1997.

Less

CV information above last modified February 20, 2026

Prithviraj Bose, M.D.

About Dr. Bose

In the News

7 things to know about myelofibrosis

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson